Interpace Biosciences (IDXG) S-1 6 Dec 21 IPO registration Financial data

Cover

Cover	9 Months Ended
	Sep. 30, 2021
Entity Addresses [Line Items]
Document Type	S-1
Amendment Flag	false
Entity Registrant Name	INTERPACE BIOSCIENCES, INC.
Entity Central Index Key	0001054102
Entity Tax Identification Number	22-2919486
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	Morris Corporate Center 1
Entity Address, Address Line Two	Building C
Entity Address, Address Line Three	300 Interpace Parkway
Entity Address, City or Town	Parsippany
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07054
City Area Code	(855) 776-6419
Local Phone Number	776-6419
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Business Contact [Member]
Entity Addresses [Line Items]
Entity Address, Address Line One	Morris Corporate Center 1
Entity Address, Address Line Two	Building C
Entity Address, Address Line Three	300 Interpace Parkway
Entity Address, City or Town	Parsippany
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07054

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Current assets:
Cash and cash equivalents	$ 3,180	$ 2,772	$ 2,321
Restricted cash	250	600
Accounts receivable, net of allowance for doubtful accounts of $275 and $25, respectively	6,518	8,028	10,338
Other current assets	3,135	2,722	3,851
Total current assets	13,083	14,122	16,510
Property and equipment, net	6,484	7,349	6,814
Other intangible assets, net	8,014	11,351	15,849
Goodwill	8,433	8,433	8,433
Operating lease right of use assets	3,989	4,384	3,892
Other long-term assets	304	42	42
Total assets	40,307	45,681	51,540
Current liabilities:
Accounts payable	2,427	4,511	4,709
Accrued salary and bonus	2,728	3,161	2,341
Notes payable - related parties	7,872
Other accrued expenses	9,043	9,795	9,476
Current liabilities from discontinued operations	766	766	766
Total current liabilities	22,836	18,233	17,292
Contingent consideration	1,663	1,818	2,391
Operating lease liabilities, net of current portion	3,152	3,540	2,591
Other long-term liabilities	4,768	4,637	4,573
Line of credit			3,000
Total liabilities	32,419	28,228	29,847
Commitments and contingencies (Note 12)
Preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 Series B issued and outstanding	46,536	46,536
Stockholders’ equity:
Common stock, $.01 par value; 100,000,000 shares authorized; 4,075,257 and 3,932,370 shares issued, respectively; 4,055,593 and 3,920,589 shares outstanding, respectively	403	402	393
Additional paid-in capital	186,052	184,404	182,514
Accumulated deficit	(223,330)	(212,116)	(185,665)
Treasury stock, at cost (19,664 and 11,781 shares, respectively)	(1,773)	(1,773)	(1,721)
Total stockholders' equity	(38,648)	(29,083)	(4,479)
Total liabilities and stockholders' equity		(855)	25,368
Total liabilities, preferred stock and stockholders' equity	$ 40,307	45,681	51,540
Series A Preferred Stock [Member]
Current liabilities:
Preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 Series B issued and outstanding			26,172
Series B Preferred Stock [Member]
Current liabilities:
Preferred stock, $.01 par value; 5,000,000 shares authorized, 47,000 Series B issued and outstanding		$ 46,536

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Allowance for doubtful accounts	$ 72	$ 275	$ 25
Temporary equity, par value	$ 0.01	$ 0.01
Temporary equity, shares authorized	5,000,000	5,000,000	5,000,000
Common stock, par value	$ 0.01	$ 0.01	$ 0.01
Common stock, shares authorized	100,000,000	100,000,000	100,000,000
Common stock, shares issued	4,194,111	4,075,257	3,932,370
Common stock, shares outstanding	4,174,447	4,055,593	3,920,589
Treasury stock, shares	19,664	19,664	11,781
Series B Preferred Stock [Member]
Temporary equity, shares issued	47,000	47,000	47,000
Temporary equity, shares outstanding	47,000	47,000	47,000
Series A Preferred Stock [Member]
Temporary equity, shares issued		270	270
Temporary equity, shares outstanding		270	270

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Revenue, net	$ 9,472	$ 8,248	$ 30,461	$ 22,752	$ 32,398	$ 24,220
Cost of revenue (excluding amortization of $4,461 and $3,989, respectively)	5,848	5,194	16,965	15,156	21,673	15,888
Gross profit	3,624	3,054	13,496	7,596	10,725	8,332
Operating expenses:
Sales and marketing	2,456	2,699	7,585	6,776	9,254	11,116
Research and development	416	763	1,475	2,123	2,795	2,810
General and administrative	3,278	3,795	9,582	12,683	20,770	14,363
Acquisition related expense	363	687	2,474	798		2,534
Gain on DiamiR transaction			(235)
Acquisition related amortization expense	1,112	1,115	3,336	3,346	4,461	3,989
Change in fair value of contingent consideration			(57)		(489)	(44)
Total operating expenses	7,625	9,059	24,217	25,726	36,791	34,768
Operating loss	(4,001)	(6,005)	(10,721)	(18,130)	(26,066)	(26,436)
Interest accretion expense	(106)	(138)	(375)	(414)	(549)	(440)
Related party interest	(151)		(372)
Other income (expense), net	45	(12)	(255)	473	467	196
Loss from continuing operations before tax	(4,213)	(6,155)	(11,723)	(18,071)	(26,148)	(26,680)
Provision (benefit) for income taxes	(714)	14	(684)	43	53	(28)
Loss from continuing operations	(3,499)	(6,169)	(11,039)	(18,114)	(26,201)	(26,652)
Loss from discontinued operations, net of tax	(62)	(65)	(175)	(194)	(250)	(88)
Net loss	(3,561)	(6,234)	(11,214)	(18,308)	(26,451)	(26,740)
Less dividends on preferred stock						(429)
Less adjustment for preferred stock deemed dividend				(3,033)	(3,033)
Net loss attributable to common stockholders	$ (3,561)	$ (6,234)	$ (11,214)	$ (21,341)	$ (29,484)	$ (27,169)
Basic and diluted (loss) income per share of common stock:
From continuing operations	$ (0.84)	$ (1.53)	$ (2.68)	$ (5.25)	$ (7.26)	$ (7.23)
From discontinued operations	(0.01)	(0.01)	(0.04)	(0.05)	(0.06)	(0.02)
Net loss per basic and diluted share of common stock	$ (0.85)	$ (1.54)	$ (2.72)	$ (5.30)	$ (7.32)	$ (7.25)
Weighted average number of common shares and common share equivalents outstanding:
Basic	4,165	4,038	4,119	4,025	4,029	3,746
Diluted	4,165	4,038	4,119	4,025	4,029	3,746

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Operations (Parenthetical) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Statement [Abstract]
Amortization	$ 1,112	$ 1,115	$ 3,336	$ 3,346	$ 4,461	$ 3,989

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Stockholders' Deficit - USD ($) $ in Thousands	Common Stock [Member]	Total	Treasury Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance, shares at Dec. 31, 2018	2,877		7
Balance at Dec. 31, 2018	$ 287		$ (1,680)	$ 175,820	$ (158,981)
Common stock issued, shares	9
Common stock issued	$ 1
Restricted stock issued, shares
Restricted stock issued
Common stock issued through market sales, shares
Common stock issued through market sales
Treasury stock purchased			$ (32)
Treasury stock purchased, shares			3
Common stock issued through offering, net of expenses	$ 94			5,868
Common stock issued through offerings, shares	933
Adoption of ASC 842					55
Extinguishment of Series A Shares
Beneficial Conversion Feature in connection with Series B Issuance
Amortization of Beneficial Conversion Feature
Stock-based compensation expense				266
Net loss					(3,326)
Balance, ending balance shares at Mar. 31, 2019	3,819		10
Balance at Mar. 31, 2019	$ 382		$ (1,712)	181,954	(162,252)
Treasury stock purchased			$ 32
Balance, shares at Dec. 31, 2018	2,877		7
Balance at Dec. 31, 2018	$ 287		$ (1,680)	175,820	(158,981)
Net loss		$ (26,740)
Balance, ending balance shares at Dec. 31, 2019	3,932		12
Balance at Dec. 31, 2019	$ 393	(4,479)	$ (1,721)	182,514	(185,665)
Balance, shares at Mar. 31, 2019	3,819		10
Balance at Mar. 31, 2019	$ 382		$ (1,712)	181,954	(162,252)
Common stock issued, shares	10
Common stock issued	$ 1			72
Treasury stock purchased
Treasury stock purchased, shares
Stock-based compensation expense				205
Net loss					(5,304)
Balance, ending balance shares at Jun. 30, 2019	3,829		10
Balance at Jun. 30, 2019	$ 383		$ (1,712)	182,231	(167,556)
Treasury stock purchased
Common stock issued, shares
Common stock issued
Treasury stock purchased
Treasury stock purchased, shares
Dividends accrued				(75)
Stock-based compensation expense				205
Net loss					(7,446)
Balance, ending balance shares at Sep. 30, 2019	3,829		10
Balance at Sep. 30, 2019	$ 383		$ (1,712)	182,361	(175,002)
Treasury stock purchased
Common stock issued, shares	5
Common stock issued
Common stock issued through market sales, shares	98
Common stock issued through market sales	$ 10			218
Treasury stock purchased			$ (9)
Treasury stock purchased, shares			2
Dividends accrued				(354)
Stock-based compensation expense				289
Net loss					(10,663)
Balance, ending balance shares at Dec. 31, 2019	3,932		12
Balance at Dec. 31, 2019	$ 393	(4,479)	$ (1,721)	182,514	(185,665)
Treasury stock purchased			9
Common stock issued, shares	37
Common stock issued	$ 1
Restricted stock issued, shares	6
Restricted stock issued
Common stock issued through market sales, shares	80
Common stock issued through market sales	$ 8			476
Common stock issued through ESPP, shares
Common stock issued through ESPP
Treasury stock purchased
Treasury stock purchased, shares
Common stock issued through offering, net of expenses
Common stock issued through offerings, shares
Adoption of ASC 842
Extinguishment of Series A Shares				(828)
Beneficial Conversion Feature in connection with Series B Issuance				2,205
Amortization of Beneficial Conversion Feature				(2,205)
Stock-based compensation expense				418
Net loss					(6,494)
Balance, ending balance shares at Mar. 31, 2020	4,055		12
Balance at Mar. 31, 2020	$ 402		$ (1,721)	182,580	(192,159)
Treasury stock purchased
Balance, shares at Dec. 31, 2019	3,932		12
Balance at Dec. 31, 2019	$ 393	(4,479)	$ (1,721)	182,514	(185,665)
Net loss		(18,308)
Balance, ending balance shares at Sep. 30, 2020	4,060		19
Balance at Sep. 30, 2020	$ 402	(21,798)	$ (1,770)	183,543	(203,973)
Balance, shares at Dec. 31, 2019	3,932		12
Balance at Dec. 31, 2019	$ 393	(4,479)	$ (1,721)	182,514	(185,665)
Net loss		(26,451)
Balance, ending balance shares at Dec. 31, 2020	4,075		20
Balance at Dec. 31, 2020	$ 402	(29,083)	$ (1,773)	184,404	(212,116)
Balance, shares at Mar. 31, 2020	4,055		12
Balance at Mar. 31, 2020	$ 402		$ (1,721)	182,580	(192,159)
Common stock issued, shares
Common stock issued
Treasury stock purchased			$ (49)
Treasury stock purchased, shares			7
Stock-based compensation expense				400
Net loss					(5,580)
Balance, ending balance shares at Jun. 30, 2020	4,055		19
Balance at Jun. 30, 2020	$ 402		$ (1,770)	182,980	(197,739)
Treasury stock purchased			49
Common stock issued, shares	5
Common stock issued
Common stock issued through ESPP, shares
Common stock issued through ESPP
Treasury stock purchased
Treasury stock purchased, shares
Dividends accrued
Stock-based compensation expense				563
Net loss		(6,234)			(6,234)
Balance, ending balance shares at Sep. 30, 2020	4,060		19
Balance at Sep. 30, 2020	$ 402	(21,798)	$ (1,770)	183,543	(203,973)
Treasury stock purchased
Common stock issued, shares	15
Common stock issued
Common stock issued through market sales, shares
Common stock issued through market sales
Treasury stock purchased			$ (3)
Treasury stock purchased, shares			1
Dividends accrued
Stock-based compensation expense				861
Net loss					(8,143)
Balance, ending balance shares at Dec. 31, 2020	4,075		20
Balance at Dec. 31, 2020	$ 402	(29,083)	$ (1,773)	184,404	(212,116)
Treasury stock purchased			3
Common stock issued, shares	9
Common stock issued				108
Restricted stock issued, shares	12
Restricted stock issued
Common stock issued through market sales, shares
Common stock issued through market sales
Common stock issued through ESPP, shares	36
Common stock issued through ESPP
Treasury stock purchased
Treasury stock purchased, shares
Extinguishment of Series A Shares
Beneficial Conversion Feature in connection with Series B Issuance
Amortization of Beneficial Conversion Feature
Stock-based compensation expense				286
Net loss					(4,207)
Balance, ending balance shares at Mar. 31, 2021	4,132,000		20
Balance at Mar. 31, 2021	$ 402		$ (1,773)	184,798	(216,323)
Treasury stock purchased
Balance, shares at Dec. 31, 2020	4,075		20
Balance at Dec. 31, 2020	$ 402	(29,083)	$ (1,773)	184,404	(212,116)
Net loss		(11,214)
Balance, ending balance shares at Sep. 30, 2021	4,194		20
Balance at Sep. 30, 2021	$ 403	(38,648)	$ (1,773)	186,052	(223,330)
Balance, shares at Mar. 31, 2021	4,132,000		20
Balance at Mar. 31, 2021	$ 402		$ (1,773)	184,798	(216,323)
Common stock issued, shares	10
Common stock issued
Treasury stock purchased
Treasury stock purchased, shares
Stock-based compensation expense				551
Net loss					(3,446)
Balance, ending balance shares at Jun. 30, 2021	4,142		20
Balance at Jun. 30, 2021	$ 402		$ (1,773)	185,349	(219,769)
Treasury stock purchased
Common stock issued, shares	13
Common stock issued				226
Common stock issued through ESPP, shares	39
Common stock issued through ESPP	$ 1
Treasury stock purchased
Treasury stock purchased, shares
Stock-based compensation expense				477
Net loss		(3,561)			(3,561)
Balance, ending balance shares at Sep. 30, 2021	4,194		20
Balance at Sep. 30, 2021	$ 403	$ (38,648)	$ (1,773)	$ 186,052	$ (223,330)
Treasury stock purchased

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Cash Flows From Operating Activities
Net loss	$ (11,214)	$ (18,308)	$ (26,451)	$ (26,740)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	4,350	4,102	5,501	4,524
Interest accretion	375	414	549	440
Reversal of 2019 bonus accrual		(1,156)	(1,156)
Bad debt expense	(140)	250	585	499
Mark to market on warrants	137	(62)	(61)	(279)
Stock-based compensation	1,228	1,354	2,187	1,535
Amortization of deferred financing fees	110
Accrued interest - Related Parties	372
ESPP expense	86	27	55
Change in fair value of contingent consideration	(57)		(489)	(44)
Deferred income taxes			37	18
Change in estimate on collectability of accounts receivable				3,479
Asset impairment			37
Gain on DiamiR transaction	(235)
Other gains and expenses, net	(2)			(18)
Other changes in operating assets and liabilities:
Decrease (increase) in accounts receivable	1,788	1,625	1,725	(1,102)
Decrease in other current assets	(413)	(898)	241	129
Increase in other long-term assets	(14)			11
Decrease in accounts payable	(2,084)	(1,319)	(198)	(938)
Increase in accrued salaries and bonus	(433)	129	1,976	362
Increase (decrease) in accrued liabilities	(1,349)	1,472	1,395	(1,301)
Increase in long-term liabilities	(6)	(25)	88	454
Net cash used in operating activities	(7,501)	(12,395)	(13,979)	(18,957)
Cash Flows From Investing Activity
Purchase of property and equipment	(192)	(1,275)	(1,575)	(131)
Acquisition of Biopharma, net of cash acquired				13,829
Sale of property and equipment	39			13
Net cash used in investing activities	(153)	(1,275)	(1,575)	(13,947)
Cash Flows From Financing Activities
Issuance of common stock, net of expenses	335	434	434	6,478
Issuance of Series B preferred stock, net of expenses		19,223	19,223
Issuance of preferred stock, net of expenses				25,744
Payment of CGIX note and related interest				(6,024)
Loan proceeds - related parties	7,500
Deferred financing fees	(123)
Payments on line of credit		(3,000)
(Payments) borrowings on Line of Credit			(3,000)	3,000
Cash paid for repurchase of restricted shares			(52)	(41)
Net cash provided by financing activities	7,712	16,657	16,605	29,157
Net increase (decrease) in cash, cash equivalents and restricted cash	58	2,987	1,051	(3,747)
Cash, cash equivalents and restricted cash – beginning	3,372	2,321	2,321	6,068
Cash, cash equivalents and restricted cash – ending	$ 3,430	$ 5,308	$ 3,372	$ 2,321

OVERVIEW

OVERVIEW	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
OVERVIEW	OVERVIEW Nature of Business Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs. COVID-19 pandemic The outbreak of the COVID-19 pandemic continues to impact a significant portion of the regions in which we operate. The continuing impact that the COVID-19 pandemic will have on our operations, including duration, severity and scope, remains highly uncertain and cannot be fully predicted at this time. While we believe we have generally recovered from the adverse impact that the COVID-19 pandemic had on our business during 2020, we believe that the COVID-19 pandemic could continue to adversely impact our results of operations, cash flows and financial condition in the future. As our business operations continue to be impacted by the pandemic, we continue to monitor the situation and the guidance that is being provided by relevant federal, state and local public health authorities. We may take additional actions based upon their recommendations. However, it is possible that we may have to make further adjustments to our operating plans in reaction to developments that are beyond our control. While we do not anticipate any lab closures at this time beyond periodic, temporary work stoppages to clean and disinfect the labs, this could change in the future based upon conditions caused by the pandemic. It is also possible that we could experience supply chain shortages if the pandemic worsens and if one or more suppliers is unable to continue to provide us with supplies. For the foreseeable future, however, we do not anticipate supply chain shortages of critical supplies. We have developed and will continue to update our contingency plans in order to mitigate pandemic-related, adverse financial impacts upon our business. Transition costs To optimize the operations of laboratory operations within our pharma services, we transitioned activities from the Rutherford, NJ facility to our Morrisville, NC facility. We invested several million dollars to facilitate this relocation, including but not limited to the transfer of personnel, expansion of the Morrisville facility and validation of transferred processes. We believe that this investment will result in a reduction in future operating costs; however, it is not certain whether we will fully realize the anticipated savings. We have also undergone several other cost-cutting initiatives and those costs are categorized as transition expenses as well.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	2. BASIS OF PRESENTATION The accompanying unaudited interim condensed consolidated financial statements and related notes (the “Interim Financial Statements”) should be read in conjunction with the consolidated financial statements of the Company and its wholly-owned subsidiaries (Interpace Diagnostics Lab Inc., Interpace Diagnostics Corporation, Interpace Pharma Solutions, Inc. and Interpace Diagnostics, LLC), and related notes as included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2020, as filed with the Securities & Exchange Commission (“SEC”) on April 1, 2021 and as amended on April 29, 2021 and August 20, 2021. The condensed Interim Financial Statements of the Company have been prepared in accordance with generally accepted accounting principles in the United States (“GAAP”) for interim financial reporting and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by GAAP for complete financial statements. The condensed Interim Financial Statements include all normal recurring adjustments that, in the judgment of management, are necessary for a fair presentation of such interim financial statements. Discontinued operations include the Company’s wholly owned subsidiaries: Group DCA, LLC, InServe Support Solutions; and TVG, Inc. and its Commercial Services business unit which was sold on December 22, 2015. All significant intercompany balances and transactions have been eliminated in consolidation. Operating results for the nine-month period ended September 30, 2021 are not necessarily indicative of the results that may be expected for the fiscal year ending December 31, 2021.

LIQUIDITY

LIQUIDITY	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY	3. LIQUIDITY The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty. As of September 30, 2021, the Company had cash and cash equivalents, net of restricted cash of $ 3.2 million, net accounts receivable of $ 6.5 million, total current assets, net of restricted cash of $ 12.8 million and total current liabilities of $ 22.8 million. For the nine month period ended September 30, 2021, the Company had a net loss of $ 11.2 million and cash used in operating activities was $ 7.5 million. As of November 5, 2021 we had approximately $ 2.4 million of cash on hand, net of restricted cash. The Company has and may continue to delay, scale-back, or eliminate certain of its activities and other aspects of its operations until such time as the Company is successful in securing additional funding. The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources. The delisting from Nasdaq of our common stock which is now quoted for trading on OTCQX and the Company’s resulting inability to use Form S-3 for offerings by it may each have an adverse impact on our ability to raise additional capital. The quotation of our common stock on OTCQX may provide significantly less liquidity than when our stock was listed on Nasdaq and we may experience greater difficulty in raising capital through the public or private sale of equity securities. The future success of the Company is dependent upon its ability to obtain additional funding. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. In October 2021, the Company entered into a $7.5 million revolving credit facility with Comerica Bank (“Comerica Loan Agreement”). In addition, also in October 2021, the Company entered into a new $8.0 million term loan with BroadOak Fund V, L.P. (“BroadOak”) (“BroadOak Term Loan”), the proceeds of which were used to repay in full at their maturity the notes extended by Ampersand 2018 Limited Partnership (“Ampersand”) and 1315 Capital II, L.P. (“1315 Capital”). See Note 20, Subsequent Events	4. Going Concern LIQUIDITY The accompanying consolidated financial statements have been prepared on a basis that assumes that the Company will continue as a going concern and that contemplates the continuity of operations, the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. Accordingly, the accompanying consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts of liabilities that might result from the outcome of this uncertainty. As of December 31, 2020, the Company had cash and cash equivalents of $ 2.8 8.0 14.1 18.2 26.5 14.0 3.4 Revolver Subsequent Events In September 2019, we entered into the Equity Distribution Agreement (the “Equity Distribution Agreement”) with Oppenheimer & Co. Inc., as sales agent (the “Agent”), pursuant to which we, from time to time, issued and sold shares of our common stock with an aggregate offering price of up to $ 3.7 178,000 0.7 In addition, we are currently ineligible to use a Form S-3 shelf registration statement. In January 2020, we sold 20,000 19.2 Equity During April 2020, the Company applied for various federal stimulus grants and advances made available under Title 1 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (the “CARES Act”). As of September 30, 2020, we received $ 2.1 0.65 2.1 During April and early May 2020, the Company made payments totaling $ 888,000 On January 7, 2021, the Company entered into a $ 3 2 8.0 June 30, 2021 Subsequent Events The Company’s cash and cash equivalents balance is decreasing and we will not generate positive cash flows from operations for the year ending December 31, 2021. We intend to meet our ongoing capital needs by using our available cash, including the loans from Ampersand and 1315 Capital, as well as revenue growth and margin improvement; collection of accounts receivable; containment of costs; and the potential use of other financing options. The Company has and may continue to delay, scale-back, or eliminate certain of its activities and other aspects of its operations until such time as the Company is successful in securing additional funding. The Company is exploring various dilutive and non-dilutive sources of funding, including equity and debt financings, strategic alliances, business development and other sources. As a result of the Company’s Common Stock being delisted from Nasdaq due to its failure to meet minimum stockholders’ equity requirements, the Company’s ability to raise additional capital may be materially adversely impacted. In addition, the Company’s inability to use Form S-3 after it files its Form 10-K for the fiscal year ended December 31, 2020 may have an adverse impact on our ability to raise additional capital. The future success of the Company is dependent upon its ability to obtain additional funding. There can be no assurance, however, that the Company will be successful in obtaining such funding in sufficient amounts, on terms acceptable to the Company, or at all. As of the date of this Report, the Company currently anticipates that current cash and cash equivalents will be sufficient to meet its anticipated cash requirements through the end of the second quarter. These factors raise substantial doubt about the Company’s ability to continue as a going concern. As of March 25, 2021 we had approximately $ 3.2

SUMMARY OF SIGNIFICANT ACCOUNTI

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	9 Months Ended
	Sep. 30, 2021
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	4. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Accounting Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates. Revenue Recognition Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become known. For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract while performance-related obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer. Deferred Revenue For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract. Financing and Payment For non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical services are typically thirty days and in our pharma services, up to sixty days. Commercial third-party-payers are required to respond to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers. We bill Medicare directly for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full. Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed in the period in which they have been earned. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations. Accounts Receivable The Company’s accounts receivables represent unconditional rights to consideration and are generated using its clinical services and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer. Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7, Leases Other Current Assets Other current assets consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF OTHER CURRENT ASSETS September 30, 2021 December 31, 2020 (unaudited) Lab supply inventory $ 2,271 $ 2,052 Prepaid expenses 734 625 Other 130 45 Funds in escrow - - Total other current assets $ 3,135 $ 2,722 Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related amortization expense in the condensed consolidated statements of operations. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. Basic and Diluted Net Loss per Share A reconciliation of the number of shares of common stock, par value $ 0.01 SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Basic weighted average number of common shares 4,165 4,038 4,119 4,025 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 4,165 4,038 4,119 4,025 The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Options 684 878 684 878 Restricted stock and restricted stock units (RSUs) 366 28 366 28 Warrants 1,405 1,405 1,405 1,405 2,455 2,311 2,455 2,311 Reclassifications The Company reclassified certain prior period balances to conform to the current year presentation.

GOODWILL AND OTHER INTANGIBLE A

GOODWILL AND OTHER INTANGIBLE ASSETS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
GOODWILL AND OTHER INTANGIBLE ASSETS	5. GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill is attributable to the acquisition of our pharma services in July 2019. The carrying value of the intangible assets acquired was $ 15.6 8.3 7.3 0.1 8.4 SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE As of As of Life Carrying Carrying (Years) Amount Amount (unaudited) Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett’s test 9 6,682 6,682 BioPharma acquisition: Trademarks 10 1,600 1,600 Customer relationships 8 5,700 5,700 CLIA Lab 2.3 609 609 Total $ 39,251 $ 39,251 Accumulated Amortization $ (31,237 ) $ (27,900 ) Net Carrying Value $ 8,014 $ 11,351 Amortization expense was approximately $ 1.1 3.3 SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE 2021 2022 2023 2024 2025 $ 1,112 $ 2,155 $ 2,099 $ 873 $ 873 The following table displays a roll forward of the carrying amount of goodwill from December 31, 2020 to September 30, 2021: SCHEDULE OF GOODWILL CARRYING VALUE Carrying Amount Balance as of December 31, 2020 $ 8,433 Adjustments - Balance as of September 30, 2021 $ 8,433	8. Goodwill and Other Intangible Assets GOODWILL AND OTHER INTANGIBLE ASSETS Goodwill is attributable to the acquisition of the Biopharma business from CGI in July 2019. The carrying value of the intangible assets acquired was $ 15.6 8.3 7.3 8.4 SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE As of As of Life Carrying Carrying (Years) Amount Amount Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett’s test 9 6,682 6,719 BioPharma acquisition: Trademarks 10 1,600 1,600 Customer relationships 8 5,700 5,700 CLIA Lab 2.3 $ 609 $ 609 Total $ 39,251 $ 39,288 Accumulated Amortization $ (27,900 ) $ (23,439 ) Net Carrying Value $ 11,351 $ 15,849 The following table displays a roll forward of the carrying amount of goodwill from January 1, 2019 to December 31, 2020: SCHEDULE OF GOODWILL CARRYING VALUE Carrying Amount Balance as of January 1, 2019 $ - Goodwill acquired 8,273 Adjustments 160 Balance as of December 31, 2019 8,433 Adjustments - Balance as of December 31, 2020 $ 8,433 Amortization expense was approximately $ 4.5 4.0 Schedule of Future Estimated Amortization Expense 2021 2022 2023 2024 2025 $ 4,078 $ 2,156 $ 1,745 $ 873 $ 873

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	6. FAIR VALUE MEASUREMENTS Cash and cash equivalents, accounts receivable and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the condensed consolidated financial statements include contingent consideration and warrant liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows: Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities. Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities. Level 3: Valuations incorporate certain assumptions and projections in determining the fair value assigned to such assets or liabilities. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below: SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS As of September 30, 2021 Fair Value Measurements Carrying Fair As of September 30, 2021 Amount Value Level 1 Level 2 Level 3 (unaudited) Liabilities: Contingent consideration: Asuragen (1) $ 2,136 $ 2,136 $ $ - $ 2,136 Other long-term liabilities: Warrant liability (2) 158 158 - - 158 $ 2,294 $ 2,294 $ - $ - $ 2,294 As of December 31, 2020 Fair Value Measurements Carrying Fair As of December 31, 2020 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 2,216 $ 2,216 $ - $ - $ 2,216 Other long-term liabilities: Warrant liability (2) 21 21 - - 21 $ 2,237 $ 2,237 $ - $ - $ 2,237 (1)(2) Accrued Expenses and Long-Term Liabilities (1) See Note 9, Accrued Expenses and Long-Term Liabilities (2) See Note 9, Accrued Expenses and Long-Term Liabilities In connection with the acquisition of certain assets from Asuragen, Inc., the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement. A roll forward of the carrying value of the Contingent Consideration Liability and the 2017 Underwriters’ Warrants to September 30, 2021 is as follows: SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION Cancellation of Obligation/ Adjustment to Fair Value/ December 31, 2020 Payments Accretion Conversions Exercises Mark to Market September 30, (unaudited) Contingent consideration liability $ 2,216 $ (398 ) $ 375 $ $ (57 ) $ 2,136 Underwriters Warrants 21 - - - 137 158 $ 2,237 $ (398 ) $ 375 $ - $ 80 $ 2,294 Certain of the Company’s non-financial assets, such as other intangible assets and goodwill, are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.	6. Fair Value Measurements FAIR VALUE MEASUREMENTS Cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their relative short-term nature. The Company’s financial liabilities reflected at fair value in the consolidated financial statements include contingent consideration and warrant liability. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In determining fair value, the Company uses various methods including market, income and cost approaches. Based on these approaches, the Company often utilizes certain assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and/or the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market-corroborated, or generally unobservable inputs. The Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs. Based upon observable inputs used in the valuation techniques, the Company is required to provide information according to the fair value hierarchy. The fair value hierarchy ranks the quality and reliability of the information used to determine fair values into three broad levels as follows: Level 1: Valuations for assets and liabilities traded in active markets from readily available pricing sources for market transactions involving identical assets or liabilities. Level 2: Valuations for assets and liabilities traded in less active dealer or broker markets. Valuations are obtained from third-party pricing services for identical or similar assets or liabilities. Level 3: Valuations for assets and liabilities include certain unobservable inputs in the assumptions and projections used in determining the fair value assigned to such assets or liabilities. In instances where the determination of the fair value measurement is based on inputs from different levels of the fair value hierarchy, the level in the fair value hierarchy within which the entire fair value measurement falls is based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular input to the fair value measurement in its entirety requires judgment and considers factors specific to the asset or liability. The valuation methodologies used for the Company’s financial instruments measured on a recurring basis at fair value, including the general classification of such instruments pursuant to the valuation hierarchy, is set forth in the tables below. SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS As of December 31, 2020 Fair Value Measurements Carrying Fair As of December 31, 2020 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 2,216 $ 2,216 $ - $ - $ 2,216 Other long-term liabilities: Warrant liability (2) 21 21 - - 21 $ 2,237 $ 2,237 $ - $ - $ 2,237 As of December 31, 2019 Fair Value Measurements Carrying Fair As of December 31, 2019 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 2,893 $ 2,893 $ - $ - $ 2,893 Other long-term liabilities: Warrant liability (2) 82 82 - - 82 $ 2,975 $ 2,975 $ - $ - $ 2,975 In connection with the acquisition of certain assets from Asuragen, the Company recorded contingent consideration related to contingent payments and other revenue-based payments. The Company determined the fair value of the contingent consideration based on a probability-weighted income approach derived from revenue estimates. The fair value measurement is based on significant inputs not observable in the market and thus represents a Level 3 measurement. SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION Cancellation Adjustment of Obligation/ to Fair Value/ December 31, Payments Accretion Conversions Exercises Mark to Market December 31, Asuragen $ 2,893 $ (737 ) $ 549 $ - $ (489 ) $ 2,216 Underwriters Warrants 82 - - - (61 ) 21 $ 2,975 $ (737 ) $ 549 $ - $ (550 ) $ 2,237 Certain of the Company’s non-financial assets, such as other intangible assets are measured at fair value on a nonrecurring basis when there is an indicator of impairment and recorded at fair value only when an impairment charge is recognized.

LEASES

LEASES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Leases
LEASES	7. LEASES Finance lease assets are included in fixed assets, net of accumulated depreciation. The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet: SCHEDULE OF FINANCING AND OPERATING LEASES Classification on the Balance Sheet September 30, December 31, (unaudited) Assets Financing lease assets Property and equipment, net $ 652 $ 597 Operating lease assets Operating lease right of use assets 3,989 4,384 Total lease assets $ 4,641 $ 4,981 Liabilities Current Financing lease liabilities Other accrued expenses $ 98 $ 177 Operating lease liabilities Other accrued expenses 1,030 1,027 Total current lease liabilities $ 1,128 $ 1,204 Noncurrent Financing lease liabilities Other long-term liabilities 75 138 Operating lease liabilities Operating lease liabilities, net of current portion 3,152 3,540 Total long-term lease liabilities 3,227 3,678 Total lease liabilities $ 4,355 $ 4,882 The weighted average remaining lease term for the Company’s operating leases was 6.6 7.1 6.4% 6.0% The table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of September 30, 2021: SCHEDULE OF MATURITIES OF OPERATING AND FINANCING LEASE LIABILITIES Operating Leases Financing Leases 2021 (remaining through December 31) 312 39 2022 1,192 86 2023 794 60 2024 473 - 2025 402 - 2026 414 - Thereafter 1,510 - Total minimum lease payments 5,097 185 Less: amount of lease payments representing effects of discounting 915 12 Present value of future minimum lease payments 4,182 173 Less: current obligations under leases 1,030 98 Long-term lease obligations $ 3,152 $ 75 As of September 30, 2021, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year were as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES Less than 1 to 3 3 to 5 After Total 1 Year Years Years 5 Years Operating lease obligations $ 5,097 $ 312 $ 1,986 $ 875 $ 1,924 Total $ 5,097 $ 312 $ 1,986 $ 875 $ 1,924	9. Leases LEASES In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842), which establishes a ROU model that requires a lessee to record a ROU asset and a lease liability, measured on a discounted basis, on the balance sheet for all leases with terms longer than 12 months. Effective January 1, 2019, the Company adopted the provisions of Topic 842 using the alternative modified transition method, with a cumulative effect adjustment to the opening balance of accumulated deficit on the date of adoption, and prior periods not restated, as allowed under the provisions of Topic 842. The Company also elected to use the practical expedients permitted under the transition guidance of Topic 842, which provides for the following: the carryforward of the Company’s historical lease classification, no requirement for reassessment of whether an expired or existing contract contains an embedded lease, no reassessment of initial direct costs for any leases that exist prior to the adoption of the new standard, and the election to consolidate lease and non-lease components. The Company also elected to keep all leases with an initial term of 12 months or less off the balance sheet. The Company recorded $ 2.4 2.5 0.1 2.2 0.5 The table below presents the lease-related assets and liabilities recorded in the Consolidated Balance Sheet: SCHEDULE OF FINANCING AND OPERATING LEASES Classification on the Balance Sheet December 31, 2020 (unaudited) Assets Financing lease assets Property and equipment, net $ 597 Operating lease assets Operating lease right of use assets 4,384 Total lease assets $ 4,981 Liabilities Current Financing lease liabilities Other accrued expenses $ 177 Operating lease liabilities Other accrued expenses 1,027 Total current lease liabilities $ 1,204 Noncurrent Financing lease liabilities Other long-term liabilities 138 Operating lease liabilities Operating lease liabilities, net of current portion 3,540 Total long-term lease liabilities 3,678 Total lease liabilities $ 4,882 The weighted average remaining lease term for the Company’s operating leases was 7.1 6.0 0.5 In June 2020, the Company entered into an amendment of its North Carolina lease extending it for an additional ten years, commencing on June 1, 2020 and continuing until May 31, 2030. The minimum rent per rentable square foot pursuant to the amendment is $14.10 from June 1, 2020 to May 31, 2021, with annual increases of 3 the Company has two options to extend the term for a period of five years the Company has the irrevocable right to terminate the lease on November 30, 2025, as well as on November 30, 2027. 2.8 The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Consolidated Balance Sheet as of December 31, 2020: Schedule of Maturities of Operating and Financing Lease Liabilities Operating Leases Financing Leases 2021 1,235 185 2022 1,028 78 2023 629 65 2024 390 - 2024-2030 2,327 Total minimum lease payments 5,609 329 Less: amount of lease payments representing effects of discounting 1,042 14 Present value of future minimum lease payments 4,567 315 Less: current obligations under leases 1,027 177 Long-term lease obligations $ 3,540 $ 138

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	8. COMMITMENTS AND CONTINGENCIES Litigation From time to time, the Company may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. When the Company is aware of a claim or potential claim, it assesses the likelihood of any loss or exposure. If it is probable that a loss will result and the amount of the loss can be reasonably estimated, the Company will record a liability for the loss. In addition to the estimated loss, the recorded liability includes probable and estimable legal costs associated with the claim or potential claim. Litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm the Company’s business. There is currently litigation involving the Company at this time. Due to the nature of the businesses in which the Company is engaged, it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products or services that the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities. There is also the risk of employment related litigation and other litigation in the ordinary course of business. The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.	12. Commitments and Contingencies COMMITMENTS AND CONTINGENCIES The Company leases facilities and certain equipment under agreements classified as operating leases, which expire at various dates through May 2030 2.1 1.3 As of December 31, 2020, contractual obligations with terms exceeding one SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES Less than 1 to 3 3 to 5 After Total 1 Year Years Years 5 Years Operating lease obligations $ 5,609 $ 1,235 $ 1,657 $ 793 $ 1,924 Litigation Due to the nature of the businesses in which the Company is engaged it is subject to certain risks. Such risks include, among others, risk of liability for personal injury or death to persons using products the Company promotes or commercializes. There can be no assurance that substantial claims or liabilities will not arise in the future due to the nature of the Company’s business activities and recent increases in litigation related to healthcare products. The Company could also be held liable for errors and omissions of its employees in connection with the services it performs that are outside the scope of any indemnity or insurance policy. The Company could be materially adversely affected if it were required to pay damages or incur defense costs in connection with a claim that is outside the scope of an indemnification agreement; if the indemnity, although applicable, is not performed in accordance with its terms; or if the Company’s liability exceeds the amount of applicable insurance or indemnity.

ACCRUED EXPENSES AND LONG-TERM

ACCRUED EXPENSES AND LONG-TERM LIABILITIES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND LONG-TERM LIABILITIES	9. ACCRUED EXPENSES AND LONG-TERM LIABILITIES Other accrued expenses consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF OTHER ACCRUED EXPENSES September 30, 2021 December 31, 2020 (unaudited) Accrued royalties $ 3,572 $ 2,710 Upfront Medicare payment - 2,066 Operating lease liabilities 1,030 1,027 All others 1,056 1,182 Accrued professional fees 931 854 Unclaimed property 565 565 Contingent consideration 473 398 Accrued pharma services invoices 438 108 Taxes payable 248 334 Accrued lab costs - diagnostics 514 161 Financing lease liabilities 98 177 ESPP payable 37 108 Accrued sales and marketing - diagnostics 41 51 Deferred revenue 40 54 Total other accrued expenses $ 9,043 $ 9,795 Long-term liabilities consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF LONG TERM LIABILITIES September 30, 2021 December 31, 2020 (unaudited) Uncertain tax positions $ 4,517 $ 4,342 Warrant liability 158 21 Financing lease liabilities 75 138 Deferred revenue 18 136 Other - 138 Total other long-term liabilities $ 4,768 $ 4,637	11. Accrued Expenses and Other Long-Term Liabilities Other accrued expenses consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF OTHER ACCRUED EXPENSES December 31, 2020 December 31, 2019 Accrued royalties $ 2,710 $ 1,934 Contingent consideration 398 502 Upfront Medicare payment 2,066 - Operating lease liability 1,027 1,321 Financing lease liability 177 184 Deferred revenue 54 457 Payable to CGI - 888 Accrued sales and marketing - diagnostics 51 197 Accrued lab costs - diagnostics 161 163 Accrued professional fees 854 1,399 Taxes payable 334 403 Unclaimed property 565 565 All others 1,398 1,463 Total other accrued expenses $ 9,795 $ 9,476 Other long-term liabilities consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF LONG TERM LIABILITIES December 31, 2020 December 31, 2019 Warrant liability $ 21 $ 82 Uncertain tax positions 4,342 4,081 Deferred revenue 136 269 Other 138 141 Total other long-term liabilities $ 4,637 $ 4,573 In the third quarter of 2020, the Company reversed approximately $ 1.2

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	10. STOCK-BASED COMPENSATION Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board. The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the nine-month periods ended September 30, 2021 and 2020. SCHEDULE OF FAIR VALUE ASSUMPTIONS OF STOCK OPTIONS September 30, 2021 September 30, 2020 (unaudited) Risk-free interest rate 0.78 % 0.79 % Expected life 6.0 6.6 Expected volatility 134.79 % 122.24 % Dividend yield - - During March 2021, the Company granted 312,500 6.00 152,500 5.00 0.5 0.6 1.3 1.4 SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Cost of revenue $ 52 $ 60 $ 154 $ 187 Sales and marketing 76 39 201 136 Research and development 24 30 83 99 General and administrative* 325 434 876 959 Total stock compensation expense $ 477 $ 563 $ 1,314 $ 1,381 * Includes ESPP expense	15. Stock-Based Compensation STOCK-BASED COMPENSATION The Company’s stock-incentive program is a long-term retention program that is intended to attract, retain and provide incentives for talented employees, officers and directors, and to align stockholder and employee interests. Currently, the Company is able to grant options, stock appreciation rights (“SARs”) and restricted shares from the Interpace Biosciences, Inc. 2019 Equity Incentive Plan. No new grants may be made under the Company’s prior stock incentive plan, the Interpace Diagnostics Group, Inc. (now known as Interpace Biosciences, Inc.) Amended and Restated 2004 Stock Award and Incentive Plan (the “2004 Plan”). Unless earlier terminated by action of the Company’s board of directors, the 2004 Plan will remain in effect until such time as no stock remains available for delivery and the Company has no further rights or obligations under the 2004 Plan with respect to outstanding awards thereunder. Historically, stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and RSUs granted to Board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options and SARs. The determination of the fair value of stock-based payment awards on the date of grant using an option-pricing model is affected by the Company’s stock price as well as assumptions regarding a number of complex and subjective variables. These variables include the Company’s expected stock price volatility over the term of the awards, actual and projected employee stock option exercise behaviors, risk-free interest rate and expected dividends. Expected volatility is based on historical volatility. As there is no trading volume for the Company’s options, implied volatility is not representative of the Company’s current volatility so the historical volatility of the Company’s common stock is determined to be more indicative of the Company’s expected future stock performance. The expected life is determined using the safe-harbor method. The Company expects to use this simplified method for valuing employee options until more detailed information about exercise behavior becomes available over time. The Company bases the risk-free interest rate on U.S. Treasury zero-coupon issues with remaining terms similar to the expected term on the options. The Company does not anticipate paying any cash dividends in the foreseeable future and therefore uses an expected dividend yield of zero in the option valuation model. The Company is required to estimate forfeitures at the time of grant and revise those estimates in subsequent periods if actual forfeitures differ from those estimates. The Company uses historical data to estimate pre-vesting option forfeitures and records stock-based compensation expense only for those awards that are expected to vest. The Company recognizes compensation cost, net of estimated forfeitures, arising from the issuance of stock options and SARs on a straight-line basis over the vesting period of the grant. The Company began an employee stock purchase plan in 2020 and recognized approximately $ 0.04 The estimated compensation cost associated with the granting of restricted stock and restricted stock units is based on the fair value of the Company’s common stock on the date of grant. The Company recognizes the compensation cost, net of estimated forfeitures, arising from the issuance of restricted stock and restricted stock units on a straight-line basis over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. The following table provides the weighted average assumptions used in determining the fair value of the stock options granted during the years ended December 31, 2020 and December 31, 2019. Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions December 31, 2020 December 31, 2019 Risk-free interest rate 0.75 % 2.34 % Expected life 6.5 5.9 Expected volatility 123.71 % 128.58 % Dividend yield - - The weighted-average fair value of stock options granted during the year ended December 31, 2020 was estimated to be $ 5.36 8.50 Stock-based compensation for the years ended December 31, 2020 and 2019 is as follows: Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award 2020 2019 RSUs and restricted stock $ 176 $ 243 Performance-based awards 265 - Common stock awards 116 - Options 1,630 722 Total stock-based compensation expense $ 2,187 $ 965 A summary of stock option and SARs activity for the year ended December 31, 2020, and changes during such year, is presented below: Schedule of Stock Option Activity Weighted- Weighted-Average Average Remaining Aggregate Grant Contractual Intrinsic Shares Price Period (in years) Value Outstanding at January 1, 2020 415,678 $ 12.50 8.45 $ Granted 525,550 6.24 9.39 - Exercised - Forfeited or expired (92,409 ) 11.18 - Outstanding at December 31, 2020 848,819 8.76 8.59 - Exercisable at December 31, 2020 361,501 11.81 7.77 - Vested and expected to vest 659,465 9.48 8.39 - A summary of the status of the Company’s non-vested options for the year ended December 31, 2020, and changes during such year, is presented below: Schedule of Non Vested Option Activity Shares Weighted- Average Grant Date Fair Value Nonvested at January 1, 2020 213,472 $ 8.80 Granted 525,550 5.36 Vested (197,998 ) 7.34 Forfeited (53,706 ) 7.86 Nonvested at December 31, 2020 487,318 $ 5.81 The aggregate fair value of options vested during the years ended December 31, 2020 and 2019 was $ 1.5 0.5 9.00 A summary of the Company’s non-vested shares of restricted stock and restricted stock units for the year ended December 31, 2020, and changes during such year, is presented below: Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity Weighted- Average Average Remaining Aggregate Grant Date Vesting Intrinsic Shares Fair Value Period (in years) Value Nonvested at January 1, 2020 49,366 $ 10.04 1.11 $ 246,830 Granted 236,321 3.43 - - Vested (43,976 ) 9.52 - - Forfeited (2,254 ) 10.10 - - Nonvested at December 31, 2020 239,457 $ 3.61 1.75 $ 751,895 The aggregate fair value of restricted stock units vested during each of the years ended December 31, 2020 and 2019 was $ 0.4 0.2 As of December 31, 2020, there was approximately $ 2.5

INCOME TAXES

INCOME TAXES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
INCOME TAXES	11. INCOME TAXES Generally, accounting standards require companies to provide for income taxes each quarter based on their estimate of the effective tax rate for the full year. The authoritative guidance for accounting for income taxes allows use of the discrete method when it provides a better estimate of income tax expense. Due to the Company’s valuation allowance position, it is the Company’s position that the discrete method provides a more accurate estimate of income tax expense and therefore income tax expense for the current quarter has been presented using the discrete method. As the year progresses, the Company refines its estimate based on the facts and circumstances by each tax jurisdiction. The following table summarizes income tax expense on loss from continuing operations and the effective tax rate for three- and nine-month periods ended September 30, 2021 and 2020: SCHEDULE OF EFFECTIVE INCOME TAX RATE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) (Benefit) provision for income tax $ (714 ) $ 14 $ (684 ) $ 43 Effective income tax rate 16.9 % 0.2 % 5.8 % 0.2 % The Company participated in the State of New Jersey’s Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by The New Jersey Economic Development Authority. The Program enables approved biotechnology companies with unused net operating losses (NOLs) and unused research and development credits to sell these benefits for at least 80% of the value of the tax benefits to unaffiliated, profitable corporate taxpayers in the State of New Jersey. The Program is administered by The New Jersey Economic Development Authority and the New Jersey Department of the Treasury’s Division of Taxation. In July 2021, the Company completed the sale of NOLs totaling approximately $0.7 million. This amount is a current state tax benefit and is reflected in the statement of operations for the three- and nine-months ended September 30, 2021. Income tax expense for both the three- and nine-month periods ended September 30, 2020 was primarily due to minimum state and local taxes.	17. Income Taxes INCOME TAXES The benefit from income taxes on continuing operations for the years ended December 31, 2020 and 2019 is comprised of the following: Schedule of Components of Income Tax Expense (Benefit) 2020 2019 Current: Federal $ - $ (46 ) State 16 - Total current 16 (46 ) Deferred: Federal 23 11 State 14 7 Total deferred 37 18 Benefit from income taxes $ 53 $ (28 ) The Company performs an analysis each year to determine whether the expected future income will more likely than not be sufficient to realize the deferred tax assets. The Company’s recent operating results and projections of future income weighed heavily in the Company’s overall assessment. As a result of this analysis, the Company continues to maintain a full valuation allowance against its federal and state net deferred tax assets at December 31, 2020 as the Company believes that it is more likely than not that these assets will not be realized. In the current year, the company maintains a full valuation allowance in consolidation and no separate company deferred tax liability recorded will be recorded. The tax effects of significant items comprising the Company’s deferred tax assets and (liabilities) as of December 31, 2020 and 2019 are as follows: Schedule of Deferred Tax Assets and Liabilities 2020 2019 Deferred tax assets: Federal net operating loss carryforwards $ 17,015 $ 11,664 State net operating loss carryforwards 2,953 1,834 Compensation 1,492 1,399 Allowances and reserves 436 457 Intangible assets 292 589 State taxes 900 848 Credit carryforward 229 229 163(j) interest 745 141 Leases 54 23 Deferred revenue 95 88 Valuation allowance (23,684 ) (17,027 ) Gross deferred tax assets 527 245 Deferred tax liability: Property and equipment (582 ) (263 ) Deferred tax liability-net valuation allowance $ (55 ) $ (18 ) The Company’s deferred tax asset and deferred tax liabilities are included within Other long-term liabilities 81.0 48.3 Under current federal income tax law, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of Federal Taxable Income, and current state net operating losses not utilized begin to expire this year. The NOL carry forwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL, and tax credit carry forwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code of 1986, as amended, or the Code, as well as similar state tax provisions. The amount of the annual limitation, if any, will be determined based on the value of our company immediately prior to an ownership change. Subsequent ownership changes may further affect the limitation in future years. Additionally, U.S. tax laws limit the time during which these carry forwards may be applied against future taxes, therefore, we may not be able to take full advantage of these carry forwards for federal income tax purposes. During 2020, the Company completed an assessment of the available NOLs under Section 382 and determined that the Company underwent an ownership change in 2017 and as a result, NOLs attributable to the pre-ownership change are subject to a substantial annual limitation under Section 382 of the Internal Revenue Code due to the ownership changes. The Company has adjusted their NOL carryforwards to address the impact of the 382 ownership change. This resulted in a reduction of available Federal and State NOLs of $ 153.8 60.6 A reconciliation of the difference between the federal statutory tax rates and the Company’s effective tax rate from continuing operations is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2020 2019 Federal statutory rate 21.0 % 21.0 % State income tax rate, net of Federal tax benefit 4.0 % 3.0 % Meals and entertainment (0.1 )% (0.2 )% Valuation allowance (25.0 )% (23.8 )% Naked credit (0.1 )% (0.1 )% Discontinued operations allocation 0.0 % 0.2 % Effective tax rate (0.2 )% 0.1 % The following table summarizes the change in uncertain tax benefit reserves for the two years ended December 31, 2020: Schedule of Unrecognized Tax Benefits Roll Forward Unrecognized Tax Benefits Balance of unrecognized benefits as of January 1, 2019 $ 877 Additions for tax positions of prior years - Balance as of January 1, 2020 $ 877 Additions for tax positions of prior years - Balance as of December 31, 2020 $ 877 As of December 31, 2020 and 2019, the total amount of gross unrecognized tax benefits was $ 0.9 0.9 0.9 0.9 The Company recognized interest and penalties of $ 0.3 0.3 3.4 3.1 Other long-term liabilities Management plans to commence filing tax clearance certificates in states and related tax jurisdictions in which un-recognized tax benefits attributable to its former operating entities are recorded as long-term liabilities on the accompanying balance sheet. This process can range from 6 to 18 months before the Company receives clearance as to balances, if any, it may owe to a particular state or tax jurisdiction. Upon receipt and acknowledgment from a state or tax jurisdiction, the Company will settle the remaining obligation or reverse the recorded amount owed during the period in which the tax clearance certificate is obtained. The Company and its subsidiaries file a U.S. Federal consolidated income tax return and consolidated and separate income tax returns in numerous states and local tax jurisdictions. The following tax years remain subject to examination as of December 31, 2020: Schedule of Tax Years Subject to Examination Jurisdiction Tax Years Federal 2016 2020 State and Local 2015 2020 To the extent there was a failure to file a tax return in a previous year; the statute of limitation will not begin until the return is filed. There were no examinations in process by the Internal Revenue Service as of December 31, 2020. In 2014, the Company was selected for examination by the Internal Revenue Service for the tax periods ending December 31, 2012 and December 31, 2011 that concluded in 2016 with no adjustments. The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017 and became effective for tax years beginning after December 31, 2017. The TCJA had significant changes to U.S. tax law, lowering U.S. corporate income tax rates, implementing a territorial tax system, imposing a one-time transition tax on deemed repatriated earnings of foreign subsidiaries and modified the taxation of other income and expense items. The TCJA reduces the U.S. corporate income tax rate from 34% to 21 21 22,768,303 22,768,303 Due to the timing of the new tax law and the substantial changes it brings, the staff of the Securities and Exchange Commission (the “SEC”) issued Staff Accounting Bulletin No. 118 (“SAB 118”), which provides registrants a measurement period to report the impact of the new US tax law. During the measurement period, provisional amounts for the effects of the law are recorded to the extent a reasonable estimate can be made. To the extent that all information necessary is not available, prepared or analyzed, companies may recognize provisional estimated amounts for a period of up to one year following enactment of the TCJA. The Company did not have any changes to provisional estimates.

SEGMENT INFORMATION

SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2021
Segment Reporting [Abstract]
SEGMENT INFORMATION	12. SEGMENT INFORMATION We operate under one

DISCONTINUED OPERATIONS

DISCONTINUED OPERATIONS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
DISCONTINUED OPERATIONS	13. DISCONTINUED OPERATIONS The components of liabilities classified as discontinued operations consist of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF DISCONTINUED OPERATIONS September 30, 2021 December 31, 2020 (unaudited) Accrued liabilities 766 766 Current liabilities from discontinued operations 766 766 Total liabilities $ 766 $ 766 The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the condensed consolidated statements of operations for the three- and nine-months ended September 30, 2021 and 2020. Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Income from discontinued operations, before tax $ - $ - $ - $ - Income tax expense 62 65 175 194 Loss from discontinued operations, net of tax $ (62 ) $ (65 ) $ (175 ) $ (194 )	5. Discontinued Operations DISCONTINUED OPERATIONS The Company accounts for business dispositions and its businesses held for sale in accordance with ASC 205-20, Discontinued Operations. ASC 205-20 requires the results of operations of business dispositions to be segregated from continuing operations and reflected as discontinued operations in current and prior periods. The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of December 31, 2020 and December 31, 2019: Schedule of Discontinued Operations Amount Recognized in Balance Sheet December 31, 2020 December 31, 2019 Accrued liabilities $ 766 $ 766 Current liabilities from discontinued operations 766 766 Total liabilities $ 766 $ 766 The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the consolidated statements of operations for the years ended December 31, 2020 and 2019. Schedule of Discontinued Operations Condensed Consolidated Statements of Operations 2020 2019 Years Ended December 31, 2020 2019 Income from discontinued operations, before tax $ - $ 220 Income tax expense 250 308 Loss from discontinued operations, net of tax $ (250 ) $ (88 )

NOTES PAYABLE _ RELATED PARTIES

NOTES PAYABLE – RELATED PARTIES	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
NOTES PAYABLE – RELATED PARTIES	14. NOTES PAYABLE – RELATED PARTIES Secured Promissory Notes On January 7, 2021, the Company entered into promissory notes with Ampersand, in the amount of $ 3 2 Ampersand holds 28,000 shares of the Company’s Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of 4,666,666 shares of our Common Stock, and 1315 Capital holds 19,000 shares of the Company Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of 3,166,668 shares of our Common Stock. On an as-converted basis, such shares would represent approximately 38.9 % and 26.4 % of our fully-diluted shares of Common Stock, respectively. In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and any public offering of securities, and (2) designate two directors to our Board of Directors; provided, that certain of such rights held by 1315 Capital have been delegated pursuant to the related Support Agreement (See Note 16, Equity The rate of interest on the Notes is equal to eight percent ( 8.0 On May 10, 2021, (i) the Company and Ampersand amended the Ampersand Note to increase its principal amount to $ 4.5 3.0 7.5 June 30, 2021 8 On June 24, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. Except with respect to their respective maturity dates, the terms of the Notes are otherwise unchanged. The Security Agreement remains in full force and effect, and was not amended in connection with the amendments to the Notes. On August 31, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) September 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On August 31, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. On September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) October 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. Through September 30, 2021, approximately $ 0.1 In the case of the amendments, the Company reviewed the changes in accordance with ASC 470 and determined they should be treated as modifications. As of September 30, 2021, the Company has incurred approximately $ 18,000 in additional deferred financing expenses associated with the amendments. In connection with the Security Agreement, the Notes were secured by a first priority lien and security interest on substantially all of the assets of the Company. In connection with entering into the Comerica Loan Agreement, the Security Agreement lien and secured interest became subordinate to the Comerica Loan. Additionally, if a change of control of the Company occurs (as defined in the Notes) the Company is required to make a prepayment of the Notes in an amount equal to the unpaid principal amount, all accrued and unpaid interest, and all other amounts payable under the Notes out of the net cash proceeds received by the Company from the consummation of the transactions related to such change of control. The Company may prepay the Notes in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of prepayment. No prepaid amount may be re-borrowed. The Notes contain certain negative covenants which prevent the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year. The Notes Subsequent Events	19. Revolver On November 13, 2018 the Company, Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC entered into a Loan and Security Agreement (the “SVB Loan Agreement”) with Silicon Valley Bank (“SVB”), which provided for up to $ 4.0 850,000 3.75 zero 3.0 On October 19, 2020, the Company entered into the Second Amendment, which amended the SVB Loan Agreement. Under the terms of the Second Amendment, Interpace Pharma Solutions (“IPS”) joined the SVB Loan Agreement as a borrower and granted SVB a continuing lien upon and security interest in all of the assets of IPS. Additionally, SVB waived certain existing or potential defaults under the SVB Loan Agreement, including the Company’s failure to meet certain financial covenants (specifically, the adjusted quick ratio requirement) for the months ended July 31, 2020 and August 31, 2020 and the Company’s reporting requirements under the SVB Loan Agreement. SVB agreed to forebear from exercising its rights and remedies in connection with the Company’s reporting requirements until the earlier to occur of (a) the occurrence of any event of default (as defined in the SVB Loan Agreement) other than any arising due to the Company’s reporting requirements which were waived by SVB, or (b) December 31, 2020. The Second Amendment also modified the SVB Loan Agreement to, among other things, a) exclude compliance by the Company with the adjusted quick ratio covenant requirement for the month of October 2020 as well as any month thereafter prior to the Funding Date of the first Advance (in each case, as defined in the SVB Loan Agreement), if any, b) require delivery of certain insurance policy endorsements which have been provided by the Company, c) increase the maximum aggregate amount utilized for the issuance of the Letter of Credit by SVB in favor of the Company’s landlord for its Pittsburgh, Pennsylvania laboratory facility from $ 250,000 1,000,000 1.0 4.25 0.50 The Second Amendment provided that any future Credit Extension (as defined in the SVB Loan Agreement) by SVB to the Company will be made in SVB’s sole and absolute discretion. The Company agreed to reimburse SVB for all out-of-pocket reasonable and documented legal fees and expenses incurred in connection with the Second Amendment. On January 5, 2021, the Company terminated the SVB Loan Agreement in accordance with the terms of the agreement. In connection with the termination, SVB waived its right to any termination fees and released its security interest in the assets of the Company.

SUPPLEMENTAL CASH FLOW INFORMAT

SUPPLEMENTAL CASH FLOW INFORMATION	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	15. SUPPLEMENTAL CASH FLOW INFORMATION Supplemental Disclosures of Non Cash Activities (in thousands) SCHEDULE OF SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Nine Months Ended September 30, 2021 2020 (unaudited) Operating Taxes accrued for repurchase of restricted shares $ - $ 49 Investing Preferred Stock Deemed Dividend $ - $ 3,033 Investment in DiamiR 248 -	20. Supplemental Cash Flow Information SUPPLEMENTAL CASH FLOW INFORMATION SCHEDULE OF SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION For The Years Ended December 31, 2020 2019 Net cash used in operating activities of discontinued operations $ - $ (30 ) Net cash provided by investing activities of discontinued operations $ - $ - Supplemental Disclosure of Other Cash Flow Information (in thousands) Cash paid for taxes $ 218 $ 227 Cash paid for interest $ 60 $ 170 Supplemental Disclosures of Non Cash Activities (in thousands) Years Ended December 31, 2020 2019 Operating Adoption of ASC 842 - right of use asset $ - $ 2,449 Adoption of ASC 842 - operating lease liability $ - $ 2,536 Investing Preferred Stock Deemed Dividend $ 3,033 $ - Financing Accrued financing costs $ 31 $ 342 Accrued preferred dividends $ - $ 429

EQUITY

EQUITY	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Equity [Abstract]
EQUITY	16. EQUITY Preferred Stock Issuance: Securities Purchase and Exchange Agreement On January 10, 2020, the Company entered into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital and Ampersand (collectively, the “Investors”) pursuant to which the Company agreed to sell to the Investors an aggregate of $ 20.0 1,000 19,000 19.0 1,000 1.0 In addition, the Company agreed to exchange $ 27.0 0.01 270 100,000 27,000 6.00 8.00 6 34.0 A convertible financial instrument includes a beneficial conversion feature if its conversion price is lower than the Company’s stock price at the commitment date. The Company determined that the sale of the Series B Preferred resulted in a beneficial conversion feature with an intrinsic value of $ 2.2 6.79 6.00 In April 2020, the Company entered into support agreements with each of the Series B Investors, pursuant to which Ampersand and 1315 Capital, respectively, consented to, and agreed to vote (by proxy or otherwise), all shares of Series B Preferred Stock registered in its name or beneficially owned by it and/or over which it exercises voting control as of the date of the Support Agreement and any other shares of Series B Preferred Stock legally or beneficially held or acquired by such Series B Investor after the date of the Support Agreement or over which it exercises voting control, in favor of any Fundamental Action desired to be taken by the Company as determined by the Board. For purposes of each Support Agreement, “Fundamental Action” means any action proposed to be taken by the Company and set forth in Section 4(d)(i), 4(d)(ii), 4(d)(v), 4(d)(vi), 4(d)(viii) or 4(d)(ix) of the Certificate of Designation of Series B Preferred Stock or Section 8.5.1.1, 8.5.1.2, 8.5.1.5, 8.5.1.6, 8.5.1.8 or 8.5.1.9 of the Amended and Restated Investor Rights Agreement. The support agreement between the Company and Ampersand was terminated by mutual agreement on July 9, 2020; however, the support agreement entered into with 1315 Capital remains in effect. During October 2021, Ampersand and 1315 Capital provided consent to the Company to enter into the Comerica Loan Agreement and the BroadOak Term Loan.	13. Equity EQUITY Public Offering On January 25, 2019, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with H.C. Wainwright & Co., LLC (“Wainwright”) with respect to the issuance and sale of an aggregate of 933,334 140,000 7.50 6.975 The Company received net proceeds, after deducting underwriter discounts and commissions and other expenses related to the offering, in the amount of approximately $ 5.9 Preferred Stock Issuance The Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) on July 15, 2019 with Ampersand 2018 Limited Partnership (the “Investor”), a fund managed by Ampersand Capital Partners, providing for the issuance and sale to the Investor of up to an aggregate of $ 27.0 0.01 100 The initial closing, which was consummated promptly after the execution of the Securities Purchase Agreement, involved the issuance of 60 6.0 80 8.0 13.1 The Securities Purchase Agreement contemplated a second closing (the “Second Closing”), which would only be effected following the fulfillment to the Investor’s satisfaction of customary conditions, including, among others, the approval by the stockholders of the Company, as required under the rules of the Nasdaq Stock Market LLC (the “Nasdaq Listing Rules”), of the issuance of shares of common stock upon conversion of the Preferred Stock in excess of the aggregate number of shares of common stock that the Company may issue upon conversion of the Preferred Stock without breaching its obligations under the Nasdaq Listing Rules (the “Stockholder Approval”). The terms of the Series A-1 provided that each share of Series A-1 would automatically convert into one share of Series A upon the Company obtaining the Stockholder Approval. See Note 21, Subsequent Events, Stockholder Approval was obtained on October 10, 2019 for the Securities Purchase Agreement discussed above and each share of Series A-1 issued to the Investor at the initial closing automatically converted into one share of Series A on that day. On October 16, 2019, the Company and the Investor consummated the Second Closing. At the Second Closing, the Company issued to the Investor 130 13.0 The Series A was offered and sold pursuant to an exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”) and Rule 506 of Regulation D promulgated thereunder. The shares to be issued upon conversion of the Series A have not been registered under the Securities Act and may not be offered or sold in the United States in the absence of an effective registration statement or exemption from the registration requirements. Preferred Stock Issuance: Securities Purchase and Exchange Agreement On January 10, 2020, the Company entered into a Securities Purchase and Exchange Agreement (the “Securities Purchase and Exchange Agreement”) with 1315 Capital and Ampersand 2018 Limited Partnership (“Ampersand” and, together with 1315 Capital, the “Investors”) pursuant to which the Company agreed to sell to the Investors an aggregate of $ 20.0 1,000 19,000 19.0 1,000 1.0 In addition, the Company agreed to exchange $ 27.0 0.01 270 100,000 27,000 6.00 8.00 6 34.0 A convertible financial instrument includes a beneficial conversion feature if its conversion price is lower than the Company’s stock price at the commitment date. The Company determined that the sale of the Series B Preferred resulted in a beneficial conversion feature with an intrinsic value of $ 2.2 6.79 6.00 In April 2020, the Company entered into support agreements with each of the Series B Investors, pursuant to which Ampersand and 1315 Capital, respectively, consented to, and agreed to vote (by proxy or otherwise), all shares of Series B Preferred Stock registered in its name or beneficially owned by it and/or over which it exercises voting control as of the date of the Support Agreement and any other shares of Series B Preferred Stock legally or beneficially held or acquired by such Series B Investor after the date of the Support Agreement or over which it exercises voting control, in favor of any Fundamental Action desired to be taken by the Company as determined by the Board. For purposes of each Support Agreement, “Fundamental Action” means any action proposed to be taken by the Company and set forth in Section 4(d)(i), 4(d)(ii), 4(d)(v), 4(d)(vi), 4(d)(viii) or 4(d)(ix) of the Certificate of Designation of Series B Preferred Stock or Section 8.5.1.1, 8.5.1.2, 8.5.1.5, 8.5.1.6, 8.5.1.8 or 8.5.1.9 of the Amended and Restated Investor Rights Agreement. The support agreement between the Company and Ampersand was terminated by mutual agreement on July 9, 2020; however, the support agreement entered into with 1315 Capital remains in effect. As of December 31, 2020 and 2019, there were 47,000 270 ATM Arrangement On September 20, 2019, the Company entered into an Equity Distribution Agreement with Oppenheimer & Co. Inc., as Agent, pursuant to which the Company may, from time to time, issue and sell shares of its Common Stock, at an aggregate offering price of up to $ 4.8 Subject to the terms and conditions of the Equity Distribution Agreement, the Agent will use its commercially reasonable efforts to sell the Shares from time to time, based upon the Company’s instructions. The Company has no obligation to sell any of the Shares and may, at any time, suspend sales under the Equity Distribution Agreement or terminate the Equity Distribution Agreement in accordance with its terms. The Company has provided the Agent with customary indemnification rights, and the Agent will be entitled to a fixed commission of 3.0 97,817 0.2 178,000 0.7 As a result of the January 10, 2020 Securities Purchase and Exchange Agreement, additional Shares may no longer be sold under the ATM arrangement without a majority approval by the holders of the Series B Preferred Stock in accordance with the Amended and Restated Investor Rights Agreement entered into on that date. Since our common stock has been delisted by The Nasdaq Stock Market LLC (“Nasdaq”) due to our failure to meet minimum stockholders’ equity requirements, we are no longer eligible to sell under the Equity Distribution Agreement. In addition, we are currently ineligible to use a Form S-3 shelf registration statement. See Note 21, Subsequent Events

WARRANTS

WARRANTS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Warrants
WARRANTS	17. WARRANTS Warrants outstanding and warrant activity for the nine-months ended September 30, 2021 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY Description Classification Exercise Price Expiration Date Warrants Issued Balance Warrants Cancelled/ Expired Balance Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 85,500 - 85,500 RedPath Warrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 10,000 - 10,000 Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 53,500 - 53,500 Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 870,214 - 870,214 Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 320,000 - 320,000 Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 65,434 - 65,434 1,975,934 1,404,648 - 1,404,648 The weighted average exercise price of the warrants is $ 15.97 0.7	14. Warrants WARRANTS Warrants outstanding and warrant activity for the year ended December 31, 2020 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY Description Classification Exercise Price Expiration Date Warrants Issued Balance Warrants Cancelled/ Expired Balance Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 85,500 85,500 RedPath Warrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 10,000 10,000 Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 53,500 53,500 Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 870,214 870,214 Vendor Warrants, issued August 6, 2017 Equity $ 12.50 August 2020 15,000 15,000 (15,000 ) - Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 320,000 320,000 Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 65,434 65,434 1,990,934 1,419,648 (15,000 ) 1,404,648 The weighted average exercise price of the warrants is $ 15.97 1.4

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounting Changes and Error Corrections [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	18. RECENT ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Guidance In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment was effective for annual periods beginning after December 15, 2020. The Company adopted this pronouncement on January 1, 2021 and the impact was not material to the Company’s Consolidated Financial Statements. In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company does not expect this will have any impact on its unaudited consolidated financial statements.	3. Recent Accounting Standards Recently Adopted Accounting Guidance In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which changes the accounting for implementation costs incurred in a cloud computing arrangement that is a service contract. The update aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The implementation costs should be presented accordingly as other assets, current and non-current on the balance sheet and expensed over the term of the hosting arrangement. The Company adopted this pronouncement on January 1, 2020 and the impact was not material to the Company’s Consolidated Financial Statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement: Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies are required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this pronouncement on January 1, 2020 and the impact was not material to the Company’s Consolidated Financial Statements. Accounting Pronouncements Pending Adoption Standards not yet effective In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment is effective for annual periods beginning after December 15, 2020. We do not expect that the requirements of ASU 2017-04 will have a material impact on our consolidated financial statements.

TRANSITION EXPENSES

TRANSITION EXPENSES	9 Months Ended
	Sep. 30, 2021
Transition Expenses
TRANSITION EXPENSES	19. TRANSITION EXPENSES These expenses are primarily related to the Rutherford, NJ lab closing and subsequent move to North Carolina, as well as other cost-saving initiatives, primarily reductions in headcount as well as certain lergal expenses. The following is a roll forward of the transition expenses liabilities: Schedule of Transition Expenses 1 2 3 4 Facilities/ Personnel Infrastructure Legal Total (unaudited) Balance at December 31, 2020 $ 885 $ 269 $ - $ 1,154 Transition expenses 1,044 925 505 2,474 Payments (1,929 ) (1,164 ) (269 ) (3,362 ) Balance at September 30, 2021 $ - $ 30 $ 236 $ 266

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	20. SUBSEQUENT EVENTS Revolving Line of Credit On October 13, 2021, the Company and its subsidiaries entered into a Loan and Security Agreement (the “Comerica Loan Agreement”) with Comerica Bank (“Comerica”), providing for a revolving credit facility of up to $ 7,500,000 The amount that may be borrowed under the Credit Facility is the lower of (i) the revolving limit of $ 7,500,000 80 2,000,000 250,000 5,000,000 80 300,000 0.50 2.5 0.25 The Credit Facility matures on September 30, 2023 The Comerica Loan Agreement contains affirmative and negative restrictive covenants that are applicable whether or not any amounts are outstanding under the Comerica Loan Agreement. These restrictive covenants could adversely affect our ability to conduct our business. The Comerica Loan Agreement also contains customary events of default. As a condition for Comerica to extend the Credit Facility to the Company and its subsidiaries, the Company’s existing creditors, Ampersand and 1315 Capital (the “Existing Creditors”), entered into that certain Subordination Agreement, dated as of October 13, 2021, pursuant to which each Existing Creditor agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to such Existing Creditor to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Subordination Agreement”). Each Existing Creditor further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Subordination Agreement provides that it is solely for the benefit of Comerica and each of the Existing Creditors and is not for the benefit of the Company or any of its subsidiaries. BroadOak Loan and Repayment of Promissory Notes On October 29, 2021, the Company and its subsidiaries entered into a Loan and Security Agreement (the “BroadOak Loan Agreement”) with BroadOak, providing for a term loan in the aggregate principal amount of $ 8,000,000 4.5 3 The Term Loan matures upon the earlier of (i) October 31, 2024 9 Company 7,500,000 The Term Loan has an origination fee of 3 The BroadOak Loan Agreement contains affirmative and negative restrictive covenants that are applicable from and after the date of the Term Loan advance. These restrictive covenants could adversely affect our ability to conduct our business. The BroadOak Loan Agreement also contains customary events of default. The representations, warranties and covenants contained in the BroadOak Loan Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties, including being qualified by confidential disclosures exchanged between the parties in connection with the execution of such agreement. The representations and warranties may have been made for the purposes of allocating contractual risk between the parties to such agreement instead of establishing these matters as facts, and may be subject to standards of materiality applicable to the contracting parties that differ from those applicable to investors. Investors are not third-party beneficiaries under such agreement and should not rely on the representations, warranties and covenants or any descriptions thereof as characterizations of the actual state of facts or condition of the Company or any of its subsidiaries or affiliates. Moreover, information concerning the subject matter of the representations and warranties may change after the date of such agreement, and this subsequent information may or may not be fully reflected in the Company’s public disclosure. In connection with the BroadOak Loan Agreement, the Company and its subsidiaries entered into that certain First Amendment to Loan and Security Agreement and Consent with Comerica, dated as of November 1, 2021 (the “Comerica Amendment”), pursuant to which Comerica consented to the Company’s and its subsidiaries’ entry into the BroadOak Loan Agreement, and amended that certain Loan and Security Agreement among Comerica, the Company and its subsidiaries (the “Comerica Loan Agreement”) to, among other things, permit the indebtedness, liens and encumbrances contemplated by the BroadOak Loan Agreement. As a condition for BroadOak to extend the Term Loan to the Company and its subsidiaries, the Company’s existing creditor, Comerica, and BroadOak entered into that certain Subordination and Intercreditor Agreement, dated as of November 1, 2021, pursuant to which BroadOak agreed to subordinate all of the indebtedness and obligations of the Company and its subsidiaries owing to BroadOak to all of the indebtedness and obligations of the Company and its subsidiaries owing to Comerica (the “Intercreditor Agreement”). BroadOak further agreed to subordinate all of its respective security interests in assets or property of the Company and its subsidiaries to Comerica’s security interests in such assets or property. The Intercreditor Agreement provides that it is solely for the benefit of BroadOak and Comerica and is not for the benefit of the Company or any of its subsidiaries.	21. Subsequent Events SUBSEQUENT EVENTS Nasdaq delisting On February 16, 2021, the Company received a delisting determination letter (the “Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Staff has determined to delist the Company’s common stock from Nasdaq due to the Company’s failure to regain compliance with the Nasdaq Capital Market’s minimum $ 2,500,000 Nasdaq commenced with delisting the Company’s common stock from the Nasdaq Capital Market and, suspended trading in the Company’s common stock effective at the open of business on February 25, 2021. On February 24, 2021, the Company was approved to have its common stock quoted on the OTCQX® Best Market tier of the OTC Markets Group Inc. (the “OTCQX”), an electronic quotation service operated by OTC Markets Group Inc. The trading of the Company’s common stock commenced on OTCQX at the open of business on February 25, 2021 under the trading symbol IDXG. Secured Promissory Notes On January 7, 2021, the Company entered into promissory notes with Ampersand, in the amount of $ 3 2 Ampersand holds 28,000 4,666,666 19,000 3,166,668 39.3 26.7 In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and (2) designate two directors to our Board of Directors. As a result, the Company considers the Notes and Security Agreement to be a related party transaction. The rate of interest on the Notes is equal to eight percent ( 8.0 In connection with the Security Agreement, the Notes are secured by a first priority lien and security interest on substantially all of the assets of the Company. Additionally, if a change of control of the Company occurs (as defined in the Notes) the Company is required to make a prepayment of the Notes in an amount equal to the unpaid principal amount, all accrued and unpaid interest, and all other amounts payable under the Notes out of the net cash proceeds received by the Company from the consummation of the transactions related to such change of control. The Company may prepay the Notes in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of prepayment. No prepaid amount may be re-borrowed. The Notes contain certain negative covenants which prevent the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $ 4.5 45 10 Revolving line of credit On January 5, 2021, the Company terminated the SVB Loan Agreement, see Note 19, Revolver Disposition of New Haven Laboratory On March 17, 2021 the Company announced that it has entered into a definitive agreement to sell its New Haven, CT CLIA certified, CAP accredited laboratory to DiamiR Biosciences, Corp. (“DiamiR”). Under the agreement, DiamiR will provide overflow lab testing in support of the Company’s molecular thyroid testing products at its main laboratory in Pittsburgh, PA. DiamiR will also support specific Interpace assay development and validation services on behalf of the Company for the next three quarters. Subject to specific terms and conditions of the agreement being met, it is anticipated that the transaction will close by the end of April 2021. INTERPACE BIOSCIENCES, INC.

Nature of Business and Signific

Nature of Business and Significant Accounting Policies	12 Months Ended
	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business and Significant Accounting Policies	1. Nature of Business Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs. Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The consolidated financial statements include the accounts of Interpace Biosciences, Inc. fka Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc. fka Interpace Biopharma, Inc. Discontinued operations include the Company’s wholly-owned subsidiaries: Group DCA, LLC (“Group DCA”), InServe Support Solutions (Pharmakon), and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (“CSO”) business unit. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has one Accounting Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts and notes, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates. Reverse stock split On January 15, 2020, the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. 39,323,701 3,932,370 39,205,895 3,920,589 ly adjusted to give effect to the reverse stock split for all periods presented. Immaterial Revision In 2020, the Company completed an Internal Revenue Code Section 382 analysis of its historical net operating loss carry-forward amount. As a result, the prior year net operating loss carry-forward was determined to be limited. See Note 17 Income Taxes Cash and Cash Equivalents Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase. Accounts Receivable, Net The Company’s accounts receivables represent unconditional rights to consideration and are generated using its proprietary tests and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer. Other current assets Other current assets consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF OTHER CURRENT ASSETS December 31, 2020 December 31, 2019 Lab supply inventory $ 2,052 $ 1,825 Prepaid expenses 625 971 Funds in escrow - 888 Other 45 167 Total other current assets $ 2,722 $ 3,851 Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is recognized on a straight-line basis, using the estimated useful lives of: seven twelve years two five years three twelve years three ten years Software Costs Internal-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining internal-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three seven years External-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining external-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three years See Note 7, Property and Equipment Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years ten years The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment. Additionally, the Company concluded that amortization of both the Barrett’s intangible asset and its Thyroid intangible assets should have begun at the point in which the asset was ready for use. The Company’s policy had been to amortize such assets upon launch of the test. Contingencies In the normal course of business, the Company is subject to various contingencies. Contingencies are recorded in the consolidated financial statements when it is probable that a liability will be incurred and the amount of the loss is reasonably estimable, or otherwise disclosed, in accordance with ASC 450, Contingencies. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, when applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. The Company is not currently involved in any legal proceedings of a material nature and, accordingly, the Company has not accrued estimated costs related to any legal claims. Revenue Recognition Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known. During 2019, the Company recorded a reduction to revenue of $ 3.5 For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer. The Company elected the practical expedient to expense contract costs as incurred related to clinical services because the contract term is less than one year. Contract costs for pharma services were not significant. Cost of revenue Cost of revenue consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty expenses, and facility expenses. Stock-Based Compensation The compensation cost associated with the granting of stock-based awards is based on the grant date fair value of the stock award. The Company recognizes the compensation cost, net of estimated forfeitures, over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. Forfeitures are initially estimated based on historical information and subsequently updated over the life of the awards to ultimately reflect actual forfeitures. As a result, changes in forfeiture activity can influence the amount of stock compensation cost recognized from period to period. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options and stock appreciation rights (“SARs”). The determination of the fair value of stock-based payment awards is made on the date of grant and is affected by the Company’s stock price as well as assumptions made regarding a number of complex and subjective variables. These assumptions include: expected stock price volatility over the term of the awards; actual and projected employee stock option exercise behaviors; the risk-free interest rate; and expected dividend yield. The fair value of restricted stock units, or RSUs, and restricted shares is equal to the closing stock price on the date of grant. In 2020, the Company issued performance-based options and RSUs based on achieving stock price or certain other financial metrics. These require the Company to assess the likelihood of achieving certain performance milestones on a quarterly basis. In these instances, the Company has the initial valuation model prepared by an outside expert. See Note 15, Stock-Based Compensation, Treasury Stock Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Upon reissuance of shares, the Company records any difference between the weighted-average cost of such shares and any proceeds received as an adjustment to additional paid-in capital. Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 9, Leases Income taxes Income taxes are based on income for financial reporting purposes calculated using the Company’s expected annual effective rate and reflect a current tax liability or asset for the estimated taxes payable or recoverable on the current year tax return and expected annual changes in deferred taxes. Any interest or penalties on income tax are recognized as a component of income tax expense. The Company accounts for income taxes using the asset and liability method. This method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities based on enacted tax laws and rates. Deferred tax expense (benefit) is the result of changes in the deferred tax asset and liability. A valuation allowance is established, when necessary, to reduce the deferred income tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The Company operates in multiple tax jurisdictions and pays or provides for the payment of taxes in each jurisdiction where it conducts business and is subject to taxation. The breadth of the Company’s operations and the complexity of the tax law require assessments of uncertainties and judgments in estimating the ultimate taxes the Company will pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of proposed assessments arising from federal and state audits. Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement. Th Significant judgment is also required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. Deferred tax assets are regularly reviewed for recoverability. The Company currently has significant deferred tax assets resulting from net operating loss carryforwards and deductible temporary differences, which should reduce taxable income in future periods, if generated. The realization of these assets is dependent on generating future taxable income. Income (Loss) per Share Basic earnings per common share are computed by dividing net income by the weighted average number of shares outstanding during the year including any unvested share-based payment awards that contain nonforfeitable rights to dividends. Diluted earnings per common share are computed by dividing net income by the sum of the weighted average number of shares outstanding and dilutive common shares under the treasury method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid), are participating securities and are included in the computation of earnings per share pursuant to the two-class method. As a result of the losses incurred in both 2020 and 2019, the potentially dilutive common shares have been excluded from the earnings per share computation for these periods because its inclusion would have been anti-dilutive. Additionally, preferred shares have been excluded in the denominator of the earnings per share computation, on an if-converted basis, as such shares would have been anti-dilutive.

Acquisition

Acquisition	12 Months Ended
	Dec. 31, 2020
Business Combination and Asset Acquisition [Abstract]
Acquisition	2. Acquisition On July 15, 2019, the Company entered into an Asset Purchase Agreement to acquire certain assets and assumed certain liabilities relating to Cancer Genetics, Inc.’s (“CGI”) biopharma business (“BioPharma”) for $ 23.5 1.98 13.8 7,692,300 The BioPharma business (presently known as Interpace Pharma Solutions, Inc. or “pharma services”) provides pharmaceutical and biotech companies and non-profit entities performing clinical trials with lab testing services for patient stratification and treatment selection through an extensive suite of molecular and biomarker-based testing services, DNA- and RNA- extraction and customized assay development and trial design consultation. The Base Purchase Price was subject to two additional adjustments following the closing: for the finalized net worth (assets less liabilities) of BioPharma as of June 30, 2019 (the “NWA”), subject to a cap of $ 775,000 830,000 735,000 January 15, 2020 6,024,489 887,858 735,000 152,858 The transaction was accounted for using the acquisition method of accounting for business combinations in accordance with GAAP. Under this method, the total consideration transferred to consummate the acquisition is being allocated to the identifiable tangible and intangible assets acquired and liabilities assumed based on their respective fair values as of the closing date of the acquisition. The acquisition method of accounting requires extensive use of estimates and judgments to allocate the consideration transferred to the identifiable tangible and intangible assets acquired and liabilities assumed. In connection with the transaction, the Company recorded $ 8.3 7.3 8.4 ten years eight years Goodwill and Other Intangible Assets, 2.5 The reconciliation of consideration given for BioPharma to the allocation of the purchase price of assets and liabilities acquired based on their relative fair values was as follows: Schedule of Assets Acquired and Liabilities Assumed Cash $ 13,829 Subordinated note payable 6,822 Total consideration $ 20,651 Assets acquired Accounts receivable $ 3,731 Accrued revenue 289 Lab supplies 877 Prepaid expenses 266 Property and equipment 6,412 Operating lease assets 2,187 Acquired identifiable intangible assets: Trademarks and trade name 1,600 Customer relationships 5,700 Total acquired identifiable intangible assets 7,300 Goodwill 8,273 Total assets acquired 29,335 Liabilities assumed Accounts payable (4,535 ) Accrued liabilities (435 ) Deferred revenue (1,076 ) Operating lease liabilities (2,187 ) Finance lease liabilities (451 ) Total liabilities assumed (8,684 ) Net assets acquired $ 20,651 The following unaudited pro forma consolidated revenues for the year ended December 31, 2019 assume that the Company had acquired Biopharma Solutions as of January 1, 2019. The pro forma revenues include estimates and assumptions which management believes are reasonable. However, pro forma revenues are not necessarily indicative of the revenues that would have occurred if the acquisition had been consummated as of the date indicated, nor are they necessarily indicative of future revenues. Schedule of ProForma Information Year Ended December 31, 2019 Revenue $ 31,722 The BioPharma business had not historically been accounted for as a separate entity, subsidiary or division of CGI. In addition, stand-alone financial statements related to BioPharma have not been prepared previously as CGI’s financial system was not designed to provide complete financial information of BioPharma. Therefore, the Company was not able to estimate the pro forma impact to net loss or the net loss per share of BioPharma for the year ended December 31, 2019.

Recent Accounting Standards

Recent Accounting Standards	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounting Changes and Error Corrections [Abstract]
Recent Accounting Standards	18. RECENT ACCOUNTING PRONOUNCEMENTS Recently Adopted Accounting Guidance In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment was effective for annual periods beginning after December 15, 2020. The Company adopted this pronouncement on January 1, 2021 and the impact was not material to the Company’s Consolidated Financial Statements. In February 2020, the FASB issued ASU 2020-02, Financial Instruments-Credit Losses (Topic 326) and Leases (Topic 842) - Amendments to SEC Paragraphs Pursuant to SEC Staff Accounting Bulletin No. 119 and Update to SEC Section on Effective Date Related to Accounting Standards Update No. 2016-02, Leases (Topic 842) which amends the effective date of the original pronouncement for smaller reporting companies. ASU 2016-13 and its amendments will be effective for the Company for interim and annual periods in fiscal years beginning after December 15, 2022. The Company believes the adoption will modify the way the Company analyzes financial instruments, but it does not anticipate a material impact on results of operations. The Company is in the process of determining the effects adoption will have on its consolidated financial statements. In August 2020, the FASB issued ASU 2020-06, Debt – Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815 – 40), (“ASU 2020-06”). ASU 2020-06 simplifies the accounting for certain financial instruments with characteristics of liabilities and equity, including convertible instruments and contracts on an entity’s own equity. The ASU2020-06 amendments are effective for fiscal years beginning after December 15, 2023, and interim periods within those fiscal years. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, including interim periods within those fiscal years. The Company does not expect this will have any impact on its unaudited consolidated financial statements.	3. Recent Accounting Standards Recently Adopted Accounting Guidance In August 2018, the FASB issued ASU No. 2018-15, Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract, which changes the accounting for implementation costs incurred in a cloud computing arrangement that is a service contract. The update aligns the requirements for capitalizing implementation costs incurred in a hosting arrangement with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The implementation costs should be presented accordingly as other assets, current and non-current on the balance sheet and expensed over the term of the hosting arrangement. The Company adopted this pronouncement on January 1, 2020 and the impact was not material to the Company’s Consolidated Financial Statements. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement: Disclosure Framework – Changes to the Disclosure Requirements for Fair Value Measurement, which adds and modifies certain disclosure requirements for fair value measurements. Under the new guidance, entities will no longer be required to disclose the amount of and reasons for transfers between Level 1 and Level 2 of the fair value hierarchy, or valuation processes for Level 3 fair value measurements. However, public companies are required to disclose the range and weighted average of significant unobservable inputs used to develop Level 3 fair value measurements, and related changes in unrealized gains and losses included in other comprehensive income. The Company adopted this pronouncement on January 1, 2020 and the impact was not material to the Company’s Consolidated Financial Statements. Accounting Pronouncements Pending Adoption Standards not yet effective In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes (“ASU 2019-12”). ASU 2019-12 will simplify the accounting for income taxes by removing certain exceptions to the general principles in Topic 740. The amendments also improve consistent application of and simplify GAAP for other areas of Topic 740 by clarifying and amending existing guidance. The amendment is effective for annual periods beginning after December 15, 2020. We do not expect that the requirements of ASU 2017-04 will have a material impact on our consolidated financial statements.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	7. Property and Equipment Property and equipment consisted of the following as of December 31, 2020 and 2019: Schedule of Property and Equipment 2020 2019 December 31, 2020 2019 Furniture and fixtures $ 339 $ 242 Lab and office equipment 7,536 6,353 Computer equipment 339 339 Internal-use software 1,572 1,276 Leasehold improvements 505 506 Property and equipment 10,291 8,716 Less accumulated depreciation and amortization (2,942 ) (1,902 ) Net property and equipment $ 7,349 $ 6,814 Depreciation and amortization expense from continuing operations was approximately $ 0.8 0.5 0.1

Retirement Plans

Retirement Plans	12 Months Ended
	Dec. 31, 2020
Retirement Benefits [Abstract]
Retirement Plans	10. Retirement Plans The Company offers an employee 401(k) saving plan. Under the Interpace Biosciences, Inc. 401(k) Plan, employees may contribute up to 50 100 3 50 3 5 0.4 0.3

Accrued Expenses and Other Long

Accrued Expenses and Other Long-Term Liabilities	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
Accrued Expenses and Other Long-Term Liabilities	9. ACCRUED EXPENSES AND LONG-TERM LIABILITIES Other accrued expenses consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF OTHER ACCRUED EXPENSES September 30, 2021 December 31, 2020 (unaudited) Accrued royalties $ 3,572 $ 2,710 Upfront Medicare payment - 2,066 Operating lease liabilities 1,030 1,027 All others 1,056 1,182 Accrued professional fees 931 854 Unclaimed property 565 565 Contingent consideration 473 398 Accrued pharma services invoices 438 108 Taxes payable 248 334 Accrued lab costs - diagnostics 514 161 Financing lease liabilities 98 177 ESPP payable 37 108 Accrued sales and marketing - diagnostics 41 51 Deferred revenue 40 54 Total other accrued expenses $ 9,043 $ 9,795 Long-term liabilities consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF LONG TERM LIABILITIES September 30, 2021 December 31, 2020 (unaudited) Uncertain tax positions $ 4,517 $ 4,342 Warrant liability 158 21 Financing lease liabilities 75 138 Deferred revenue 18 136 Other - 138 Total other long-term liabilities $ 4,768 $ 4,637	11. Accrued Expenses and Other Long-Term Liabilities Other accrued expenses consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF OTHER ACCRUED EXPENSES December 31, 2020 December 31, 2019 Accrued royalties $ 2,710 $ 1,934 Contingent consideration 398 502 Upfront Medicare payment 2,066 - Operating lease liability 1,027 1,321 Financing lease liability 177 184 Deferred revenue 54 457 Payable to CGI - 888 Accrued sales and marketing - diagnostics 51 197 Accrued lab costs - diagnostics 161 163 Accrued professional fees 854 1,399 Taxes payable 334 403 Unclaimed property 565 565 All others 1,398 1,463 Total other accrued expenses $ 9,795 $ 9,476 Other long-term liabilities consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF LONG TERM LIABILITIES December 31, 2020 December 31, 2019 Warrant liability $ 21 $ 82 Uncertain tax positions 4,342 4,081 Deferred revenue 136 269 Other 138 141 Total other long-term liabilities $ 4,637 $ 4,573 In the third quarter of 2020, the Company reversed approximately $ 1.2

Revenue Sources

Revenue Sources	12 Months Ended
	Dec. 31, 2020
Risks and Uncertainties [Abstract]
Revenue Sources	16. Revenue Sources The Company’s clinical services customers consist primarily of physicians, hospitals and clinics. Its revenue channels include Medicare, Medicare Advantage, Medicaid, Client Billings (hospitals, etc.), and commercial payers. The following sets forth the net revenue generated by revenue channel accounted for more than 10% of the Company’s revenue from continuing operations during the years ended December 31, 2020 and 2019, respectively. For the years ended December 31, 2020 and December 31, 2019, revenue from Medicare was approximately 50 44 Schedule of Revenue by Major Customers Years Ended December 31, Customer 2020 2019 Medicare $ 10,186 $ 10,605 Commercial Payers $ 4,136 $ 7,589 Medicare Advantage $ 3,566 $ 1,912 Client Billings $ 2,582 $ 3,521

Historical Basic and Diluted Ne

Historical Basic and Diluted Net Loss per Share	12 Months Ended
	Dec. 31, 2020
Earnings Per Share [Abstract]
Historical Basic and Diluted Net Loss per Share	18. Historical Basic and Diluted Net Loss per Share A reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the years ended December 31, 2020 and 2019 are as follows (rounded to thousands): Schedule of Weighted Average Number of Shares Years Ended December 31, 2020 2019 Basic weighted average number of common shares 4,029 3,746 Potential dilutive effect of stock-based awards - - Diluted weighted average number of common shares 4,029 3,746 The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Years Ended December 31, 2020 2019 Options 849 416 Restricted stock units (RSUs) 238 49 Warrants 1,405 1,420 2,492 1,885

Revolver

Revolver	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Debt Disclosure [Abstract]
Revolver	14. NOTES PAYABLE – RELATED PARTIES Secured Promissory Notes On January 7, 2021, the Company entered into promissory notes with Ampersand, in the amount of $ 3 2 Ampersand holds 28,000 shares of the Company’s Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of 4,666,666 shares of our Common Stock, and 1315 Capital holds 19,000 shares of the Company Series B Convertible Preferred Stock, which are convertible from time to time into an aggregate of 3,166,668 shares of our Common Stock. On an as-converted basis, such shares would represent approximately 38.9 % and 26.4 % of our fully-diluted shares of Common Stock, respectively. In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and any public offering of securities, and (2) designate two directors to our Board of Directors; provided, that certain of such rights held by 1315 Capital have been delegated pursuant to the related Support Agreement (See Note 16, Equity The rate of interest on the Notes is equal to eight percent ( 8.0 On May 10, 2021, (i) the Company and Ampersand amended the Ampersand Note to increase its principal amount to $ 4.5 3.0 7.5 June 30, 2021 8 On June 24, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) August 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On June 25, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. Except with respect to their respective maturity dates, the terms of the Notes are otherwise unchanged. The Security Agreement remains in full force and effect, and was not amended in connection with the amendments to the Notes. On August 31, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) September 30, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On August 31, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. On September 29, 2021, the Company and Ampersand amended the Ampersand Note to change its maturity date to the earlier of (a) October 31, 2021 and (b) the date on which all amounts become due upon the occurrence of any event of default as defined in the Ampersand Note. On September 29, 2021, the Company and 1315 Capital amended the 1315 Capital Note to change its maturity date in a similar manner. Through September 30, 2021, approximately $ 0.1 In the case of the amendments, the Company reviewed the changes in accordance with ASC 470 and determined they should be treated as modifications. As of September 30, 2021, the Company has incurred approximately $ 18,000 in additional deferred financing expenses associated with the amendments. In connection with the Security Agreement, the Notes were secured by a first priority lien and security interest on substantially all of the assets of the Company. In connection with entering into the Comerica Loan Agreement, the Security Agreement lien and secured interest became subordinate to the Comerica Loan. Additionally, if a change of control of the Company occurs (as defined in the Notes) the Company is required to make a prepayment of the Notes in an amount equal to the unpaid principal amount, all accrued and unpaid interest, and all other amounts payable under the Notes out of the net cash proceeds received by the Company from the consummation of the transactions related to such change of control. The Company may prepay the Notes in whole or in part at any time or from time to time without penalty or premium by paying the principal amount to be prepaid together with accrued interest thereon to the date of prepayment. No prepaid amount may be re-borrowed. The Notes contain certain negative covenants which prevent the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year. The Notes Subsequent Events	19. Revolver On November 13, 2018 the Company, Interpace Diagnostics Corporation, and Interpace Diagnostics, LLC entered into a Loan and Security Agreement (the “SVB Loan Agreement”) with Silicon Valley Bank (“SVB”), which provided for up to $ 4.0 850,000 3.75 zero 3.0 On October 19, 2020, the Company entered into the Second Amendment, which amended the SVB Loan Agreement. Under the terms of the Second Amendment, Interpace Pharma Solutions (“IPS”) joined the SVB Loan Agreement as a borrower and granted SVB a continuing lien upon and security interest in all of the assets of IPS. Additionally, SVB waived certain existing or potential defaults under the SVB Loan Agreement, including the Company’s failure to meet certain financial covenants (specifically, the adjusted quick ratio requirement) for the months ended July 31, 2020 and August 31, 2020 and the Company’s reporting requirements under the SVB Loan Agreement. SVB agreed to forebear from exercising its rights and remedies in connection with the Company’s reporting requirements until the earlier to occur of (a) the occurrence of any event of default (as defined in the SVB Loan Agreement) other than any arising due to the Company’s reporting requirements which were waived by SVB, or (b) December 31, 2020. The Second Amendment also modified the SVB Loan Agreement to, among other things, a) exclude compliance by the Company with the adjusted quick ratio covenant requirement for the month of October 2020 as well as any month thereafter prior to the Funding Date of the first Advance (in each case, as defined in the SVB Loan Agreement), if any, b) require delivery of certain insurance policy endorsements which have been provided by the Company, c) increase the maximum aggregate amount utilized for the issuance of the Letter of Credit by SVB in favor of the Company’s landlord for its Pittsburgh, Pennsylvania laboratory facility from $ 250,000 1,000,000 1.0 4.25 0.50 The Second Amendment provided that any future Credit Extension (as defined in the SVB Loan Agreement) by SVB to the Company will be made in SVB’s sole and absolute discretion. The Company agreed to reimburse SVB for all out-of-pocket reasonable and documented legal fees and expenses incurred in connection with the Second Amendment. On January 5, 2021, the Company terminated the SVB Loan Agreement in accordance with the terms of the agreement. In connection with the termination, SVB waived its right to any termination fees and released its security interest in the assets of the Company.

VALUATION AND QUALIFYING ACCOUN

VALUATION AND QUALIFYING ACCOUNTS	12 Months Ended
	Dec. 31, 2020
Income Tax Disclosure [Abstract]
VALUATION AND QUALIFYING ACCOUNTS	VALUATION AND QUALIFYING ACCOUNTS YEARS ENDED DECEMBER 31, 2020 AND 2019 ($ in thousands) Schedule II - Valuation and Qualifying Accounts Additions Balance at (Reductions) (1) Balance at Beginning Charged to Deductions end Description of Period Operations Other of Period 2019 Allowance for doubtful accounts $ - - 25 $ 25 Allowance for doubtful notes $ 869 - - $ 869 Tax valuation allowance (2) $ 11,031 5,996 $ 17,027 2020 Allowance for doubtful accounts $ 25 - 250 $ 275 Allowance for doubtful notes $ 869 - - $ 869 Tax valuation allowance $ 17,027 - 6,657 $ 23,684 (1) Includes payments and actual write offs, as well as changes in estimates in the reserves. (2) Opening balance has been adjusted to reflect the impact of the immaterial revision described in Note 1. PRELIMINARY PROSPECTUS Up to [●] Shares of Common Stock Issuable Upon the Exercise of Rights to Subscribe for such Shares at $[●] per Share , 2021 PART II Item 13. Other Expenses of Issuance and Distribution The following is a statement of estimated expenses in connection with the issuance and distribution of the securities being registered. The expenses relating to the registration of the securities registered hereby will be borne by the Registrant. All of such fees and expenses, except for the SEC registration fee, are estimated: SEC registration fee $ 2,781 Subscription and Information Agent fees and expenses [●] Legal fees and expenses [●] Printing expenses [●] Accounting fees and expenses [●] Other fees and expenses [●] Total $ [●] Item 14. Indemnification of Directors and Officers Our Certificate of Incorporation, as amended and as may be further amended and in effect from time to time, which we refer to as the Certificate of Incorporation, provides that our directors shall not be personally liable to us or our stockholders for monetary damages for any breach of fiduciary duty as a director, except for liability for breach of the director’s duty of loyalty to us or our stockholders, for acts or omissions not in good faith or involving intentional misconduct or a knowing violation of law, for payment of dividends or approval of stock purchases or redemptions that are prohibited by the Delaware General Corporation Law, as amended, which we refer to as the DGCL, or for any transaction from which the director derived an improper personal benefit. Under the DGCL, our directors have a fiduciary duty to us that is not eliminated by this provision of the Certificate of Incorporation and, in appropriate circumstances, equitable remedies such as injunctive or other forms of non-monetary relief will remain available. This provision also does not affect our directors’ responsibilities under any other laws, such as federal securities laws or state or federal environmental laws. Section 145 of the DGCL empowers a corporation to indemnify its directors and officers against expenses (including attorneys’ fees), judgments, fines and amounts paid in settlements actually and reasonably incurred by them in connection with any action, suit or proceeding brought by third parties by reason of the fact that they were or are directors or officers of the corporation, if they acted in good faith, in a manner they reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe that their conduct was unlawful. The DGCL provides further that the indemnification permitted thereunder shall not be deemed exclusive of any other rights to which the directors and officers may be entitled under our ByLaws, any agreement, a vote of stockholders or otherwise. The Certificate of Incorporation provides that, to the fullest extent permitted by Section 145 of the DGCL, we shall indemnify any person who is or was a director or officer of us, or is or was serving at our request as a director, officer or trustee of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise, against the expenses, liabilities or other matters referred to in or covered by Section 145 of the DGCL. Our ByLaws provide that we will indemnify any person who was or is a party or threatened to be made a party to any proceeding by reason of the fact that such person is or was a director or officer of us or is or was serving at our request as a director, officer or trustee of another corporation, partnership, joint venture, trust, employee benefit plan or other enterprise to the fullest extent permitted by the DGCL. In addition, we have entered into agreements, or will enter into agreements, with each of our directors and officers under which, among other things, we have agreed to indemnify the director or officer against expenses incurred in any proceeding, including any action by us, in which the director or officer was, is or is threatened to be made a party or a participant by reason of his or her status as a present or former director, officer, employee or agent of us or, at our request, any other corporation, partnership, joint venture, trust, employee benefit plan or other enterprise. At present, there is no pending litigation or proceeding involving any director or officer as to which indemnification will be required or permitted, and we are not aware of any threatened litigation or proceeding that may result in a claim for such indemnification. Section 145 of the DGCL also empowers a corporation to purchase insurance for its officers and directors for such liabilities. We maintain liability insurance for our officers and directors. Item 15. Recent Sales of Unregistered Securities On May 31, 2019, the Company issued 10,000 shares (as adjusted for the reverse stock split) of common stock in consideration of services to be rendered in the extension of a consulting agreement it entered into during the quarter ended June 30, 2019. The issuances were exempt from registration pursuant to the Securities Act of 1933, as amended, pursuant to Section 4(a)(2) thereof. The offer and sale of shares of common stock to the Standby Purchaser pursuant to the Standby Purchase Agreement will be effectuated in reliance upon an exemption from the registration requirements of the Securities Act pursuant to Section 4(a)(2) thereof. Item 16. Exhibits and Financial Statement Schedules Exhibit No. Description 3.1+ Conformed version of Certificate of Incorporation of Interpace Biosciences, Inc., as amended by the Certificate of Amendment, effective January 15, 2020, and the Certificate of Designation of Preferences, Rights and Limitations of Series B Convertible Preferred Stock, filed January 17, 2020, incorporated by reference to Exhibit 3.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 3.2 Amended and Restated Bylaws of Interpace Biosciences, Inc., incorporated by reference to Exhibit 3.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 14, 2019. 4.1 Description of Securities, incorporated by reference to Exhibit 4.1 of the Company’s Annual Report on Form 10-k for the year ended December 31, 2021, filed with the SEC on April 1, 2021. 4.2 Specimen Certificate Representing the Common Stock, incorporated by reference to Exhibit 4.1 of the Company’s Registration Statement on Form S-3 (File No. 333-227728), filed with the SEC on October 5, 2018. 4.3 Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 20, 2017. 4.4 Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.3 of the Company’s Current Report on Form 8-K, as amended, filed with the SEC on March 24, 2017. 4.5 Form of Underwriters’ Warrants, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K, filed with the SEC on June 21, 2017. 4.6 Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.3 of the Company’s Current Report on Form 8-K, filed with the SEC on June 21, 2017. 4.7 Form of Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 12, 2017. 4.8 Form of Underwriter Common Stock Purchase Warrant, incorporated by reference to Exhibit 4.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 29, 2019. 5.1* Opinion of Troutman Pepper Hamilton Sanders, LLP. 10.1# Amended and Restated 2004 Stock Award and Incentive Plan, incorporated by reference to Annex A of the Company’s definitive proxy statement, filed with the SEC on August 14, 2017. 10.2# Form of Restricted Stock Unit Agreement for Employees, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 15, 2018. 10.3# Form of Restricted Stock Unit Agreement for Directors, incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 15, 2018. 10.4# Form of Non-Qualified Stock Option Agreement, incorporated by reference to Exhibit 10.3 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 15, 2018. 10.5# Form of Incentive Stock Option Agreement, incorporated by reference to Exhibit 10.4 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2018, filed with the SEC on May 15, 2018. 10.6# Interpace Diagnostics Group, Inc. 2019 Equity Incentive Plan, incorporated by reference to Exhibit 4.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019. 10.7# Amendment to the Interpace Biosciences, Inc. 2019 Equity Incentive Plan, incorporated by reference to Exhibit 10.8 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on June 26, 2020. 10.8# Form of Restricted Stock Unit Grant Notice and Restricted Stock Unit Agreement under the 2019 Equity Incentive Plan, incorporated by reference to Exhibit 4.3 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019. 10.9# Form of Interpace Biosciences, Inc. 2019 Equity Incentive Plan Restricted Stock Unit And Restricted Stock Unit Agreement, incorporated by reference to Exhibit 10.9 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2020, filed with the SEC on June 26, 2020. 10.10# Form of Stock Option Grant Notice and Stock Option Agreement under the 2019 Equity Incentive Plan, incorporated by reference to Exhibit 4.4 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019. 10.11# Interpace Diagnostics Group, Inc. Employee Stock Purchase Plan, incorporated by reference to Exhibit 4.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2019, filed with the SEC on November 14, 2019. 10.12# Incentive Stock Option Agreement between Interpace Diagnostics Group, Inc. and James Early, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on October 20, 2016. 10.13# Incentive Stock Option Agreement between Interpace Diagnostics Group, Inc. and Jack E. Stover, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 20, 2016. 10.14# Employment Agreement, dated November 23, 2020, between Thomas W. Burnell and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 25, 2020. 10.15# Separation and Consulting Agreement and General Release, dated November 23, 2020, between Jack E. Stover and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 25, 2020. 10.16# Form of Indemnification Agreement by and between Interpace Diagnostics Group, Inc. and its directors and executive officers, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on August 8, 2016. 10.17# Form of Indemnification Agreement by and between Interpace Biosciences, Inc. and Indemnitee, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on January 17, 2020. 10.18 License Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference to Exhibit 10.31 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5, 2014. 10.19 CPRIT License Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference to Exhibit 10.32 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5, 2014. 10.20 Supply Agreement, dated August 13, 2014, by and between Interpace Diagnostics, LLC and Asuragen, Inc., incorporated by reference to Exhibit 10.33 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5, 2014. 10.21 Guaranty, dated August 13, 2014 by the Company in favor of Asuragen, Inc., incorporated by reference to Exhibit 10.34 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, filed with the SEC on November 5, 2014. 10.22 Morris Corporate Center Lease, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2009, filed with the SEC on November 5, 2009. 10.23 First Amendment to Lease, dated May 24, 2017, by and between Brookwood MC Investors, LLC, Brookwood MC II, LLC, and the Company, incorporated by reference to Exhibit 10.52 of the Company’s Registration Statement on Form S-1 (333-218140), as amended, filed with the SEC on June 13, 2017. 10.24 Lease, dated June 28, 2015, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference to Exhibit 10.42 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 5, 2015. 10.25 Amendment No. 1 to Lease, dated September 18, 2007, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference to Exhibit 10.43 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 5, 2015. 10.26 Amendment No. 2 to Lease, dated August 29, 2008, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference to Exhibit 10.44 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 5, 2015. 10.27 Amendment No. 3 to Lease, dated April 8, 2009, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference to Exhibit 10.45 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 5, 2015. 10.28 Amendment No. 4 to Lease, dated September 16, 2010, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference to Exhibit 10.46 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 5, 2015. 10.29 Amendment No. 5 to Lease, dated September 15, 2011, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference to Exhibit 10.47 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 5, 2015. 10.30 Amendment No. 6 to Lease, dated March 5, 2014, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference to Exhibit 10.48 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 5, 2015. 10.31 Amendment No. 7 to Lease, dated August 29, 2014, by and between WE 2 Church Street South LLC and JS Genetics, LLC, incorporated by reference to Exhibit 10.49 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2014, filed with the SEC on March 5, 2015. 10.32 Amendment No. 8 to Lease, dated December 31, 2019, by and between WE 2 Church Street South LLC and Interpace Diagnostics Lab Inc., incorporated by reference to Exhibit 10.34 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.33 Lease Agreement, dated March 31, 2017, by and between Saddle Lane Realty, LLC and the Company, incorporated by reference to Exhibit 10.53 of the Company’s Registration Statement on Form S-1 (333-218140), as amended on June 13, 2017. 10.34 First Amendment, dated September 26, 2017, by and between Saddle Lane Realty, LLC and Interpace Diagnostics Corporation, incorporated by reference to Exhibit 10.36 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time 10.35 Amendment No. 2 to Lease, dated March 15, 2018, between Saddle Lane Realty, LLC and Interpace Diagnostics Corporation, incorporated by reference to Exhibit 10.45 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2017, filed with the SEC on March 23, 2018. 10.36 Warrant Agency Agreement, dated June 21, 2017, by and between Interpace Diagnostics Group, Inc. and American Stock Transfer & Trust Company, LLC, incorporated by reference to Exhibit 1.2 of the Company’s Current Report on Form 8-K, filed with the SEC on June 21, 2017. 10.37 Office Lease Agreement, dated October 9, 2007, by and between Meadows Office, L.L.C. and Cancer Genetics, Inc., incorporated by reference to Exhibit 10.44 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.38 First Amendment to Lease, dated October 30, 2017, by and between Meadows Landmark LLC and Cancer Genetics, Inc., incorporated by reference to Exhibit 10.45 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.39 Consent to Assignment, dated July 19, 2019, by and among Meadows Landmark LLC, Cancer Genetics, Inc., and Interpace BioPharma, Inc, incorporated by reference to Exhibit 10.46 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.40 Lease Agreement, dated June 12, 2004, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.47 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.41 Letter Amendment, dated October 21, 2004, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.48 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.42 Second Amendment to Lease, dated June 17, 2005, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.49 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.43 Third Amendment to Lease, dated May 25, 2006, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.50 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.44 Fourth Amendment to Lease, dated December 20, 2007, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.51 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.45 Fifth Amendment to Lease, dated June 15, 2009, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.52 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.46 Sixth Amendment to Lease, dated June 3, 2010, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.53 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.47 Seventh Amendment to Lease, dated October 26, 2010, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.54 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.48 Eighth Amendment to Lease, dated July 27, 2011, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.55 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.49 Ninth Amendment to Lease, dated November 7, 2012, by and between Southport Business Park Limited Partnership and Gentris Corporation, incorporated by reference to Exhibit 10.56 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.50 Tenth Amendment to Lease, dated July 15, 2014, by and among Southport Business Park Limited Partnership, Gentris Corporation, and Gentris, LLC, incorporated by reference to Exhibit 10.57 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.51 Eleventh Amendment to Lease, effective as of June 1, 2020, by and between Southport Business Park Limited Partnership and Interpace Pharma Solutions, Inc., incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on June 9, 2020. 10.52 Assignment of Lease, dated July 15, 2019, by and between Cancer Genetics, Inc. and Interpace BioPharma, Inc., incorporated by reference to Exhibit 10.58 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.53 Guaranty of Lease, dated July 15, 2019, by and between Interpace Diagnostics Group, Inc. and Southport Business Park Limited Partnership, incorporated by reference to Exhibit 10.59 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019, filed with the SEC on April 22, 2020, as amended from time to time. 10.54 Securities Purchase and Exchange Agreement, dated January 10, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 14, 2020. 10.55 Amended and Restated Investor Rights Agreement, dated as of January 15, 2020, by and among Interpace Biosciences, Inc., 1315 Capital II, L.P. and Ampersand 2018 Limited Partnership, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on January 17, 2020. 10.56 Support Agreement, dated April 2, 2020, by and between 1315 Capital II, L.P. and Interpace Biosciences, Inc., incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2020, filed with the SEC on October 19, 2020. 10.57 Lease Termination Notice to Meadows Landmark, LLC for the Company’s laboratory facility at Meadows Office Complex, 201 Route 17 North, Rutherford, New Jersey, effective March 31, 2021, incorporated by reference to Exhibit 10.73 of the Company’s Annual Report on Form 10-k for the year ended December 31, 2021, filed with the SEC on October April 1, 2021. 10.58 Severance agreement and General Release, dated January 31, 2021, by and between the Company and Fred Knechtel, incorporated by reference to Exhibit 10.1 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on October May 11, 2021. 10.59 Employment agreement entered into May 10, 2021, effective February 1, 2021, between Thomas Freeburg and the Company, incorporated by reference to Exhibit 10.2 of the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021. 10.60 Asset Purchase Agreement by and among the Company and Diamir Biosciences Corp. dated March 16, 2021, incorporated by reference to Exhibit 2.1 of the Company’s Form 10-Q for the quarter ended March 31, 2021, filed with the SEC on May 11, 2021. 10.61 Loan and Security Agreement by and between Comerica Bank, Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated October 13, 2021, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on October 19, 2021. 10.62 Subordination Agreement by and between Ampersand 2018 Limited Partnership, 1315 Capital II. L.P., Comerica Bank Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated October 13, 2021, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on October 19, 2021. 10.63 Loan and Security Agreement by and between BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated October 29, 2021, incorporated by reference to Exhibit 10.1 of the Company’s Current Report on Form 8-K, filed with the SEC on November 3, 2021. 10.64 First Amendment to Loan and Security Agreement by and between Comerica Bank, Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated November 1, 2021, incorporated by reference to Exhibit 10.2 of the Company’s Current Report on Form 8-K, filed with the SEC on November 3, 2021. 10.65 Subordination and Intercreditor Agreement by and between Comerica Bank, BroadOak Fund V, L.P., Interpace Biosciences, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc., dated as of November 1, 2021, incorporated by reference to Exhibit 10.3 of the Company’s Current Report on Form 8-K, filed with the SEC on November 3, 2021. 10.66* Standby Purchase Agreement by and among Interpace Biosciences, Inc., 3K Limited Partnership, Peter H. Kamin, Peter H. Kamin Revocable Trust dated February 2003, Peter H. Kamin Childrens Trust dated March 1997 and Peter H. Kamin Family Foundation, dated [●], 2021. 10.67* Registration Rights Agreement by and between Interpace Biosciences, Inc. and 3K Limited Partnership, dated [●], 2021. 10.68* Investor Rights Agreement by and between Interpace Biosciences, Inc. and 3K Limited Partnership, dated [●], 2021. 21.1 Subsidiaries of the Registrant, incorporated by reference to Exhibit 21.1 of the Company’s Annual Report on Form 10-K for the year ended December 31, 2021, filed with the SEC on October April 1, 2021, as amended from time to time. 23.1 Consent of BDO USA, LLP, filed herewith. 23.2* Consent of Troutman Pepper Hamilton Sanders, LLP (included in Exhibit 5.1) * To be filed by amendment. # Denotes compensatory plan, compensation arrangement or management contract. Item 17. Undertakings (a) The undersigned registrant hereby undertakes: (1) To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement: (i) To include any prospectus required by Section 10(a)(3) of the Securities Act of 1933; (ii) To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant to Rule 424(b) if, in the aggregate, the changes in volume and price represent, no more than a 20% change in the maximum aggregate offering price set forth in the “Calculation of Registration Fee” table in the effective registration statement; and (iii) To include any material information with respect to the plan of distribution not previously disclosed in the registration statement or any material change to such information in the registration statement. Provided, however . (2) That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide (3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering. (4) That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser, each prospectus filed pursuant to Rule 424(b) as part of a registration statement relating to an offering, other than registration statements relying on Rule 430B or other than prospectuses filed in reliance on Rule 430A, shall be deemed to be part of and included in the registration statement as of the date it is first used after effectiveness. Provided, however (5) That, for the purpose of determining liability of the registrant under the Securities Act of 1933 to any purchaser in the initial distribution of the securities, the undersigned registrant undertakes that in a primary offering of securities of the undersigned registrant pursuant to this registration statement, regardless of the underwriting method used to sell the securities to the purchaser, if the securities are offered or sold to such purchaser by means of any of the following communications, the undersigned registrant will be a seller to the purchaser and will be considered to offer or sell such securities to such purchaser: (i) any preliminary prospectus or prospectus of the undersigned registrant relating to the offering required to be filed pursuant to Rule 424; (ii) any free writing prospectus relating to the offering prepared by or on behalf of the undersigned registrant or used or referred to by the undersigned registrant; (iii) the portion of any other free writing prospectus relating to the offering containing material information about the undersigned registrant or its securities provided by or on behalf of the undersigned registrant; and (iv) any other communication that is an offer in the offering made by the undersigned registrant to the purchaser. (b) The undersigned registrant hereby undertakes that, for purposes of determining any liability under the Securities Act of 1933, each filing of the registrant’s annual report pursuant to Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934 (and, where applicable, each filing of an employee benefit plan’s annual report pursuant to Section 15(d) of the Securities Exchange Act of 1934) that is incorporated by reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial bona fide (c) Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitte

SUMMARY OF SIGNIFICANT ACCOUN_2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
Accounting Estimates	Accounting Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates.	Accounting Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts and notes, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates.
Revenue Recognition	Revenue Recognition Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become known. For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract while performance-related obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.	Revenue Recognition Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known. During 2019, the Company recorded a reduction to revenue of $ 3.5 For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer. The Company elected the practical expedient to expense contract costs as incurred related to clinical services because the contract term is less than one year. Contract costs for pharma services were not significant.
Deferred Revenue	Deferred Revenue For our pharma services, project level fee revenue is recognized as deferred revenue and recorded at fair value. It represents payments received in advance of services rendered and is recognized ratably over the life of the contract.
Financing and Payment	Financing and Payment For non-Medicare claims, our payment terms vary by payer category. Payment terms for direct-payers in our clinical services are typically thirty days and in our pharma services, up to sixty days. Commercial third-party-payers are required to respond to a claim within a time period established by their respective state regulations, generally between thirty to sixty days. However, payment for commercial third-party claims may be subject to a denial and appeal process, which could take up to two years in some instances where multiple appeals are submitted. The Company generally appeals all denials from commercial third-party payers. We bill Medicare directly for tests performed for Medicare patients and must accept Medicare’s fee schedule for the covered tests as payment in full.
Costs to Obtain or Fulfill a Customer Contract	Costs to Obtain or Fulfill a Customer Contract Sales commissions are expensed in the period in which they have been earned. These costs are recorded in sales and marketing expense in the condensed consolidated statements of operations.
Accounts Receivable	Accounts Receivable The Company’s accounts receivables represent unconditional rights to consideration and are generated using its clinical services and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.	Accounts Receivable, Net The Company’s accounts receivables represent unconditional rights to consideration and are generated using its proprietary tests and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.
Leases	Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7, Leases	Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 9, Leases
Other Current Assets	Other Current Assets Other current assets consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF OTHER CURRENT ASSETS September 30, 2021 December 31, 2020 (unaudited) Lab supply inventory $ 2,271 $ 2,052 Prepaid expenses 734 625 Other 130 45 Funds in escrow - - Total other current assets $ 3,135 $ 2,722	Other current assets Other current assets consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF OTHER CURRENT ASSETS December 31, 2020 December 31, 2019 Lab supply inventory $ 2,052 $ 1,825 Prepaid expenses 625 971 Funds in escrow - 888 Other 45 167 Total other current assets $ 2,722 $ 3,851
Long-Lived Assets, including Finite-Lived Intangible Assets	Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related amortization expense in the condensed consolidated statements of operations. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.	Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years ten years The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment. Additionally, the Company concluded that amortization of both the Barrett’s intangible asset and its Thyroid intangible assets should have begun at the point in which the asset was ready for use. The Company’s policy had been to amortize such assets upon launch of the test.
Basic and Diluted Net Loss per Share	Basic and Diluted Net Loss per Share A reconciliation of the number of shares of common stock, par value $ 0.01 SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Basic weighted average number of common shares 4,165 4,038 4,119 4,025 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 4,165 4,038 4,119 4,025 The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Options 684 878 684 878 Restricted stock and restricted stock units (RSUs) 366 28 366 28 Warrants 1,405 1,405 1,405 1,405 2,455 2,311 2,455 2,311	Income (Loss) per Share Basic earnings per common share are computed by dividing net income by the weighted average number of shares outstanding during the year including any unvested share-based payment awards that contain nonforfeitable rights to dividends. Diluted earnings per common share are computed by dividing net income by the sum of the weighted average number of shares outstanding and dilutive common shares under the treasury method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid), are participating securities and are included in the computation of earnings per share pursuant to the two-class method. As a result of the losses incurred in both 2020 and 2019, the potentially dilutive common shares have been excluded from the earnings per share computation for these periods because its inclusion would have been anti-dilutive. Additionally, preferred shares have been excluded in the denominator of the earnings per share computation, on an if-converted basis, as such shares would have been anti-dilutive.
Reclassifications	Reclassifications The Company reclassified certain prior period balances to conform to the current year presentation.

Nature of Business and Signif_2

Nature of Business and Significant Accounting Policies (Policies)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Nature of Business		Nature of Business Interpace Biosciences, Inc. (“Interpace” or the “Company”) enables personalized medicine, offering specialized services along the therapeutic value chain from early diagnosis and prognostic planning to targeted therapeutic applications and pharma services. The Company provides molecular diagnostics, bioinformatics and pathology services for evaluation of risk of cancer by leveraging the latest technology in personalized medicine for improved patient diagnosis and management. The Company also provides pharmacogenomics testing, genotyping, biorepository and other specialized services to the pharmaceutical and biotech industries. The Company advances personalized medicine by partnering with pharmaceutical, academic, and technology leaders to effectively integrate pharmacogenomics into their drug development and clinical trial programs.
Principles of Consolidation		Principles of Consolidation The accompanying consolidated financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”). The consolidated financial statements include the accounts of Interpace Biosciences, Inc. fka Interpace Diagnostics Group, Inc., Interpace Diagnostics Corporation, Interpace Diagnostics, LLC and Interpace Pharma Solutions, Inc. fka Interpace Biopharma, Inc. Discontinued operations include the Company’s wholly-owned subsidiaries: Group DCA, LLC (“Group DCA”), InServe Support Solutions (Pharmakon), and TVG, Inc. (TVG, dissolved December 31, 2014) and its Commercial Services (“CSO”) business unit. All significant intercompany balances and transactions have been eliminated in consolidation. The Company has one
Accounting Estimates	Accounting Estimates The preparation of condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates in earnings as appropriate. Actual results could materially differ from those estimates.	Accounting Estimates The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts of assets and liabilities reported and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Management’s estimates are based on historical experience, facts and circumstances available at the time, and various other assumptions that are believed to be reasonable under the circumstances. Significant estimates include accounting for valuation allowances related to deferred income taxes, contingent consideration, allowances for doubtful accounts and notes, revenue recognition, unrecognized tax benefits, and asset impairments involving other intangible assets. The Company periodically reviews these matters and reflects changes in estimates as appropriate. Actual results could materially differ from those estimates.
Reverse stock split		Reverse stock split On January 15, 2020, the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share. 39,323,701 3,932,370 39,205,895 3,920,589 ly adjusted to give effect to the reverse stock split for all periods presented.
Immaterial Revision		Immaterial Revision In 2020, the Company completed an Internal Revenue Code Section 382 analysis of its historical net operating loss carry-forward amount. As a result, the prior year net operating loss carry-forward was determined to be limited. See Note 17 Income Taxes
Cash and Cash Equivalents		Cash and Cash Equivalents Cash and cash equivalents include unrestricted cash accounts, money market investments and highly liquid investment instruments with original maturity of three months or less at the date of purchase.
Accounts Receivable, Net	Accounts Receivable The Company’s accounts receivables represent unconditional rights to consideration and are generated using its clinical services and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third-party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.	Accounts Receivable, Net The Company’s accounts receivables represent unconditional rights to consideration and are generated using its proprietary tests and pharma services. The Company’s clinical services are fulfilled upon completion of the test, review and release of the test results. In conjunction with fulfilling these services, the Company bills the third-party payer or direct-bill payer. Contractual adjustments represent the difference between the list prices and the reimbursement rates set by third party payers, including Medicare, commercial payers, and amounts billed to direct-bill payers. Specific accounts may be written off after several appeals, which in some cases may take longer than twelve months. Pharma services represent, primarily, the performance of laboratory tests in support of clinical trials for pharma services customers. The Company bills these services directly to the customer.
Other current assets	Other Current Assets Other current assets consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF OTHER CURRENT ASSETS September 30, 2021 December 31, 2020 (unaudited) Lab supply inventory $ 2,271 $ 2,052 Prepaid expenses 734 625 Other 130 45 Funds in escrow - - Total other current assets $ 3,135 $ 2,722	Other current assets Other current assets consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF OTHER CURRENT ASSETS December 31, 2020 December 31, 2019 Lab supply inventory $ 2,052 $ 1,825 Prepaid expenses 625 971 Funds in escrow - 888 Other 45 167 Total other current assets $ 2,722 $ 3,851
Property and Equipment, net		Property and Equipment, net Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation and amortization is recognized on a straight-line basis, using the estimated useful lives of: seven twelve years two five years three twelve years three ten years
Software Costs		Software Costs Internal-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining internal-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three seven years External-Use Software - It is the Company’s policy to capitalize certain costs incurred in connection with developing or obtaining external-use software. Capitalized software costs are included in property and equipment on the consolidated balance sheet and amortized over the software’s useful life, generally three years See Note 7, Property and Equipment
Long-Lived Assets, including Finite-Lived Intangible Assets	Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years to ten years in acquisition-related amortization expense in the condensed consolidated statements of operations. The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary.	Long-Lived Assets, including Finite-Lived Intangible Assets Finite-lived intangible assets are stated at cost less accumulated amortization. Amortization of finite-lived acquired intangible assets is recognized on a straight-line basis, using the estimated useful lives of the assets of approximately two years ten years The Company reviews the recoverability of long-lived assets and finite-lived intangible assets whenever events or changes in circumstances indicate that the carrying value of such assets may not be recoverable. If the sum of the expected future undiscounted cash flows is less than the carrying amount of the asset, an impairment loss is recognized by reducing the recorded value of the asset to its fair value measured by future discounted cash flows. This analysis requires estimates of the amount and timing of projected cash flows and, where applicable, judgments associated with, among other factors, the appropriate discount rate. Such estimates are critical in determining whether any impairment charge should be recorded and the amount of such charge if an impairment loss is deemed to be necessary. As a result of overall economic conditions related to the coronavirus pandemic, the impact of the coronavirus pandemic on the Company’s financial results, and the decrease in the price of the Company’s common stock noted during the third quarter of fiscal 2020, the Company performed an internal review of its long-lived assets. Due to an extended delay in the launch of the Company’s Barrett’s test, the Company believes there was a triggering event in Fiscal 2016. The Company applied the required procedures under ASC 360 and assessed the estimated future cash flows related to the Barrett’s intangible asset on an undiscounted basis. It was determined that the carrying value of the asset was in excess of the undiscounted cash flows as of December 31, 2016. As a result, the Company performed a formal valuation of the asset on a discounted basis in order to measure the related impairment. Additionally, the Company concluded that amortization of both the Barrett’s intangible asset and its Thyroid intangible assets should have begun at the point in which the asset was ready for use. The Company’s policy had been to amortize such assets upon launch of the test.
Contingencies		Contingencies In the normal course of business, the Company is subject to various contingencies. Contingencies are recorded in the consolidated financial statements when it is probable that a liability will be incurred and the amount of the loss is reasonably estimable, or otherwise disclosed, in accordance with ASC 450, Contingencies. Significant judgment is required in both the determination of probability and the determination as to whether a loss is reasonably estimable. In the event the Company determines that a loss is not probable, but is reasonably possible, and it becomes possible to develop what the Company believes to be a reasonable range of possible loss, then the Company will include disclosures related to such matter as appropriate and in compliance with ASC 450. To the extent there is a reasonable possibility that the losses could exceed the amounts already accrued, the Company will, when applicable, adjust the accrual in the period the determination is made, disclose an estimate of the additional loss or range of loss, indicate that the estimate is immaterial with respect to its financial statements as a whole or, if the amount of such adjustment cannot be reasonably estimated, disclose that an estimate cannot be made. The Company is not currently involved in any legal proceedings of a material nature and, accordingly, the Company has not accrued estimated costs related to any legal claims.
Revenue Recognition	Revenue Recognition Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Under Accounting Standards Codification 606, revenue is recognized based on the estimated transaction price or net realizable value (“NRV”), which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which affects net revenue in the period such variances become known. For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract while performance-related obligations are satisfied at a point in time as the Company processes samples delivered by the customer. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer.	Revenue Recognition Our clinical services derive its revenues from the performance of its proprietary assays or tests. The Company’s performance obligation is fulfilled upon the completion, review and release of test results to the customer. The Company subsequently bills third-party payers or direct-bill payers for the tests performed. Revenue is recognized based on the estimated transaction price or NRV, which is determined based on historical collection rates by each payer category for each proprietary test offered by the Company. To the extent the transaction price includes variable consideration, for all third party and direct-bill payers and proprietary tests, the Company estimates the amount of variable consideration that should be included in the transaction price using the expected value method based on historical experience. For our clinical services, we regularly review the ultimate amounts received from the third-party and direct-bill payers and related estimated reimbursement rates and adjust the NRV’s and related contractual allowances accordingly. If actual collections and related NRV’s vary significantly from our estimates, we will adjust the estimates of contractual allowances, which would affect net revenue in the period such variances become known. During 2019, the Company recorded a reduction to revenue of $ 3.5 For our pharma services, project level activities, including study setup and project management, are satisfied over the life of the contract. Revenues are recognized at a point in time when the test results or other deliverables are reported to the customer. The Company elected the practical expedient to expense contract costs as incurred related to clinical services because the contract term is less than one year. Contract costs for pharma services were not significant.
Cost of revenue		Cost of revenue Cost of revenue consists primarily of the costs associated with operating our laboratories and other costs directly related to our tests. Personnel costs, which constitute the largest portion of cost of services, include all labor related costs, such as salaries, bonuses, fringe benefits and payroll taxes for laboratory personnel. Other direct costs include, but are not limited to, laboratory supplies, certain consulting expenses, royalty expenses, and facility expenses.
Stock-Based Compensation		Stock-Based Compensation The compensation cost associated with the granting of stock-based awards is based on the grant date fair value of the stock award. The Company recognizes the compensation cost, net of estimated forfeitures, over the shorter of the vesting period or the period from the grant date to the date when retirement eligibility is achieved. Forfeitures are initially estimated based on historical information and subsequently updated over the life of the awards to ultimately reflect actual forfeitures. As a result, changes in forfeiture activity can influence the amount of stock compensation cost recognized from period to period. The Company primarily uses the Black-Scholes option-pricing model to determine the fair value of stock options and stock appreciation rights (“SARs”). The determination of the fair value of stock-based payment awards is made on the date of grant and is affected by the Company’s stock price as well as assumptions made regarding a number of complex and subjective variables. These assumptions include: expected stock price volatility over the term of the awards; actual and projected employee stock option exercise behaviors; the risk-free interest rate; and expected dividend yield. The fair value of restricted stock units, or RSUs, and restricted shares is equal to the closing stock price on the date of grant. In 2020, the Company issued performance-based options and RSUs based on achieving stock price or certain other financial metrics. These require the Company to assess the likelihood of achieving certain performance milestones on a quarterly basis. In these instances, the Company has the initial valuation model prepared by an outside expert. See Note 15, Stock-Based Compensation,
Treasury Stock		Treasury Stock Treasury stock purchases are accounted for under the cost method whereby the entire cost of the acquired stock is recorded as treasury stock. Upon reissuance of shares, the Company records any difference between the weighted-average cost of such shares and any proceeds received as an adjustment to additional paid-in capital.
Leases	Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 7, Leases	Leases The Company determines if an arrangement contains a lease in whole or in part at the inception of the contract. Right-of-use (“ROU”) assets represent the Company’s right to use an underlying asset for the lease term while lease liabilities represent our obligation to make lease payments arising from the lease. All leases with terms greater than twelve months result in the recognition of a ROU asset and a liability at the lease commencement date based on the present value of the lease payments over the lease term. Unless a lease provides all of the information required to determine the implicit interest rate, we use our incremental borrowing rate based on the information available at the commencement date in determining the present value of the lease payments. We use the implicit interest rate in the lease when readily determinable. Our lease terms include all non-cancelable periods and may include options to extend (or to not terminate) the lease when it is reasonably certain that we will exercise that option. Leases with terms of twelve months or less at the commencement date are expensed on a straight-line basis over the lease term and do not result in the recognition of an asset or liability. See Note 9, Leases
Income taxes		Income taxes Income taxes are based on income for financial reporting purposes calculated using the Company’s expected annual effective rate and reflect a current tax liability or asset for the estimated taxes payable or recoverable on the current year tax return and expected annual changes in deferred taxes. Any interest or penalties on income tax are recognized as a component of income tax expense. The Company accounts for income taxes using the asset and liability method. This method requires recognition of deferred tax assets and liabilities for expected future tax consequences of temporary differences that currently exist between tax bases and financial reporting bases of the Company’s assets and liabilities based on enacted tax laws and rates. Deferred tax expense (benefit) is the result of changes in the deferred tax asset and liability. A valuation allowance is established, when necessary, to reduce the deferred income tax assets when it is more likely than not that all or a portion of a deferred tax asset will not be realized. The Company operates in multiple tax jurisdictions and pays or provides for the payment of taxes in each jurisdiction where it conducts business and is subject to taxation. The breadth of the Company’s operations and the complexity of the tax law require assessments of uncertainties and judgments in estimating the ultimate taxes the Company will pay. The final taxes paid are dependent upon many factors, including negotiations with taxing authorities in various jurisdictions, outcomes of tax litigation and resolution of proposed assessments arising from federal and state audits. Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement. Th Significant judgment is also required in evaluating the need for and magnitude of appropriate valuation allowances against deferred tax assets. Deferred tax assets are regularly reviewed for recoverability. The Company currently has significant deferred tax assets resulting from net operating loss carryforwards and deductible temporary differences, which should reduce taxable income in future periods, if generated. The realization of these assets is dependent on generating future taxable income.
Income (Loss) per Share	Basic and Diluted Net Loss per Share A reconciliation of the number of shares of common stock, par value $ 0.01 SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Basic weighted average number of common shares 4,165 4,038 4,119 4,025 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 4,165 4,038 4,119 4,025 The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Options 684 878 684 878 Restricted stock and restricted stock units (RSUs) 366 28 366 28 Warrants 1,405 1,405 1,405 1,405 2,455 2,311 2,455 2,311	Income (Loss) per Share Basic earnings per common share are computed by dividing net income by the weighted average number of shares outstanding during the year including any unvested share-based payment awards that contain nonforfeitable rights to dividends. Diluted earnings per common share are computed by dividing net income by the sum of the weighted average number of shares outstanding and dilutive common shares under the treasury method. Unvested share-based payment awards that contain nonforfeitable rights to dividends or dividend equivalents (whether paid or unpaid), are participating securities and are included in the computation of earnings per share pursuant to the two-class method. As a result of the losses incurred in both 2020 and 2019, the potentially dilutive common shares have been excluded from the earnings per share computation for these periods because its inclusion would have been anti-dilutive. Additionally, preferred shares have been excluded in the denominator of the earnings per share computation, on an if-converted basis, as such shares would have been anti-dilutive.

SUMMARY OF SIGNIFICANT ACCOUN_3

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Accounting Policies [Abstract]
SCHEDULE OF OTHER CURRENT ASSETS	Other current assets consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF OTHER CURRENT ASSETS September 30, 2021 December 31, 2020 (unaudited) Lab supply inventory $ 2,271 $ 2,052 Prepaid expenses 734 625 Other 130 45 Funds in escrow - - Total other current assets $ 3,135 $ 2,722	Other current assets consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF OTHER CURRENT ASSETS December 31, 2020 December 31, 2019 Lab supply inventory $ 2,052 $ 1,825 Prepaid expenses 625 971 Funds in escrow - 888 Other 45 167 Total other current assets $ 2,722 $ 3,851
SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE	SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Basic weighted average number of common shares 4,165 4,038 4,119 4,025 Potential dilutive effect of stock-based awards - - - - Diluted weighted average number of common shares 4,165 4,038 4,119 4,025
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Options 684 878 684 878 Restricted stock and restricted stock units (RSUs) 366 28 366 28 Warrants 1,405 1,405 1,405 1,405 2,455 2,311 2,455 2,311	The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Years Ended December 31, 2020 2019 Options 849 416 Restricted stock units (RSUs) 238 49 Warrants 1,405 1,420 2,492 1,885

GOODWILL AND OTHER INTANGIBLE_2

GOODWILL AND OTHER INTANGIBLE ASSETS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE	SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE As of As of Life Carrying Carrying (Years) Amount Amount (unaudited) Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett’s test 9 6,682 6,682 BioPharma acquisition: Trademarks 10 1,600 1,600 Customer relationships 8 5,700 5,700 CLIA Lab 2.3 609 609 Total $ 39,251 $ 39,251 Accumulated Amortization $ (31,237 ) $ (27,900 ) Net Carrying Value $ 8,014 $ 11,351	SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE As of As of Life Carrying Carrying (Years) Amount Amount Asuragen acquisition: Thyroid 9 $ 8,519 $ 8,519 RedPath acquisition: Pancreas test 7 16,141 16,141 Barrett’s test 9 6,682 6,719 BioPharma acquisition: Trademarks 10 1,600 1,600 Customer relationships 8 5,700 5,700 CLIA Lab 2.3 $ 609 $ 609 Total $ 39,251 $ 39,288 Accumulated Amortization $ (27,900 ) $ (23,439 ) Net Carrying Value $ 11,351 $ 15,849
Schedule of Future Estimated Amortization Expense	SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE 2021 2022 2023 2024 2025 $ 1,112 $ 2,155 $ 2,099 $ 873 $ 873	Schedule of Future Estimated Amortization Expense 2021 2022 2023 2024 2025 $ 4,078 $ 2,156 $ 1,745 $ 873 $ 873
SCHEDULE OF GOODWILL CARRYING VALUE	The following table displays a roll forward of the carrying amount of goodwill from December 31, 2020 to September 30, 2021: SCHEDULE OF GOODWILL CARRYING VALUE Carrying Amount Balance as of December 31, 2020 $ 8,433 Adjustments - Balance as of September 30, 2021 $ 8,433	The following table displays a roll forward of the carrying amount of goodwill from January 1, 2019 to December 31, 2020: SCHEDULE OF GOODWILL CARRYING VALUE Carrying Amount Balance as of January 1, 2019 $ - Goodwill acquired 8,273 Adjustments 160 Balance as of December 31, 2019 8,433 Adjustments - Balance as of December 31, 2020 $ 8,433

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS	SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS As of September 30, 2021 Fair Value Measurements Carrying Fair As of September 30, 2021 Amount Value Level 1 Level 2 Level 3 (unaudited) Liabilities: Contingent consideration: Asuragen (1) $ 2,136 $ 2,136 $ $ - $ 2,136 Other long-term liabilities: Warrant liability (2) 158 158 - - 158 $ 2,294 $ 2,294 $ - $ - $ 2,294 As of December 31, 2020 Fair Value Measurements Carrying Fair As of December 31, 2020 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 2,216 $ 2,216 $ - $ - $ 2,216 Other long-term liabilities: Warrant liability (2) 21 21 - - 21 $ 2,237 $ 2,237 $ - $ - $ 2,237 (1)(2) Accrued Expenses and Long-Term Liabilities (1) See Note 9, Accrued Expenses and Long-Term Liabilities (2) See Note 9, Accrued Expenses and Long-Term Liabilities	SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS As of December 31, 2020 Fair Value Measurements Carrying Fair As of December 31, 2020 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 2,216 $ 2,216 $ - $ - $ 2,216 Other long-term liabilities: Warrant liability (2) 21 21 - - 21 $ 2,237 $ 2,237 $ - $ - $ 2,237 As of December 31, 2019 Fair Value Measurements Carrying Fair As of December 31, 2019 Amount Value Level 1 Level 2 Level 3 Liabilities: Contingent consideration: Asuragen (1) $ 2,893 $ 2,893 $ - $ - $ 2,893 Other long-term liabilities: Warrant liability (2) 82 82 - - 82 $ 2,975 $ 2,975 $ - $ - $ 2,975
SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION	A roll forward of the carrying value of the Contingent Consideration Liability and the 2017 Underwriters’ Warrants to September 30, 2021 is as follows: SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION Cancellation of Obligation/ Adjustment to Fair Value/ December 31, 2020 Payments Accretion Conversions Exercises Mark to Market September 30, (unaudited) Contingent consideration liability $ 2,216 $ (398 ) $ 375 $ $ (57 ) $ 2,136 Underwriters Warrants 21 - - - 137 158 $ 2,237 $ (398 ) $ 375 $ - $ 80 $ 2,294	SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION Cancellation Adjustment of Obligation/ to Fair Value/ December 31, Payments Accretion Conversions Exercises Mark to Market December 31, Asuragen $ 2,893 $ (737 ) $ 549 $ - $ (489 ) $ 2,216 Underwriters Warrants 82 - - - (61 ) 21 $ 2,975 $ (737 ) $ 549 $ - $ (550 ) $ 2,237

LEASES (Tables)

LEASES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Leases
SCHEDULE OF FINANCING AND OPERATING LEASES	The table below presents the lease-related assets and liabilities recorded in the Condensed Consolidated Balance Sheet: SCHEDULE OF FINANCING AND OPERATING LEASES Classification on the Balance Sheet September 30, December 31, (unaudited) Assets Financing lease assets Property and equipment, net $ 652 $ 597 Operating lease assets Operating lease right of use assets 3,989 4,384 Total lease assets $ 4,641 $ 4,981 Liabilities Current Financing lease liabilities Other accrued expenses $ 98 $ 177 Operating lease liabilities Other accrued expenses 1,030 1,027 Total current lease liabilities $ 1,128 $ 1,204 Noncurrent Financing lease liabilities Other long-term liabilities 75 138 Operating lease liabilities Operating lease liabilities, net of current portion 3,152 3,540 Total long-term lease liabilities 3,227 3,678 Total lease liabilities $ 4,355 $ 4,882	The table below presents the lease-related assets and liabilities recorded in the Consolidated Balance Sheet: SCHEDULE OF FINANCING AND OPERATING LEASES Classification on the Balance Sheet December 31, 2020 (unaudited) Assets Financing lease assets Property and equipment, net $ 597 Operating lease assets Operating lease right of use assets 4,384 Total lease assets $ 4,981 Liabilities Current Financing lease liabilities Other accrued expenses $ 177 Operating lease liabilities Other accrued expenses 1,027 Total current lease liabilities $ 1,204 Noncurrent Financing lease liabilities Other long-term liabilities 138 Operating lease liabilities Operating lease liabilities, net of current portion 3,540 Total long-term lease liabilities 3,678 Total lease liabilities $ 4,882
Schedule of Maturities of Operating and Financing Lease Liabilities	The table below reconciles the cash flows to the lease liabilities recorded on the Company’s Condensed Consolidated Balance Sheet as of September 30, 2021: SCHEDULE OF MATURITIES OF OPERATING AND FINANCING LEASE LIABILITIES Operating Leases Financing Leases 2021 (remaining through December 31) 312 39 2022 1,192 86 2023 794 60 2024 473 - 2025 402 - 2026 414 - Thereafter 1,510 - Total minimum lease payments 5,097 185 Less: amount of lease payments representing effects of discounting 915 12 Present value of future minimum lease payments 4,182 173 Less: current obligations under leases 1,030 98 Long-term lease obligations $ 3,152 $ 75	The table below reconciles the undiscounted cash flows to the lease liabilities recorded on the Company’s Consolidated Balance Sheet as of December 31, 2020: Schedule of Maturities of Operating and Financing Lease Liabilities Operating Leases Financing Leases 2021 1,235 185 2022 1,028 78 2023 629 65 2024 390 - 2024-2030 2,327 Total minimum lease payments 5,609 329 Less: amount of lease payments representing effects of discounting 1,042 14 Present value of future minimum lease payments 4,567 315 Less: current obligations under leases 1,027 177 Long-term lease obligations $ 3,540 $ 138
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES	As of September 30, 2021, contractual obligations with terms exceeding one year and estimated minimum future rental payments required by non-cancelable operating leases with initial or remaining lease terms exceeding one year were as follows: SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES Less than 1 to 3 3 to 5 After Total 1 Year Years Years 5 Years Operating lease obligations $ 5,097 $ 312 $ 1,986 $ 875 $ 1,924 Total $ 5,097 $ 312 $ 1,986 $ 875 $ 1,924

ACCRUED EXPENSES AND LONG-TER_2

ACCRUED EXPENSES AND LONG-TERM LIABILITIES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
SCHEDULE OF OTHER ACCRUED EXPENSES	Other accrued expenses consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF OTHER ACCRUED EXPENSES September 30, 2021 December 31, 2020 (unaudited) Accrued royalties $ 3,572 $ 2,710 Upfront Medicare payment - 2,066 Operating lease liabilities 1,030 1,027 All others 1,056 1,182 Accrued professional fees 931 854 Unclaimed property 565 565 Contingent consideration 473 398 Accrued pharma services invoices 438 108 Taxes payable 248 334 Accrued lab costs - diagnostics 514 161 Financing lease liabilities 98 177 ESPP payable 37 108 Accrued sales and marketing - diagnostics 41 51 Deferred revenue 40 54 Total other accrued expenses $ 9,043 $ 9,795	Other accrued expenses consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF OTHER ACCRUED EXPENSES December 31, 2020 December 31, 2019 Accrued royalties $ 2,710 $ 1,934 Contingent consideration 398 502 Upfront Medicare payment 2,066 - Operating lease liability 1,027 1,321 Financing lease liability 177 184 Deferred revenue 54 457 Payable to CGI - 888 Accrued sales and marketing - diagnostics 51 197 Accrued lab costs - diagnostics 161 163 Accrued professional fees 854 1,399 Taxes payable 334 403 Unclaimed property 565 565 All others 1,398 1,463 Total other accrued expenses $ 9,795 $ 9,476
SCHEDULE OF LONG TERM LIABILITIES	Long-term liabilities consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF LONG TERM LIABILITIES September 30, 2021 December 31, 2020 (unaudited) Uncertain tax positions $ 4,517 $ 4,342 Warrant liability 158 21 Financing lease liabilities 75 138 Deferred revenue 18 136 Other - 138 Total other long-term liabilities $ 4,768 $ 4,637	Other long-term liabilities consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF LONG TERM LIABILITIES December 31, 2020 December 31, 2019 Warrant liability $ 21 $ 82 Uncertain tax positions 4,342 4,081 Deferred revenue 136 269 Other 138 141 Total other long-term liabilities $ 4,637 $ 4,573

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions	The following table provides the weighted average assumptions used in determining the fair value of the stock option awards granted during the nine-month periods ended September 30, 2021 and 2020. SCHEDULE OF FAIR VALUE ASSUMPTIONS OF STOCK OPTIONS September 30, 2021 September 30, 2020 (unaudited) Risk-free interest rate 0.78 % 0.79 % Expected life 6.0 6.6 Expected volatility 134.79 % 122.24 % Dividend yield - -	The following table provides the weighted average assumptions used in determining the fair value of the stock options granted during the years ended December 31, 2020 and December 31, 2019. Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions December 31, 2020 December 31, 2019 Risk-free interest rate 0.75 % 2.34 % Expected life 6.5 5.9 Expected volatility 123.71 % 128.58 % Dividend yield - -
SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE	SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Cost of revenue $ 52 $ 60 $ 154 $ 187 Sales and marketing 76 39 201 136 Research and development 24 30 83 99 General and administrative* 325 434 876 959 Total stock compensation expense $ 477 $ 563 $ 1,314 $ 1,381 * Includes ESPP expense
Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award		Stock-based compensation for the years ended December 31, 2020 and 2019 is as follows: Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award 2020 2019 RSUs and restricted stock $ 176 $ 243 Performance-based awards 265 - Common stock awards 116 - Options 1,630 722 Total stock-based compensation expense $ 2,187 $ 965
Schedule of Stock Option Activity		A summary of stock option and SARs activity for the year ended December 31, 2020, and changes during such year, is presented below: Schedule of Stock Option Activity Weighted- Weighted-Average Average Remaining Aggregate Grant Contractual Intrinsic Shares Price Period (in years) Value Outstanding at January 1, 2020 415,678 $ 12.50 8.45 $ Granted 525,550 6.24 9.39 - Exercised - Forfeited or expired (92,409 ) 11.18 - Outstanding at December 31, 2020 848,819 8.76 8.59 - Exercisable at December 31, 2020 361,501 11.81 7.77 - Vested and expected to vest 659,465 9.48 8.39 -
Schedule of Non Vested Option Activity		A summary of the status of the Company’s non-vested options for the year ended December 31, 2020, and changes during such year, is presented below: Schedule of Non Vested Option Activity Shares Weighted- Average Grant Date Fair Value Nonvested at January 1, 2020 213,472 $ 8.80 Granted 525,550 5.36 Vested (197,998 ) 7.34 Forfeited (53,706 ) 7.86 Nonvested at December 31, 2020 487,318 $ 5.81
Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity		A summary of the Company’s non-vested shares of restricted stock and restricted stock units for the year ended December 31, 2020, and changes during such year, is presented below: Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity Weighted- Average Average Remaining Aggregate Grant Date Vesting Intrinsic Shares Fair Value Period (in years) Value Nonvested at January 1, 2020 49,366 $ 10.04 1.11 $ 246,830 Granted 236,321 3.43 - - Vested (43,976 ) 9.52 - - Forfeited (2,254 ) 10.10 - - Nonvested at December 31, 2020 239,457 $ 3.61 1.75 $ 751,895

INCOME TAXES (Tables)

INCOME TAXES (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION	SCHEDULE OF EFFECTIVE INCOME TAX RATE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) (Benefit) provision for income tax $ (714 ) $ 14 $ (684 ) $ 43 Effective income tax rate 16.9 % 0.2 % 5.8 % 0.2 %	A reconciliation of the difference between the federal statutory tax rates and the Company’s effective tax rate from continuing operations is as follows: SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION 2020 2019 Federal statutory rate 21.0 % 21.0 % State income tax rate, net of Federal tax benefit 4.0 % 3.0 % Meals and entertainment (0.1 )% (0.2 )% Valuation allowance (25.0 )% (23.8 )% Naked credit (0.1 )% (0.1 )% Discontinued operations allocation 0.0 % 0.2 % Effective tax rate (0.2 )% 0.1 %
Schedule of Components of Income Tax Expense (Benefit)		The benefit from income taxes on continuing operations for the years ended December 31, 2020 and 2019 is comprised of the following: Schedule of Components of Income Tax Expense (Benefit) 2020 2019 Current: Federal $ - $ (46 ) State 16 - Total current 16 (46 ) Deferred: Federal 23 11 State 14 7 Total deferred 37 18 Benefit from income taxes $ 53 $ (28 )
Schedule of Deferred Tax Assets and Liabilities		The tax effects of significant items comprising the Company’s deferred tax assets and (liabilities) as of December 31, 2020 and 2019 are as follows: Schedule of Deferred Tax Assets and Liabilities 2020 2019 Deferred tax assets: Federal net operating loss carryforwards $ 17,015 $ 11,664 State net operating loss carryforwards 2,953 1,834 Compensation 1,492 1,399 Allowances and reserves 436 457 Intangible assets 292 589 State taxes 900 848 Credit carryforward 229 229 163(j) interest 745 141 Leases 54 23 Deferred revenue 95 88 Valuation allowance (23,684 ) (17,027 ) Gross deferred tax assets 527 245 Deferred tax liability: Property and equipment (582 ) (263 ) Deferred tax liability-net valuation allowance $ (55 ) $ (18 )
Schedule of Unrecognized Tax Benefits Roll Forward		The following table summarizes the change in uncertain tax benefit reserves for the two years ended December 31, 2020: Schedule of Unrecognized Tax Benefits Roll Forward Unrecognized Tax Benefits Balance of unrecognized benefits as of January 1, 2019 $ 877 Additions for tax positions of prior years - Balance as of January 1, 2020 $ 877 Additions for tax positions of prior years - Balance as of December 31, 2020 $ 877
Schedule of Tax Years Subject to Examination		Schedule of Tax Years Subject to Examination Jurisdiction Tax Years Federal 2016 2020 State and Local 2015 2020

DISCONTINUED OPERATIONS (Tables

DISCONTINUED OPERATIONS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Discontinued Operations and Disposal Groups [Abstract]
SCHEDULE OF DISCONTINUED OPERATIONS	The components of liabilities classified as discontinued operations consist of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF DISCONTINUED OPERATIONS September 30, 2021 December 31, 2020 (unaudited) Accrued liabilities 766 766 Current liabilities from discontinued operations 766 766 Total liabilities $ 766 $ 766 The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the condensed consolidated statements of operations for the three- and nine-months ended September 30, 2021 and 2020. Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Income from discontinued operations, before tax $ - $ - $ - $ - Income tax expense 62 65 175 194 Loss from discontinued operations, net of tax $ (62 ) $ (65 ) $ (175 ) $ (194 )
Schedule of Discontinued Operations Amount Recognized in Balance Sheet		The components of liabilities classified as discontinued operations relate to Commercial Services and consist of the following as of December 31, 2020 and December 31, 2019: Schedule of Discontinued Operations Amount Recognized in Balance Sheet December 31, 2020 December 31, 2019 Accrued liabilities $ 766 $ 766 Current liabilities from discontinued operations 766 766 Total liabilities $ 766 $ 766
Schedule of Discontinued Operations Condensed Consolidated Statements of Operations		The table below presents the significant components of CSO, Group DCA’s, Pharmakon’s and TVG’s results included within loss from discontinued operations, net of tax in the consolidated statements of operations for the years ended December 31, 2020 and 2019. Schedule of Discontinued Operations Condensed Consolidated Statements of Operations 2020 2019 Years Ended December 31, 2020 2019 Income from discontinued operations, before tax $ - $ 220 Income tax expense 250 308 Loss from discontinued operations, net of tax $ (250 ) $ (88 )

SUPPLEMENTAL CASH FLOW INFORM_2

SUPPLEMENTAL CASH FLOW INFORMATION (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Supplemental Cash Flow Elements [Abstract]
SCHEDULE OF SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION	SCHEDULE OF SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION Nine Months Ended September 30, 2021 2020 (unaudited) Operating Taxes accrued for repurchase of restricted shares $ - $ 49 Investing Preferred Stock Deemed Dividend $ - $ 3,033 Investment in DiamiR 248 -	SCHEDULE OF SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION For The Years Ended December 31, 2020 2019 Net cash used in operating activities of discontinued operations $ - $ (30 ) Net cash provided by investing activities of discontinued operations $ - $ - Supplemental Disclosure of Other Cash Flow Information (in thousands) Cash paid for taxes $ 218 $ 227 Cash paid for interest $ 60 $ 170 Supplemental Disclosures of Non Cash Activities (in thousands) Years Ended December 31, 2020 2019 Operating Adoption of ASC 842 - right of use asset $ - $ 2,449 Adoption of ASC 842 - operating lease liability $ - $ 2,536 Investing Preferred Stock Deemed Dividend $ 3,033 $ - Financing Accrued financing costs $ 31 $ 342 Accrued preferred dividends $ - $ 429

WARRANTS (Tables)

WARRANTS (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Warrants
SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY	Warrants outstanding and warrant activity for the nine-months ended September 30, 2021 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY Description Classification Exercise Price Expiration Date Warrants Issued Balance Warrants Cancelled/ Expired Balance Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 85,500 - 85,500 RedPath Warrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 10,000 - 10,000 Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 53,500 - 53,500 Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 870,214 - 870,214 Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 320,000 - 320,000 Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 65,434 - 65,434 1,975,934 1,404,648 - 1,404,648	Warrants outstanding and warrant activity for the year ended December 31, 2020 are as follows: SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY Description Classification Exercise Price Expiration Date Warrants Issued Balance Warrants Cancelled/ Expired Balance Private Placement Warrants, issued January 25, 2017 Equity $ 46.90 June 2022 85,500 85,500 85,500 RedPath Warrants, issued March 22, 2017 Equity $ 46.90 September 2022 10,000 10,000 10,000 Underwriters Warrants, issued June 21, 2017 Liability $ 13.20 December 2022 57,500 53,500 53,500 Base & Overallotment Warrants, issued June 21, 2017 Equity $ 12.50 June 2022 1,437,500 870,214 870,214 Vendor Warrants, issued August 6, 2017 Equity $ 12.50 August 2020 15,000 15,000 (15,000 ) - Warrants issued October 12, 2017 Equity $ 18.00 April 2022 320,000 320,000 320,000 Underwriters Warrants, issued January 25, 2019 Equity $ 9.40 January 2022 65,434 65,434 65,434 1,990,934 1,419,648 (15,000 ) 1,404,648 The weighted average exercise price of the warrants is $ 15.97 1.4

TRANSITION EXPENSES (Tables)

TRANSITION EXPENSES (Tables)	9 Months Ended
	Sep. 30, 2021
Transition Expenses
Schedule of Transition Expenses	These expenses are primarily related to the Rutherford, NJ lab closing and subsequent move to North Carolina, as well as other cost-saving initiatives, primarily reductions in headcount as well as certain lergal expenses. The following is a roll forward of the transition expenses liabilities: Schedule of Transition Expenses 1 2 3 4 Facilities/ Personnel Infrastructure Legal Total (unaudited) Balance at December 31, 2020 $ 885 $ 269 $ - $ 1,154 Transition expenses 1,044 925 505 2,474 Payments (1,929 ) (1,164 ) (269 ) (3,362 ) Balance at September 30, 2021 $ - $ 30 $ 236 $ 266

Nature of Business and Signif_3

Nature of Business and Significant Accounting Policies (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
SCHEDULE OF OTHER CURRENT ASSETS	Other current assets consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF OTHER CURRENT ASSETS September 30, 2021 December 31, 2020 (unaudited) Lab supply inventory $ 2,271 $ 2,052 Prepaid expenses 734 625 Other 130 45 Funds in escrow - - Total other current assets $ 3,135 $ 2,722	Other current assets consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF OTHER CURRENT ASSETS December 31, 2020 December 31, 2019 Lab supply inventory $ 2,052 $ 1,825 Prepaid expenses 625 971 Funds in escrow - 888 Other 45 167 Total other current assets $ 2,722 $ 3,851

Acquisition (Tables)

Acquisition (Tables)	12 Months Ended
	Dec. 31, 2020
Business Combination and Asset Acquisition [Abstract]
Schedule of Assets Acquired and Liabilities Assumed	The reconciliation of consideration given for BioPharma to the allocation of the purchase price of assets and liabilities acquired based on their relative fair values was as follows: Schedule of Assets Acquired and Liabilities Assumed Cash $ 13,829 Subordinated note payable 6,822 Total consideration $ 20,651 Assets acquired Accounts receivable $ 3,731 Accrued revenue 289 Lab supplies 877 Prepaid expenses 266 Property and equipment 6,412 Operating lease assets 2,187 Acquired identifiable intangible assets: Trademarks and trade name 1,600 Customer relationships 5,700 Total acquired identifiable intangible assets 7,300 Goodwill 8,273 Total assets acquired 29,335 Liabilities assumed Accounts payable (4,535 ) Accrued liabilities (435 ) Deferred revenue (1,076 ) Operating lease liabilities (2,187 ) Finance lease liabilities (451 ) Total liabilities assumed (8,684 ) Net assets acquired $ 20,651
Schedule of ProForma Information	Schedule of ProForma Information Year Ended December 31, 2019 Revenue $ 31,722

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Property and equipment consisted of the following as of December 31, 2020 and 2019: Schedule of Property and Equipment 2020 2019 December 31, 2020 2019 Furniture and fixtures $ 339 $ 242 Lab and office equipment 7,536 6,353 Computer equipment 339 339 Internal-use software 1,572 1,276 Leasehold improvements 505 506 Property and equipment 10,291 8,716 Less accumulated depreciation and amortization (2,942 ) (1,902 ) Net property and equipment $ 7,349 $ 6,814

Accrued Expenses and Other Lo_2

Accrued Expenses and Other Long-Term Liabilities (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Payables and Accruals [Abstract]
SCHEDULE OF OTHER ACCRUED EXPENSES	Other accrued expenses consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF OTHER ACCRUED EXPENSES September 30, 2021 December 31, 2020 (unaudited) Accrued royalties $ 3,572 $ 2,710 Upfront Medicare payment - 2,066 Operating lease liabilities 1,030 1,027 All others 1,056 1,182 Accrued professional fees 931 854 Unclaimed property 565 565 Contingent consideration 473 398 Accrued pharma services invoices 438 108 Taxes payable 248 334 Accrued lab costs - diagnostics 514 161 Financing lease liabilities 98 177 ESPP payable 37 108 Accrued sales and marketing - diagnostics 41 51 Deferred revenue 40 54 Total other accrued expenses $ 9,043 $ 9,795	Other accrued expenses consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF OTHER ACCRUED EXPENSES December 31, 2020 December 31, 2019 Accrued royalties $ 2,710 $ 1,934 Contingent consideration 398 502 Upfront Medicare payment 2,066 - Operating lease liability 1,027 1,321 Financing lease liability 177 184 Deferred revenue 54 457 Payable to CGI - 888 Accrued sales and marketing - diagnostics 51 197 Accrued lab costs - diagnostics 161 163 Accrued professional fees 854 1,399 Taxes payable 334 403 Unclaimed property 565 565 All others 1,398 1,463 Total other accrued expenses $ 9,795 $ 9,476
SCHEDULE OF LONG TERM LIABILITIES	Long-term liabilities consisted of the following as of September 30, 2021 and December 31, 2020: SCHEDULE OF LONG TERM LIABILITIES September 30, 2021 December 31, 2020 (unaudited) Uncertain tax positions $ 4,517 $ 4,342 Warrant liability 158 21 Financing lease liabilities 75 138 Deferred revenue 18 136 Other - 138 Total other long-term liabilities $ 4,768 $ 4,637	Other long-term liabilities consisted of the following as of December 31, 2020 and 2019: SCHEDULE OF LONG TERM LIABILITIES December 31, 2020 December 31, 2019 Warrant liability $ 21 $ 82 Uncertain tax positions 4,342 4,081 Deferred revenue 136 269 Other 138 141 Total other long-term liabilities $ 4,637 $ 4,573

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Tables)	12 Months Ended
	Dec. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES	As of December 31, 2020, contractual obligations with terms exceeding one SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES Less than 1 to 3 3 to 5 After Total 1 Year Years Years 5 Years Operating lease obligations $ 5,609 $ 1,235 $ 1,657 $ 793 $ 1,924

Revenue Sources (Tables)

Revenue Sources (Tables)	12 Months Ended
	Dec. 31, 2020
Risks and Uncertainties [Abstract]
Schedule of Revenue by Major Customers	Schedule of Revenue by Major Customers Years Ended December 31, Customer 2020 2019 Medicare $ 10,186 $ 10,605 Commercial Payers $ 4,136 $ 7,589 Medicare Advantage $ 3,566 $ 1,912 Client Billings $ 2,582 $ 3,521

Historical Basic and Diluted _2

Historical Basic and Diluted Net Loss per Share (Tables)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Earnings Per Share [Abstract]
Schedule of Weighted Average Number of Shares		A reconciliation of the number of shares used in the calculation of basic and diluted earnings per share for the years ended December 31, 2020 and 2019 are as follows (rounded to thousands): Schedule of Weighted Average Number of Shares Years Ended December 31, 2020 2019 Basic weighted average number of common shares 4,029 3,746 Potential dilutive effect of stock-based awards - - Diluted weighted average number of common shares 4,029 3,746
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE	SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Three Months Ended Nine Months Ended September 30, September 30, 2021 2020 2021 2020 (unaudited) (unaudited) Options 684 878 684 878 Restricted stock and restricted stock units (RSUs) 366 28 366 28 Warrants 1,405 1,405 1,405 1,405 2,455 2,311 2,455 2,311	The Company’s Series B Preferred Stock, on an as converted basis of 7,833,334 SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE Years Ended December 31, 2020 2019 Options 849 416 Restricted stock units (RSUs) 238 49 Warrants 1,405 1,420 2,492 1,885

LIQUIDITY (Details Narrative)

LIQUIDITY (Details Narrative) - USD ($)	Jan. 07, 2021	Jan. 31, 2020	Sep. 30, 2019	May 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Nov. 05, 2021	Mar. 25, 2021
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash and cash equivalents					$ 3,180,000			$ 3,180,000		$ 2,772,000	$ 2,321,000
Accounts receivable, net					6,518,000			6,518,000		8,028,000	10,338,000
Current assets					12,800,000			12,800,000
Liabilities, Current					22,800,000			22,800,000
Net loss					3,561,000	$ 6,234,000		11,214,000	$ 18,308,000	26,451,000	26,740,000
Net cash used in operating activities								7,501,000	12,395,000	13,979,000	18,957,000
Cash and cash equivalents					3,180,000			3,180,000		2,772,000	2,321,000
Total current assets					13,083,000			13,083,000		14,122,000	16,510,000
Total current liabilities					$ 22,836,000			22,836,000		$ 18,233,000	$ 17,292,000
Repayment of line of credit									3,000,000
Sale of common stock										178,000	97,817
Debt Instrument, Interest Rate										8.00%
Series B Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from public offering		$ 19,200,000
Sale of common stock		20,000
Equity Distribution Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from public offering			$ 3,700,000
ATM Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from public offering										$ 700,000
Sale of common stock										178,000
Centers for Medicare & Medicaid Services [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Loans payable						2,100,000	$ 2,100,000		2,100,000
Department of Health and Human Services [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Loans payable						$ 650,000	650,000		$ 650,000
Utilization of advance payment against cash payments							$ 2,100,000
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Proceeds from loans payable				$ 888,000
Silicon Valley Bank [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Repayment of line of credit										$ 3,400,000
Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash on hand												$ 2,400,000	$ 3,200,000
Debt Instrument, Interest Rate	8.00%
Maturity Date	Jun. 30, 2021
Subsequent Event [Member] | Secured Promissory Note [Member] | Ampersand 2018 Limited Partnership [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt Instrument, Face Amount	$ 3,000,000
Subsequent Event [Member] | Secured Promissory Note [Member] | 1315 Capital [Member] | Series B Preferred Stock [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt Instrument, Face Amount	$ 2,000,000

SCHEDULE OF OTHER CURRENT ASSET

SCHEDULE OF OTHER CURRENT ASSETS (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Lab supply inventory	$ 2,271	$ 2,052	$ 1,825
Prepaid expenses	734	625	971
Other	130	45	167
Funds in escrow			888
Total other current assets	$ 3,135	$ 2,722	$ 3,851

SCHEDULE OF BASIC AND DILUTED N

SCHEDULE OF BASIC AND DILUTED NET LOSS PER SHARE (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Accounting Policies [Abstract]
Basic weighted average number of common shares	4,165	4,038	4,119	4,025	4,029	3,746
Potential dilutive effect of stock-based awards
Diluted weighted average number of common shares	4,165	4,038	4,119	4,025	4,029	3,746

SCHEDULE OF ANTI-DILUTIVE SECUR

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earning per share	2,455	2,311	2,455	2,311	2,492	1,885
Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earning per share	684	878	684	878
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earning per share	366	28	366	28
Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earning per share	1,405	1,405	1,405	1,405	1,405	1,420
Share-based Payment Arrangement, Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earning per share					849	416
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from earning per share					238	49

SUMMARY OF SIGNIFICANT ACCOUN_4

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - $ / shares	3 Months Ended	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Common stock, par value	$ 0.01	$ 0.01	$ 0.01	$ 0.01
Series B Preferred Stock [Member]
Number preferred stocks on converted basis	7,833,334	7,833,334

SCHEDULE OF IDENTIFIABLE INTANG

SCHEDULE OF IDENTIFIABLE INTANGIBLE ASSETS CARRYING VALUE (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Assets, Gross	$ 39,251	$ 39,251	$ 39,288
Finite-lived Intangible Assets, Accumulated Amortization	(31,237)	(27,900)	(23,439)
Finite-lived Intangible Assets, Net Carrying Value	$ 8,014	$ 11,351	15,849
CLIA Lab [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	2 years 3 months 18 days	2 years 3 months 18 days
Finite-lived Intangible Assets, Gross	$ 609	$ 609	609
Asuragen Acquisition [Member] | Thyroid [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	9 years	9 years
Finite-lived Intangible Assets, Gross	$ 8,519	$ 8,519	8,519
RedPath Acquisition [Member] | Pancreas Test [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	7 years	7 years
Finite-lived Intangible Assets, Gross	$ 16,141	$ 16,141	16,141
RedPath Acquisition [Member] | Barrett's Test [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	9 years	9 years
Finite-lived Intangible Assets, Gross	$ 6,682	$ 6,682	6,719
BioPharma Acquisition [Member] | Trademarks [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	10 years	10 years
Finite-lived Intangible Assets, Gross	$ 1,600	$ 1,600	1,600
BioPharma Acquisition [Member] | Customer Relationships [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-lived Intangible Asset, Useful Life (Years)	8 years	8 years
Finite-lived Intangible Assets, Gross	$ 5,700	$ 5,700	$ 5,700

SCHEDULE OF FUTURE ESTIMATED AM

SCHEDULE OF FUTURE ESTIMATED AMORTIZATION EXPENSE (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
2021	$ 1,112
2022	2,155	$ 4,078
2023	2,099	2,156
2024	873	1,745
2025	873	873
2021	2,155	4,078
2022	2,099	2,156
2023	873	1,745
2024	$ 873	873
2025		$ 873

SCHEDULE OF GOODWILL CARRYING V

SCHEDULE OF GOODWILL CARRYING VALUE (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Balance Ending	$ 8,433	$ 8,433
Adjustments			160
Balance Ending	$ 8,433	$ 8,433	8,433
Goodwill acquired			$ 8,273

GOODWILL AND OTHER INTANGIBLE_3

GOODWILL AND OTHER INTANGIBLE ASSETS (Details Narrative) - USD ($) $ in Thousands	Jul. 15, 2019	Jul. 31, 2019	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Restructuring Cost and Reserve [Line Items]
Goodwill			$ 8,433		$ 8,433		$ 8,433	$ 8,433
Identifiable intangible assets	$ 7,300
Amortization expense			1,100	$ 1,100	3,300	$ 3,300	4,500	4,000
Amortization expense			$ 1,100	$ 1,100	$ 3,300	$ 3,300	$ 4,500	4,000
BioPharma Acquisition [Member]
Restructuring Cost and Reserve [Line Items]
Intangible assets	15,600	$ 15,600
Goodwill	8,273	8,300						$ 100
Identifiable intangible assets	$ 7,300	$ 7,300

SCHEDULE OF FINANCIAL INSTRUMEN

SCHEDULE OF FINANCIAL INSTRUMENT MEASURED ON RECURRING BASIS (Details) - USD ($) $ in Thousands	Sep. 30, 2021		Dec. 31, 2020		Dec. 31, 2019
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	$ 158	[1]	$ 21	[1]	$ 82
Fair value of liabilities	2,294		2,237		2,975
Fair Value Measured at Net Asset Value Per Share [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	158	[1]	21	[1]	82
Fair value of liabilities	2,294		2,237		2,975
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		[1]		[1]
Fair value of liabilities
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability		[1]		[1]
Fair value of liabilities
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Warrant liability	158	[1]	21	[1]	82
Fair value of liabilities	2,294		2,237		2,975
Asuragen [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	2,136	[2]	2,216	[2]	2,893
Asuragen [Member] | Fair Value Measured at Net Asset Value Per Share [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	2,136	[2]	2,216	[2]	2,893
Asuragen [Member] | Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		[2]		[2]
Asuragen [Member] | Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		[2]		[2]
Asuragen [Member] | Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration	$ 2,136	[2]	$ 2,216	[2]	$ 2,893
[1]	See Note 9, Accrued Expenses and Long-Term Liabilities
[2]	See Note 9, Accrued Expenses and Long-Term Liabilities

SCHEDULE OF FAIR VALUE, ASSETS

SCHEDULE OF FAIR VALUE, ASSETS MEASURED ON RECURRING BASIS, UNOBSERVABLE INPUT RECONCILIATION (Details) - USD ($) $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Beginning Balance	$ 2,237	$ 2,975
Payments	(398)	737
Accretion	375	549
Cancellation of Obligation/Conversions Exercises
Adjustment to Fair Value/Mark to Market	80	(550)
Ending Balance	2,294	2,237
Payments	398	(737)
Asuragen [Member]
Beginning Balance	2,216	2,893
Payments		737
Accretion		549
Cancellation of Obligation/Conversions Exercises
Adjustment to Fair Value/Mark to Market		(489)
Ending Balance		2,216
Payments		(737)
Underwriter Warrants [Member]
Beginning Balance	21	82
Payments
Accretion
Cancellation of Obligation/Conversions Exercises
Adjustment to Fair Value/Mark to Market	137	(61)
Ending Balance	158	21
Payments
Contingent Consideration Liability [Member]
Beginning Balance	2,216
Payments	(398)
Accretion	375
Cancellation of Obligation/Conversions Exercises
Adjustment to Fair Value/Mark to Market	(57)
Ending Balance	2,136	$ 2,216
Payments	$ 398

SCHEDULE OF FINANCING AND OPERA

SCHEDULE OF FINANCING AND OPERATING LEASES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Leases
Financing lease assets	$ 652	$ 597
Operating lease assets, Right of use assets	3,989	4,384	$ 3,892
Total lease assets	4,641	4,981
Current financing lease liabilities	98	177	184
Current operating lease liabilities	1,030	1,027	1,321
Total current lease liabilities	1,128	1,204
Noncurrent financing lease liabilities	75	138
Noncurrent operating lease liabilities	3,152	3,540	$ 2,591
Total long-term lease liabilities	3,227	3,678
Total lease liabilities	$ 4,355	$ 4,882

SCHEDULE OF MATURITIES OF OPERA

SCHEDULE OF MATURITIES OF OPERATING AND FINANCING LEASE LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Lessee, Lease, Description [Line Items]
Operating Leases 2021	$ 312
Operating Leases 2022		$ 1,235
Operating Leases 2022		185
Operating Leases 2023		1,028
Operating Leases 2023		78
Operating Leases 2024		629
Operating Leases 2024		65
Operating Leases 2025		390
Operating Leases 2025
Operating Leases Thereafter	1,924
Financing Leases,Total minimum lease payments	5,097	5,609
Financing Leases,Total minimum lease payments		329
Operating Leases, Less: amount of lease payments representing effects of discounting		1,042
Operating Leases, Less: amount of lease payments representing effects of discounting		14
Operating Leases, Present value of future minimum lease payments		4,567
Operating Leases, Present value of future minimum lease payments		315
Operating Leases, Less: current obligations under leases	1,030	1,027	$ 1,321
Operating Leases, Less: current obligations under leases	98	177	184
Operating Leases, Long-term lease obligations	3,152	3,540	2,591
Operating Leases, Long-term lease obligations	75	138
Operating Leases - 2021		1,235
Financing Leases - 2021		185
Operating Leases - 2022		1,028
Financing Leases - 2022		78
Operating Leases - 2023		629
Financing Leases - 2023		65
Operating Leases - 2024		390
Financing Leases - 2024
Operating Leases - 2024-2030		2,327
Operating Leases - Total minimum lease payments	5,097	5,609
Financing Leases - Total minimum lease payments		329
Operating Leases - Less: amount of lease payments representing effects of discounting		1,042
Financing Leases - Less: amount of lease payments representing effects of discounting		14
Operating Leases - Present value of future minimum lease payments		4,567
Financing Leases - Present value of future minimum lease payments		315
Current operating lease liabilities	1,030	1,027	1,321
Current financing lease liabilities	98	177	184
Operating lease liabilities, net of current portion	3,152	3,540	$ 2,591
Financing Leases - Long-term lease obligations	75	$ 138
Operating Leases [Member]
Lessee, Lease, Description [Line Items]
Operating Leases 2021	312
Operating Leases 2022	1,192
Operating Leases 2023	794
Operating Leases 2024	473
Operating Leases 2025	402
Operating Leases 2026	414
Operating Leases Thereafter	1,510
Financing Leases,Total minimum lease payments	5,097
Operating Leases, Less: amount of lease payments representing effects of discounting	915
Operating Leases, Present value of future minimum lease payments	4,182
Operating Leases, Less: current obligations under leases	1,030
Operating Leases, Long-term lease obligations	3,152
Operating Leases - 2021	1,192
Operating Leases - 2022	794
Operating Leases - 2023	473
Operating Leases - 2024	402
Operating Leases - Total minimum lease payments	5,097
Operating Leases - Less: amount of lease payments representing effects of discounting	915
Operating Leases - Present value of future minimum lease payments	4,182
Current operating lease liabilities	1,030
Operating lease liabilities, net of current portion	3,152
Financing Leases [Member]
Lessee, Lease, Description [Line Items]
Operating Leases 2021	39
Operating Leases 2022	86
Operating Leases 2023	60
Operating Leases 2024
Operating Leases 2025
Operating Leases 2026
Operating Leases Thereafter
Financing Leases,Total minimum lease payments	185
Operating Leases, Less: amount of lease payments representing effects of discounting	12
Operating Leases, Present value of future minimum lease payments	173
Operating Leases, Less: current obligations under leases	98
Operating Leases, Long-term lease obligations	75
Financing Leases - 2021	86
Financing Leases - 2022	60
Financing Leases - 2023
Financing Leases - 2024
Financing Leases - Total minimum lease payments	185
Financing Leases - Less: amount of lease payments representing effects of discounting	12
Financing Leases - Present value of future minimum lease payments	173
Current financing lease liabilities	98
Financing Leases - Long-term lease obligations	$ 75

SCHEDULE OF FUTURE MINIMUM LEAS

SCHEDULE OF FUTURE MINIMUM LEASE PAYMENTS UNDER NON-CANCELABLE LEASES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Leases
Operating lease obligations, Total	$ 5,097	$ 5,609
Operating lease obligations, Less than 1 Year	312
Operating lease obligations, 1 to 3 Years	1,986
Operating lease obligations, 3 to 5 Years	875
Operating lease obligations, After 5 Years	$ 1,924
Operating lease obligations, Total		5,609
Operating lease obligations, Less than 1 Year		1,235
Operating lease obligations, 1 to 3 Years		1,657
Operating lease obligations, 3 to 5 Years		793
Operating lease obligations, After 5 Years		$ 1,924

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($) $ in Thousands	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2021	Dec. 31, 2020	Sep. 30, 2020	Jan. 02, 2020	Dec. 31, 2019
Weighted average remaining lease term			6 years 7 months 6 days	7 years 1 month 6 days
Weighted average discount rate leases percentage			6.40%	6.00%
Right-of-use lease assets			$ 3,989	$ 4,384			$ 3,892
Lease liabilities				4,567
Finance lease assets			$ 652	597
Finance lease liabilities				$ 315
North Carolina Lease [Member]
Weighted average remaining lease term					5 years
Lease, description		In June 2020, the Company entered into an amendment of its North Carolina lease extending it for an additional ten years, commencing on June 1, 2020 and continuing until May 31, 2030. The minimum rent per rentable square foot pursuant to the amendment is $14.10 from June 1, 2020 to May 31, 2021, with annual increases of 3%
Lease rent increasing percentage		3.00%
Lessee, operating lease, option to extend		the Company has two options to extend the term for a period of five years each.
Lessee, operating lease, option to terminate		the Company has the irrevocable right to terminate the lease on November 30, 2025, as well as on November 30, 2027.
Increase decrease in operating lease asset and liability	$ 2,800
Accounting Standards Update 2016-02 [Member]
Right-of-use lease assets						$ 2,400
Lease liabilities						2,500
Cumulative adjustment to opening accumulated deficit						100
Accounting Standards Update 2016-02 [Member] | BioPharma Acquisition [Member]
Right-of-use lease assets						2,200
Finance lease assets						500
Finance lease liabilities						$ 500

SCHEDULE OF OTHER ACCRUED EXPEN

SCHEDULE OF OTHER ACCRUED EXPENSES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Accrued royalties	$ 3,572	$ 2,710	$ 1,934
Upfront Medicare payment		2,066
Operating lease liability	1,030	1,027	1,321
All others	1,056	1,182
Accrued professional fees	931	854	1,399
Unclaimed property	565	565	565
Contingent consideration	473	398	502
Accrued pharma services invoices	438	108
Taxes payable	248	334	403
Accrued lab costs - diagnostics	514	161	163
Financing lease liability	98	177	184
ESPP payable	37	108
Accrued sales and marketing - diagnostics	41	51	197
Deferred revenue	40	54	457
Total other accrued expenses	$ 9,043	9,795	9,476
Payable to CGI			888
All others		$ 1,398	$ 1,463

SCHEDULE OF LONG TERM LIABILITI

SCHEDULE OF LONG TERM LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Payables and Accruals [Abstract]
Uncertain tax positions	$ 4,517	$ 4,342	$ 4,081
Warrant liability	158	21	82
Financing lease liabilities	75	138
Deferred revenue	18	136	269
Other		138	141
Total other long-term liabilities	$ 4,768	$ 4,637	$ 4,573

SCHEDULE OF FAIR VALUE ASSUMPTI

SCHEDULE OF FAIR VALUE ASSUMPTIONS OF STOCK OPTIONS (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.78%	0.79%	0.75%	2.34%
Expected life	6 years	6 years 7 months 6 days	6 years 6 months	5 years 10 months 24 days
Expected volatility	134.79%	122.24%	123.71%	128.58%
Dividend yield

SCHEDULE OF STOCK-BASED COMPENS

SCHEDULE OF STOCK-BASED COMPENSATION EXPENSE (Details) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended		12 Months Ended
		Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense		$ 477	$ 563	$ 1,314	$ 1,381	$ 2,187	$ 965
Cost of Sales [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense		52	60	154	187
Selling and Marketing Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense		76	39	201	136
Research and Development Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense		24	30	83	99
General and Administrative Expense [Member]
Share-based Payment Arrangement, Expensed and Capitalized, Amount [Line Items]
Total stock compensation expense	[1]	$ 325	$ 434	$ 876	$ 959
[1]	Includes ESPP expense

STOCK-BASED COMPENSATION (Detai

STOCK-BASED COMPENSATION (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			312,500		525,550
Share-based compensation arrangements, options, grants in period, weighted average exercise price			$ 6		$ 5.36	$ 8.50
Stock Issued During Period, Shares, Restricted Stock Award, Gross			152,500
Shares Issued, Price Per Share	$ 5		$ 5
Share-based Payment Arrangement, Expense	$ 477	$ 563	$ 1,314	$ 1,381	$ 2,187	$ 965
Share-based compensation aggregate fair value of option					1,500	$ 500
Weighted-average grant date fair value of options vested						$ 9
Aggregate fair value of restricted stock units					400	$ 200
Total unrecognized compensation cost related to unvested stock options and restricted stock units					2,500
Share-based compensation expense			$ 1,228	$ 1,354	2,187	$ 1,535
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense					$ 40
Stock Incentive Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation arrangement by share-based payment award, description			stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, with expiration 10 years from the date they are granted, and generally vest over a one to three-year period for employees and members of the Board.		stock options have been granted with an exercise price equal to the market value of the common stock on the date of grant, expire 10 years from the date they are granted, and generally vested over a one to three-year period for employees and members of the Board. Upon exercise, new shares will be issued by the Company. The restricted shares and restricted stock units (“RSUs”) granted to employees generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances. Restricted shares and RSUs granted to Board members generally have a three-year graded vesting period and are subject to accelerated vesting and forfeiture under certain circumstances.

SCHEDULE OF EFFECTIVE INCOME TA

SCHEDULE OF EFFECTIVE INCOME TAX RATE (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
(Benefit) provision for income tax	$ (714)	$ 14	$ (684)	$ 43	$ 53	$ (28)
Effective income tax rate	16.90%	0.20%	5.80%	0.20%	(0.20%)	0.10%

SEGMENT INFORMATION (Details Na

SEGMENT INFORMATION (Details Narrative)	9 Months Ended
	Sep. 30, 2021Integer
Segment Reporting [Abstract]
Number of segments	1

SCHEDULE OF DISCONTINUED OPERAT

SCHEDULE OF DISCONTINUED OPERATIONS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Accrued liabilities	$ 766		$ 766		$ 766	$ 766
Current liabilities from discontinued operations	766		766		766	766
Total liabilities	766		766		766	766
Income from discontinued operations, before tax						220
Income tax expense	62	65	175	194	250	308
Loss from discontinued operations, net of tax	$ (62)	$ (65)	$ (175)	$ (194)	$ (250)	$ (88)

NOTES PAYABLE _ RELATED PARTI_2

NOTES PAYABLE – RELATED PARTIES (Details Narrative) - USD ($)	May 10, 2021	Jan. 07, 2021	Sep. 30, 2021
Debt Instrument, Description		In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and any public offering of securities, and (2) designate two directors to our Board of Directors; provided, that certain of such rights held by 1315 Capital have been delegated pursuant to the related Support Agreement (See Note 16, Equity). As a result, the Company considers the Notes and Security Agreement to be a related party transaction.
Financing fees			$ 100,000
Debt Issuance Costs, Net			$ 18,000
Description of funded debt amount		The Notes contain certain negative covenants which prevent the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year.
Ampersand 2018 Limited Partnership [Member]
Interest rate		8.00%
Ampersand 2018 Limited Partnership [Member] | Series B Convertible Preferred Stock [Member]
[custom:NumberOfHoldsShares]		28,000
Stock Issued During Period, Shares, Conversion of Convertible Securities		4,666,666
[custom:FullyDilutedPercentageOfCommonStock]		38.90%
1315 Capital [Member] | Series B Convertible Preferred Stock [Member]
[custom:NumberOfHoldsShares]		19,000
Stock Issued During Period, Shares, Conversion of Convertible Securities		3,166,668
[custom:FullyDilutedPercentageOfCommonStock]		26.40%
Security Agreement [Member]
Promissory note	$ 7,500,000
Interest rate	8.00%
Debt Instrument, Maturity Date	Jun. 30, 2021
Security Agreement [Member] | Ampersand 2018 Limited Partnership [Member]
Promissory note	$ 4,500,000	$ 3,000,000
Security Agreement [Member] | 1315 Capital [Member]
Promissory note	$ 3,000,000	$ 2,000,000

SCHEDULE OF SUPPLEMENTAL DISCLO

SCHEDULE OF SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION (Details) - USD ($) $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Supplemental Cash Flow Elements [Abstract]
Taxes accrued for repurchase of restricted shares		$ 49
Preferred Stock Deemed Dividend		3,033	$ 3,033
Investment in DiamiR	$ 248
Net cash used in operating activities of discontinued operations				(30)
Net cash provided by investing activities of discontinued operations
Cash paid for taxes			218	227
Cash paid for interest			60	170
Adoption of ASC 842 - right of use asset				2,449
Adoption of ASC 842 - operating lease liability				2,536
Accrued financing costs			31	342
Accrued preferred dividends				$ 429

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Jan. 15, 2020	Jan. 10, 2020	Oct. 16, 2019	Jul. 15, 2019	Jan. 25, 2019	Jan. 31, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019	Sep. 20, 2019
Class of Stock [Line Items]
Preferred stock dividend percentage							6.00%		6.00%
Shares granted							312,500		525,550
Received net proceeds							$ 335	$ 434	$ 434	$ 6,478
Preferred price per share							$ 5
Proceeds from issuance of stock								$ 19,223	$ 19,223
Sale of stock									178,000	97,817
Proceeds from sale of stock									$ 700	$ 200
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock adjusted conversion	$ 6
Company achieve revenue target						$ 34,000			$ 34,000
Intrinsic value of beneficial conversion feature	$ 2,200
Intrinsic value of effective conversion price per share	$ 6.79
Sale of stock						20,000
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Aggregate of shares issued							27,000
Preferred stock adjusted conversion							$ 6		$ 6
Preferred stock, shares issued									47,000	47,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Aggregate of shares issued							270		270
Value of preferred stock exchanged							$ 27,000		$ 27,000
Preferred stock par/stated value							$ 0.01		$ 0.01
Preferred shares stated value							100,000		100,000
Preferred stock adjusted conversion							$ 8		$ 8
Preferred stock, shares issued									27,000	270
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock aggregate value		$ 20,000
Issuance price of preferred stock		$ 1,000
Preferred price per share		$ 1,000
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | 1315 Capital [Member]
Class of Stock [Line Items]
Preferred stock aggregate value		$ 19,000
Aggregate of shares issued		19,000
Security Purchase and Exchange Agreement [Member] | Series B Preferred Stock [Member] | Ampersand 2018 Limited Partnership [Member]
Class of Stock [Line Items]
Preferred stock aggregate value		$ 1,000
Aggregate of shares issued		1,000
Underwriting Agreement [Member]
Class of Stock [Line Items]
Aggregate of shares issued					933,334
Shares granted					140,000
Common stock price, per share					$ 7.50
Effective price per share					$ 6.975
Received net proceeds					$ 5,900
Security Purchase Agreement [Member] | Investor [Member]
Class of Stock [Line Items]
Business combination consideration shares			130
Business combination consideration amount			$ 13,000
Security Purchase Agreement [Member] | Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock par/stated value				$ 100,000
Preferred price per share				$ 0.01
Security Purchase Agreement [Member] | Convertible Preferred Stock [Member] | Maximum [Member]
Class of Stock [Line Items]
Proceeds from preferred stock value				$ 27,000
Security Purchase Agreement [Member] | 60 Newly Created Series A Preferred Stock [Member]
Class of Stock [Line Items]
Business combination consideration shares				60
Business combination consideration amount				$ 6,000
Security Purchase Agreement [Member] | 60 Newly Created Series A -1 Preferred Stock [Member]
Class of Stock [Line Items]
Business combination consideration shares				80
Business combination consideration amount				$ 8,000
Proceeds from issuance of stock				$ 13,100
Equity Distribution Agreement [Member]
Class of Stock [Line Items]
Aggregate offering price											$ 4,800
Fixed percentage of commission											3.00%

SCHEDULE OF WARRANTS OUTSTANDIN

SCHEDULE OF WARRANTS OUTSTANDING AND WARRANTS ACTIVITY (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Warrants Issued	1,975,934	1,990,934
Warrants	1,404,648,000	1,404,648	1,419,648
Warrants Cancelled/Expired		15,000
Warrants Cancelled/Expired		(15,000)
Private Placement Warrants[Member]
Description	Private Placement Warrants, issued January 25, 2017	Private Placement Warrants, issued January 25, 2017
Classification	Equity	Equity
Exercise Price	$ 46.90	$ 46.90
Expiration Date	June 2022	June 2022
Warrants Issued	85,500	85,500
Warrants	85,500	85,500	85,500
Warrants Cancelled/Expired
Warrants Cancelled/Expired
RedPath Warrants [Member]
Description	RedPath Warrants, issued March 22, 2017	RedPath Warrants, issued March 22, 2017
Classification	Equity	Equity
Exercise Price	$ 46.90	$ 46.90
Expiration Date	September 2022	September 2022
Warrants Issued	10,000	10,000
Warrants	10,000	10,000	10,000
Warrants Cancelled/Expired
Warrants Cancelled/Expired
Underwriter Warrants [Member]
Description	Underwriters Warrants, issued June 21, 2017	Underwriters Warrants, issued June 21, 2017
Classification	Liability	Liability
Exercise Price	$ 13.20	$ 13.20
Expiration Date	December 2022	December 2022
Warrants Issued	57,500	57,500
Warrants	53,500	53,500	53,500
Warrants Cancelled/Expired
Warrants Cancelled/Expired
Base & Overallotment Warrants [Member]
Description	Base & Overallotment Warrants, issued June 21, 2017	Base & Overallotment Warrants, issued June 21, 2017
Classification	Equity	Equity
Exercise Price	$ 12.50	$ 12.50
Expiration Date	June 2022	June 2022
Warrants Issued	1,437,500	1,437,500
Warrants	870,214	870,214	870,214
Warrants Cancelled/Expired
Warrants Cancelled/Expired
Warrants Issued [Member]
Description	Warrants issued October 12, 2017	Warrants issued October 12, 2017
Classification	Equity	Equity
Exercise Price	$ 18	$ 18
Expiration Date	April 2022	April 2022
Warrants Issued	320,000	320,000
Warrants	320,000	320,000	320,000
Warrants Cancelled/Expired
Warrants Cancelled/Expired
Underwriters Warrants [Member]
Description	Underwriters Warrants, issued January 25, 2019	Underwriters Warrants, issued January 25, 2019
Classification	Equity	Equity
Exercise Price	$ 9.40	$ 9.40
Expiration Date	January 2022	January 2022
Warrants Issued	65,434	65,434
Warrants	65,434	65,434	65,434
Warrants Cancelled/Expired
Warrants Cancelled/Expired
Vendor Warrants[Member]
Description		Vendor Warrants, issued August 6, 2017
Classification		Equity
Exercise Price		$ 12.50
Expiration Date		August 2020
Warrants Issued		15,000
Warrants			15,000
Warrants Cancelled/Expired		15,000
Warrants Cancelled/Expired		(15,000)

WARRANTS (Details Narrative)

WARRANTS (Details Narrative) - Warrant [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Weighted average exercise price	$ 15.97	$ 15.97
Weighted average remaining contractual life	8 months 12 days	1 year 4 months 24 days

Schedule of Transition Expenses

Schedule of Transition Expenses (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2021USD ($)
Balance at December 31, 2020	$ 1,154
Transition expenses	2,474
Payments	(3,362)
Balance at September 30, 2021	266
Personnel [Member]
Balance at December 31, 2020	885
Transition expenses	1,044
Payments	(1,929)
Balance at September 30, 2021
Facilities and Infrastructure [Member]
Balance at December 31, 2020	269
Transition expenses	925
Payments	(1,164)
Balance at September 30, 2021	30
Legal [Member]
Balance at December 31, 2020
Transition expenses	505
Payments	(269)
Balance at September 30, 2021	$ 236

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)	Oct. 29, 2021	Oct. 13, 2021	Sep. 29, 2021	Jan. 07, 2021	Jan. 07, 2021	Jan. 10, 2020	Dec. 31, 2020	Jun. 30, 2022	Feb. 16, 2021	Dec. 31, 2019
Subsequent Event [Line Items]
Line of credit, principal										$ 3,000,000
Rate of interest							8.00%
Debt description					In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and any public offering of securities, and (2) designate two directors to our Board of Directors; provided, that certain of such rights held by 1315 Capital have been delegated pursuant to the related Support Agreement (See Note 16, Equity). As a result, the Company considers the Notes and Security Agreement to be a related party transaction.
Description of funded debt amount					The Notes contain certain negative covenants which prevent the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year.
Funded debt amount							$ 4,500,000
Debt Instrument, Convertible, If-converted Value in Excess of Principal						$ 45,000,000
Debt threshold percentage							10.00%
1315 Capital [Member] | Series B Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of holds shares					19,000
Number of convertible, common stock					3,166,668
Fully diluted percentage of common stock					26.40%
Ampersand 2018 Limited Partnership [Member] | Series B Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of holds shares					28,000
Number of convertible, common stock					4,666,666
Fully diluted percentage of common stock					38.90%
Term Loan [Member] | Ampersand [Member]
Subsequent Event [Line Items]
Repayment of notes			$ 4,500,000
Term Loan [Member] | 1315 Capital [Member]
Subsequent Event [Line Items]
Repayment of notes			$ 3,000,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Debt instrument, maturity date				Jun. 30, 2021
Rate of interest				8.00%	8.00%
Debt description					In addition, pursuant to the terms of the Series B Convertible Preferred Stock certificate of designation and an amended and restated investor rights agreement among the Company and Ampersand and 1315 Capital, they each have the right to (1) approve certain of our actions, including our borrowing of money and (2) designate two directors to our Board of Directors. As a result, the Company considers the Notes and Security Agreement to be a related party transaction.
Description of funded debt amount					The Notes contain certain negative covenants which prevent the Company from issuing any debt securities pursuant to which the Company issues shares, warrants or any other convertible security in the same transaction or a series of related transactions, except that Company may incur or enter into any capitalized and operating leases in the ordinary course of business consistent with past practice, or borrowed money or funded debt in an amount not to exceed $4.5 million (the “Debt Threshold”) that is subordinated to the Notes on terms acceptable to Ampersand and 1315 Capital; provided, that if the aggregate consolidated revenue recognized by the Company as reported on Form 10-K as filed with the SEC for any fiscal year ending after January 10, 2020 exceeds $45 million dollars, the Debt Threshold for the following fiscal year shall increase to an amount equal to: (x) ten percent (10%); multiplied by (y) the consolidated revenue as reported by the Company on Form 10-K as filed with the SEC for the previous fiscal year.
Subsequent Event [Member] | 1315 Capital [Member]
Subsequent Event [Line Items]
Promissory note				$ 2,000,000	$ 2,000,000
Subsequent Event [Member] | 1315 Capital [Member] | Series B Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of holds shares					19,000
Number of convertible, common stock					3,166,668
Fully diluted percentage of common stock					26.70%
Subsequent Event [Member] | The Nasdaq Stock Market LLC [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Minimum capital requirement for continued listing									$ 2,500,000
Subsequent Event [Member] | Ampersand 2018 Limited Partnership [Member]
Subsequent Event [Line Items]
Promissory note				$ 3,000,000	$ 3,000,000
Subsequent Event [Member] | Ampersand 2018 Limited Partnership [Member] | Series B Convertible Preferred Stock [Member]
Subsequent Event [Line Items]
Number of holds shares					28,000
Number of convertible, common stock					4,666,666
Fully diluted percentage of common stock					39.30%
Subsequent Event [Member] | Term Loan [Member] | Broad Oak [Member]
Subsequent Event [Line Items]
Debt instrument, face amount	$ 8,000,000
Subsequent Event [Member] | Term Loan [Member] | Ampersand 2018 [Member]
Subsequent Event [Line Items]
Debt instrument, maturity date	Oct. 31, 2024
Rate of interest	9.00%
Percentage of debt origination fee	3.00%
Subsequent Event [Member] | Loan And Security Agreement [Member]
Subsequent Event [Line Items]
Line of credit, principal		$ 7,500,000
Percentage of accounts receivable		80.00%
Line of credit facility, maximum capacity		$ 5,000,000
Revolving Line option credit card services borrowing limit		$ 300,000
Percentage of line of credit interest		0.50%
Percentage of line of credit unused facility fee		0.25%
Line of credit, maturity date		Sep. 30, 2023
Subsequent Event [Member] | Loan And Security Agreement [Member] | London Interbank Offered Rate (LIBOR) [Member]
Subsequent Event [Line Items]
Percentage of line of credit interest		2.50%
Subsequent Event [Member] | Loan And Security Agreement [Member] | Forecast [Member]
Subsequent Event [Line Items]
Line of credit reductions								$ 250,000
Subsequent Event [Member] | Loan And Security Agreement [Member] | Accounts Receivable [Member]
Subsequent Event [Line Items]
Line of credit, principal		$ 2,000,000
Subsequent Event [Member] | Loan And Security Agreement [Member] | Comerica Bank [Member]
Subsequent Event [Line Items]
Line of credit, principal	$ 7,500,000	$ 7,500,000
Debt instrument interest, description	The Term Loan has an origination fee of 3% of the Term Loan amount, and a terminal payment equal to (i) 15% of the original principal amount of the Term Loan if the change of control occurs on or prior to the first anniversary of the funding of the Term Loan, (ii) 20% of the original principal amount of the Term Loan if the change of control occurs after the first anniversary but on or prior to the second anniversary of the funding of the Term Loan and (iii) 30% of the original principal amount of the Term Loan if the change of control occurs after the second anniversary of the funding of the Term Loan, or if the Term Loan is repaid on its maturity date.

Nature of Business and Signif_4

Nature of Business and Significant Accounting Policies (Details Narrative) $ in Millions	Jan. 15, 2020	Dec. 31, 2020USD ($)Integershares	Sep. 30, 2021shares	Dec. 31, 2019shares	Dec. 30, 2019shares
Property, Plant and Equipment [Line Items]
Number of reportable segments | Integer		1
Reverse stock split description	On January 15, 2020, the Company effected a one-for-ten reverse split of its issued and outstanding shares of its common stock (the “Reverse Stock Split”). Every 10 shares of common stock issued and outstanding were automatically combined into one share of issued and outstanding common stock, without any change in the par value per share.
Shares issued		4,075,257	4,194,111	3,932,370	39,323,701
Shares outstanding		4,055,593	4,174,447	3,920,589	39,205,895
Reduction of revenues | $		$ 3.5
Income tax examination, likelihood of unfavorable settlement		Uncertain tax positions are recognized in the financial statements when it is more likely than not (i.e., a likelihood of more than fifty percent) that a position taken or expected to be taken in a tax return would be sustained upon examination by tax authorities that have full knowledge of all relevant information. A recognized tax position is then measured as the largest amount of benefit that is greater than fifty percent likely to be realized upon ultimate settlement. Th
Minimum [Member]
Property, Plant and Equipment [Line Items]
Finite-lived intangible asset, useful life		2 years
Maximum [Member]
Property, Plant and Equipment [Line Items]
Finite-lived intangible asset, useful life		10 years
Furniture and Fixtures [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		7 years
Furniture and Fixtures [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		12 years
Office and Computer Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		2 years
Office and Computer Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		5 years
Lab Equipment [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		3 years
Lab Equipment [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		12 years
Leasehold Improvements [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		3 years
Leasehold Improvements [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		10 years
Software for Internal Use [Member] | Minimum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		3 years
Software for Internal Use [Member] | Maximum [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		7 years
Software for External Use [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, useful life		3 years

Schedule of Assets Acquired and

Schedule of Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Jul. 15, 2019	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019	Jul. 31, 2019	Dec. 31, 2018
Business Acquisition [Line Items]
Total acquired identifiable intangible assets	$ 7,300
Goodwill		$ 8,433	$ 8,433	$ 8,433
BioPharma Acquisition [Member]
Business Acquisition [Line Items]
Cash	13,829
Subordinated note payable	6,822
Total consideration	20,651
Accounts receivable	3,731
Accrued revenue	289
Lab supplies	877
Prepaid expenses	266
Property and equipment	6,412
Operating lease assets	2,187
Total acquired identifiable intangible assets	7,300				$ 7,300
Goodwill	8,273			$ 100	$ 8,300
Total assets acquired	29,335
Accounts payable	(4,535)
Accrued liabilities	(435)
Deferred revenue	(1,076)
Operating lease liabilities	(2,187)
Finance lease liabilities	(451)
Total liabilities assumed	(8,684)
Net assets acquired	20,651
BioPharma Acquisition [Member] | Trademarks and Trade Names [Member]
Business Acquisition [Line Items]
Total acquired identifiable intangible assets	1,600
BioPharma Acquisition [Member] | Customer Relationships [Member]
Business Acquisition [Line Items]
Total acquired identifiable intangible assets	$ 5,700

Schedule of ProForma Informatio

Schedule of ProForma Information (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2019USD ($)
Business Combination and Asset Acquisition [Abstract]
Revenue	$ 31,722

Acquisition (Details Narrative)

Acquisition (Details Narrative) - USD ($)	Oct. 18, 2019	Jul. 15, 2019	Jun. 30, 2019	Dec. 31, 2019
Acquired Finite-Lived Intangible Assets [Line Items]
Cliam offset amount				$ 735,000
Expiration period of claim				Jan. 15, 2020
Payment settlement	$ 6,024,489
Repayments of debt	887,858
Goodwill		$ 8,300,000
Finite lived intangible assets		$ 7,300,000
Finite lived intangible assets weighted-average amortization period		8 years 4 months 24 days
Business transaction expenses		$ 2,500,000
Trademarks [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets weighted-average amortization period		10 years
Customer Relationships [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Finite lived intangible assets weighted-average amortization period		8 years
Indemnification Holdback [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Repayments of debt	735,000
AR Holdback [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Repayments of debt	$ 152,858
CGI Bio Pharma [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Business combination consideration amount			$ 775,000
Accounts receivable				$ 830,000
Asset Purchase Agreement [Member] | Inital Tranche [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Payment of preferred stock financing		$ 13,800,000
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Assets and assumed certain liabilities		23,500,000
Proceeds from debt		7,692,300
Asset Purchase Agreement [Member] | CGI Bio Pharma [Member] | Base Purchase Price [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Assets and assumed certain liabilities		$ 1,980,000

Schedule of Discontinued Oper_2

Schedule of Discontinued Operations Amount Recognized in Balance Sheet (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Accrued liabilities	$ 766	$ 766	$ 766
Current liabilities from discontinued operations	766	766	766
Total liabilities	$ 766	$ 766	$ 766

Schedule of Discontinued Oper_3

Schedule of Discontinued Operations Condensed Consolidated Statements of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Discontinued Operations and Disposal Groups [Abstract]
Income from discontinued operations, before tax						$ 220
Income tax expense	62	65	175	194	250	308
Loss from discontinued operations, net of tax	$ (62)	$ (65)	$ (175)	$ (194)	$ (250)	$ (88)

Schedule of Property and Equipm

Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Abstract]
Furniture and fixtures		$ 339	$ 242
Lab and office equipment		7,536	6,353
Computer equipment		339	339
Internal-use software		1,572	1,276
Leasehold improvements		505	506
Property and equipment		10,291	8,716
Less accumulated depreciation and amortization		(2,942)	(1,902)
Net property and equipment	$ 6,484	$ 7,349	$ 6,814

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Property, Plant and Equipment [Line Items]
Depreciation and amortization expense					$ 800	$ 500
Amortization expense	$ 1,112	$ 1,115	$ 3,336	$ 3,346	4,461	$ 3,989
Software Development [Member]
Property, Plant and Equipment [Line Items]
Amortization expense					$ 100

Retirement Plans (Details Narra

Retirement Plans (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, maximum annual contributions per employee, percent	50.00%
Defined contribution plan, employer matching contribution, percent	100.00%
Defined contribution plan employer matching contribution at fifty percent	50.00%
Contribution expense	$ 0.4	$ 0.3
Minimum [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan, employer matching contribution, percent	3.00%
Defined contribution plan employer matching contribution at fifty percent	3.00%
Maximum [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined contribution plan employer matching contribution at fifty percent	5.00%

Accrued Expenses and Other Lo_3

Accrued Expenses and Other Long-Term Liabilities (Details Narrative) $ in Millions	Dec. 31, 2020USD ($)
Payables and Accruals [Abstract]
Accrued bonus	$ 1.2

COMMITMENTS AND CONTINGENCIES_2

COMMITMENTS AND CONTINGENCIES (Details Narrative) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Operating lease expire date description	expire at various dates through May 2030
Total expense	$ 2.1	$ 1.3

Schedule of Share-Based Payment

Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions (Details)	9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Risk-free interest rate	0.78%	0.79%	0.75%	2.34%
Expected life	6 years	6 years 7 months 6 days	6 years 6 months	5 years 10 months 24 days
Expected volatility	134.79%	122.24%	123.71%	128.58%
Dividend yield

Schedule of Share-Based Compens

Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense	$ 477	$ 563	$ 1,314	$ 1,381	$ 2,187	$ 965
R S Usand Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense					176	243
Performance Shares [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense					265
Share-based Payment Arrangement [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense					116
Share-based Payment Arrangement, Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total stock-based compensation expense					$ 1,630	$ 722

Schedule of Stock Option Activi

Schedule of Stock Option Activity (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020
Share-based Payment Arrangement [Abstract]
Shares outstanding beginning balance	848,819	415,678
Weighted average grant price outstanding beginning balance	$ 8.76	$ 12.50
Weighted average remaining contractual period outstanding beginning balance		8 years 5 months 12 days
Aggregate intrinsic value outstanding beginning balance
Shares granted	312,500	525,550
Weighted average grant price granted		$ 6.24
Weighted average remaining contractual period granted		9 years 4 months 20 days
Aggregate intrinsic value granted
Shares exercised
Shares forfeited or expired		(92,409)
Weighted average grant price forfeited or expired		$ 11.18
Aggregate intrinsic value forfeited or expired
Shares outstanding ending balance		848,819
Weighted average grant price outstanding ending balance		$ 8.76
Weighted average remaining contractual period outstanding ending balance		8 years 7 months 2 days
Aggregate intrinsic value outstanding ending balance
Shares exercisable ending balance		361,501
Weighted average grant price exercisable ending balance		$ 11.81
Weighted average remaining contractual period exercisable ending balance		7 years 9 months 7 days
Aggregate intrinsic value exercisable ending balance
Shares vested and expected to vest		659,465
Weighted average grant price vested and expected to vest		$ 9.48
Weighted average remaining contractual period vested and expected to vest		8 years 4 months 20 days
Aggregate intrinsic value vested and expected to vest

Schedule of Non Vested Option A

Schedule of Non Vested Option Activity (Details) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Payment Arrangement [Abstract]
Non-vested Shares outstanding beginning balance	487,318,000		213,472,000
Non-vested weighted average grant date fair value outstanding beginning balance	$ 5.81	$ 8.80
Non-vested Shares granted	312,500	525,550
Non-vested weighted average grant date fair value granted	$ 6	$ 5.36	$ 8.50
Non-vested Shares vested		(197,998,000)
Non-vested weighted average grant date fair value exercised		$ 7.34
Non-vested Shares forfeited		(53,706,000)
Non-vested weighted average grant date fair value forfeited		$ 7.86
Non-vested Shares outstanding ending balance		487,318,000
Non-vested weighted average grant date fair value outstanding ending balance		$ 5.81	$ 8.80

Schedule of Share-Based Compe_2

Schedule of Share-Based Compensation, Restricted Stock and Restricted Stock Units Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended	12 Months Ended
	Sep. 30, 2021	Dec. 31, 2020	Dec. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested Shares granted	1,975,934	1,990,934
Non-vested Aggregate Intrinsic Value Vested		$ 1,500	$ 500
Non-vested Shares Forfeited		(15,000)
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Non-vested Shares beginning balance	239,457		49,366
Non-vested Weighted Average Grant Date Fair Value beginning balance	$ 3.61		$ 10.04
Non-vested Average Remaining Vesting Period Beginning balance		1 year 1 month 9 days
Non-vested Aggregate Intrinsic Value Beginning balance	$ 751,895		$ 246,830
Non-vested Shares granted		236,321
Non-vested Weighted Average Grant Date Fair Value Granted		$ 3.43
Non-vested Aggregate Intrinsic Value Granted
Non-vested Shares Vested		(43,976)
Non-vested Weighted Average Grant Date Fair Value Vested		$ 9.52
Non-vested Aggregate Intrinsic Value Vested
Non-vested Shares Forfeited		(2,254)
Non-vested Weighted Average Grant Date Fair Value Forfeited		$ 10.10
Non-vested Aggregate Intrinsic Value Forfeited
Non-vested Shares ending balance		239,457
Non-vested Weighted Average Grant Date Fair Value Ending balance		$ 3.61
Non-vested Average Remaining Vesting Period Ending balance		1 year 9 months
Non-vested Aggregate Intrinsic Value Ending balance		$ 751,895

Schedule of Revenue by Major Cu

Schedule of Revenue by Major Customers (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Revenue	$ 9,472	$ 8,248	$ 30,461	$ 22,752	$ 32,398	$ 24,220
Medicare Customer [Member]
Revenue					10,186	10,605
Commercial Payers Customer [Member]
Revenue					4,136	7,589
Medicare Advantage Customer [Member]
Revenue					3,566	1,912
Client Billings Customer [Member]
Revenue					$ 2,582	$ 3,521

Revenue Sources (Details Narrat

Revenue Sources (Details Narrative)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Revenue Benchmark [Member] | Medicare [Member] | Customer Concentration Risk [Member]
Concentration Risk [Line Items]
Revenue from continuing operations	50.00%	44.00%

Schedule of Components of Incom

Schedule of Components of Income Tax Expense (Benefit) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal						$ (46)
State					16
Total current					16	(46)
Federal					23	11
State					14	7
Total deferred					37	18
Benefit from income taxes	$ (714)	$ 14	$ (684)	$ 43	$ 53	$ (28)

Schedule of Deferred Tax Assets

Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 03, 2020	Dec. 03, 2019
Income Tax Disclosure [Abstract]
Federal net operating loss carryforwards	$ 17,015	$ 11,664
State net operating loss carryforwards	2,953	1,834
Compensation	1,492	1,399
Allowances and reserves	436	457
Intangible assets	292	589
State taxes	900	848
Credit carryforward	229	229
163(j) interest	745	141
Leases	54	23
Deferred revenue	95	88
Valuation allowance	(23,684)	(17,027)
Gross deferred tax assets	527	245
Property and equipment	(582)	(263)
Deferred tax liability-net valuation allowance	$ (55)	$ (18)

SCHEDULE OF EFFECTIVE INCOME _2

SCHEDULE OF EFFECTIVE INCOME TAX RATE RECONCILIATION (Details)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Federal statutory rate					21.00%	21.00%
State income tax rate, net of Federal tax benefit					4.00%	3.00%
Meals and entertainment					(0.10%)	(0.20%)
Valuation allowance					(25.00%)	(23.80%)
Naked credit					(0.10%)	(0.10%)
Discontinued operations allocation					0.00%	0.20%
Effective tax rate	16.90%	0.20%	5.80%	0.20%	(0.20%)	0.10%

Schedule of Unrecognized Tax Be

Schedule of Unrecognized Tax Benefits Roll Forward (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Abstract]
Unrecognized tax benefits beginning balance	$ 877	$ 877
Additions for tax positions of prior years
Unrecognized tax benefits ending balance	$ 877	$ 877

Schedule of Tax Years Subject t

Schedule of Tax Years Subject to Examination (Details)	12 Months Ended
	Dec. 31, 2020
Domestic Tax Authority [Member] | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open tax year	2016
Domestic Tax Authority [Member] | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open tax year	2020
State and Local Jurisdiction [Member] | Earliest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open tax year	2015
State and Local Jurisdiction [Member] | Latest Tax Year [Member]
Operating Loss Carryforwards [Line Items]
Open tax year	2020

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative) - USD ($)	12 Months Ended
	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Operating Loss Carryforwards [Line Items]
Federal net income loss percentage	Under current federal income tax law, federal NOLs incurred in tax years beginning after December 31, 2017 may be carried forward indefinitely, but the deductibility of such federal NOLs is limited to 80% of Federal Taxable Income, and current state net operating losses not utilized begin to expire this year.
Unrecognized tax benefits	$ 877,000	$ 877,000	$ 877,000
Unrecognized tax benefits would affect the effective tax rate	900,000	900,000
Income tax examination penalties and interest expense	300,000	300,000
Income tax examination penalties and interest accrued	$ 3,400,000	$ 3,100,000
Income tax examination, description	The Tax Cuts and Jobs Act (the “TCJA”) was enacted on December 22, 2017 and became effective for tax years beginning after December 31, 2017. The TCJA had significant changes to U.S. tax law, lowering U.S. corporate income tax rates, implementing a territorial tax system, imposing a one-time transition tax on deemed repatriated earnings of foreign subsidiaries and modified the taxation of other income and expense items.
Us corporate tax percentage	21.00%	21.00%
Deferred tax assets	$ 22,768,303
Valuation allowance	22,768,303
Domestic Tax Authority [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	81,000,000
Reduction in operating loss carryforwards	153,800,000
State and Local Jurisdiction [Member]
Operating Loss Carryforwards [Line Items]
Operating loss carryforwards	48,300,000
Reduction in operating loss carryforwards	$ 60,600,000

Schedule of Weighted Average Nu

Schedule of Weighted Average Number of Shares (Details) - shares shares in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020	Dec. 31, 2020	Dec. 31, 2019
Earnings Per Share [Abstract]
Basic weighted average number of common shares	4,165	4,038	4,119	4,025	4,029	3,746
Potential dilutive effect of stock-based awards
Diluted weighted average number of common shares	4,165	4,038	4,119	4,025	4,029	3,746

Revolver (Details Narrative)

Revolver (Details Narrative) - USD ($)	Oct. 19, 2020	Dec. 31, 2020	Dec. 31, 2019	Nov. 13, 2018
Debt Instrument [Line Items]
Line of credit facility			$ 3,000,000
Revolver [Member]
Debt Instrument [Line Items]
Line of credit		$ 0	$ 3,000,000
SVB Loan Agreement [Member]
Debt Instrument [Line Items]
Debt instrument flotation interest rate	4.25%
SVB Loan Agreement [Member] | Above Prime Rate [Member]
Debt Instrument [Line Items]
Debt instrument flotation interest rate	1.00%	0.50%
SVB Loan Agreement [Member] | Minimum [Member]
Debt Instrument [Line Items]
Line of credit facility	$ 250,000
SVB Loan Agreement [Member] | Maximum [Member]
Debt Instrument [Line Items]
Line of credit facility	$ 1,000,000
SVB Loan Agreement [Member] | Silicon Valley Bank [Member]
Debt Instrument [Line Items]
Line of credit				$ 4,000,000
Line of credit outstanding accounts receivable				3,750,000
SVB Loan Agreement [Member] | Silicon Valley Bank [Member] | Term Loan [Member]
Debt Instrument [Line Items]
Line of credit				$ 850,000

Schedule II - Valuation and Qua

Schedule II - Valuation and Qualifying Accounts (Details) - USD ($) $ in Thousands		12 Months Ended
		Dec. 31, 2020	Dec. 31, 2019
SEC Schedule, 12-09, Allowance, Credit Loss [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period		$ 25
Additions (Reductions) Charged to Operations
Deductions Other	[1]	250	25
Balance at end of Period		275	25
Allowance for Doubtful Notes [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period		869	869
Additions (Reductions) Charged to Operations
Deductions Other	[1]
Balance at end of Period		869	869
SEC Schedule, 12-09, Valuation Allowance, Other Tax Carryforward [Member]
SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	[2]	17,027	11,031
Additions (Reductions) Charged to Operations				[2]
Deductions Other	[1]	6,657	5,996	[2]
Balance at end of Period		$ 23,684	$ 17,027	[2]
[1]	Includes payments and actual write offs, as well as changes in estimates in the reserves.
[2]	Opening balance has been adjusted to reflect the impact of the immaterial revision described in Note 1.